

CITATION REPORT

List of articles citing

Final version of 2009 AJCC melanoma staging and classification

DOI: 10.1200/jco.2009.23.4799

Journal of Clinical Oncology, 2009, 27, 6199-206.

Source: <https://exaly.com/paper-pdf/46621614/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2290	Appearance of malignant melanoma after a non-cutaneous cancer diagnosis. 2013 , 7, 315		1
2289	Surgical excision margins for primary cutaneous melanoma. 2009 , CD004835		88
2288	Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. 2010 , 32, 650-4		56
2287	Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. 2010 , 20, 501-6		6
2286	Genetic determinants of disease progression and survival in melanoma. 2010 , 20, e8-e9		
2285	Sarcoidosis induced by interferon- α in melanoma patients: incidence, clinical manifestations, and management strategies. 2010 , 33, 834-9		30
2284	P26b Outcome of sentinel node negative patients with primary cutaneous melanoma-prognostic factors and survival probabilities. 2010 , 20, e54-e55		4
2283	P28 Treatment of lentigo maligna with imiquimod: a follow up of 61 patients. 2010 , 20, e55		
2282	Cutaneous melanoma in the elderly: epidemiology and management. 2010 , 6, 383-392		
2281	Advances and short comings in the early diagnosis of melanoma. 2010 , 20, 450-8		11
2280	2010 TNM staging system for cutaneous melanoma...and beyond. 2010 , 17, 1475-7		98
2279	Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database. 2010 , 17, 2006-14		87
2278	The prognostic value of tumor mitotic rate and other clinicopathologic factors in patients with locoregional recurrences of melanoma. 2010 , 17, 2992-9		7
2277	Detection of melanoma nodal metastases; differences in detection between elderly and younger patients do not affect survival. 2010 , 17, 3008-14		10
2276	Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden. 2010 , 17, 3314-23		7
2275	The prognostic significance of nonsentinel lymph node metastasis in melanoma. 2010 , 17, 3330-5		28
2274	Premalignant epithelial disorders of the vulva: squamous vulvar intraepithelial neoplasia, vulvar Paget's disease and melanoma in situ. 2010 , 89, 741-8		33

2273	[Current aspects of adjuvant therapy of malignant melanoma]. 2010 , 61, 523-31; quiz 532-3	3
2272	Diagnostik des malignen Melanoms. 2010 , 16, 1121-1130	
2271	Schildwachterlymphknotenbiopsie beim Melanom. 2010 , 16, 1140-1149	3
2270	Adjuvante systemische Therapie des Melanoms. 2010 , 16, 1150-1159	
2269	Systemische Therapie des metastasierten Melanoms. 2010 , 16, 1160-1166	1
2268	Surveillance after surgical treatment of melanoma: futility of routine chest radiography. 2010 , 148, 711-6; discussion 716-7	20
2267	Dermatopathology of skin cancer in solid organ transplant recipients. 2010 , 24, 172-89	27
2266	Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients. 2010 , 10, 63	28
2265	The persistent anchor of lymph node removal in patients with melanoma. 2010 , 116, 1150-2	
2264	Characteristics of the coexistence of melanoma and renal cell carcinoma. 2010 , 116, 5716-24	15
2263	Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. 2010 , 101, 669-76	48
2262	The role of spectrophotometry in the diagnosis of melanoma. 2010 , 10, 5	11
2261	Cutaneous metastases from internal malignancies. 2010 , 23, 567-80	42
2260	Prognostic models for melanoma. 2010 , 37 Suppl 1, 68-75	4
2259	New research advances for treating metastatic melanoma. 2010 , 49, 712-4	
2258	Is GP-led follow-up feasible?. 2010 , 102, 1445-6	4
2257	Tattoo pigment mimicking metastatic malignant melanoma in an axillary sentinel lymph node. 2010 , 2010, bcr0120102607-bcr0120102607	78
2256	Surgery of primary melanomas. 2010 , 2, 824-41	10

2255	Prognostic significance of melanoma differentiation and trans-differentiation. 2010 , 2, 989-99		7
2254	Methyl sulfone induces loss of metastatic properties and reemergence of normal phenotypes in a metastatic cloudman S-91 (M3) murine melanoma cell line. 2010 , 5, e11788		28
2253	Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review. 2010 , 5, 39-48		7
2252	Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival. 2010 , 107, E46; author reply E47		2
2251	Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2452-9	2.2	320
2250	Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer. 2010 , 56, 1148-57		58
2249	From melanocyte to metastatic malignant melanoma. 2010 , 2010,		82
2248	Mucosal melanomas: a case-based review of the literature. 2010 , 15, 772-81		79
2247	Advances in systemic treatment of melanoma. 2010 , 21 Suppl 7, vii339-44		37
2246	PLX4032: does it keep its promise for metastatic melanoma treatment?. 2010 , 19, 1439-49		20
2245	Some of the 2009 American Joint Committee on Cancer melanoma staging and classification is not evidence based. <i>Journal of Clinical Oncology</i> , 2010 , 28, e479; author reply e480-1	2.2	1
2244	Reply to J.M. Thomas et al. <i>Journal of Clinical Oncology</i> , 2010 , 28, e480-e481	2.2	1
2243	Melanoma MicroRNA signature predicts post-recurrence survival. 2010 , 16, 1577-86		180
2242	Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine. 2010 , 130, 2514-6		9
2241	The biology behind prognostic factors of cutaneous melanoma. 2010 , 22, 163-8		36
2240	No role for melanoma treatment in the association between melanoma and amyotrophic lateral sclerosis or Parkinson's disease. 2010 , 35, 303-4		5
2239	Contrast-enhanced ultrasound: a filter role in AJCC stage I/II melanoma patients. 2010 , 79, 370-5		15
2238	P27 New therapeutic strategies for stage III melanoma. 2010 , 20, e55		

2237	Melanoma Staging. 2010 , 2, 254-259	1
2236	Case records of the Massachusetts General Hospital. Case 30-2010. A 15-year-old boy with a recurrent skin lesion. 2010 , 363, 1352-60	
2235	Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. 2010 , 10, 1081-7	82
2234	S100A13 is a new angiogenic marker in human melanoma. 2010 , 23, 804-13	51
2233	[New breakthroughs in Oncodermatology]. 2010 , 137 Suppl 4, S158-64	
2232	High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study. 2010 , 8, 115	28
2231	Initial Evaluation, Diagnosis, Staging, Treatment, and Follow-up of Patients with Primary Cutaneous Malignant Melanoma. Consensus Statement of the Network of Catalan and Balearic Melanoma Centers. 2010 , 101, 129-142	
2230	Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. 2010 , 70, 5213-9	562
2229	CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients. 2010 , 36, 1211-4	26
2228	Implications of the 2009 American Joint Committee on Cancer Melanoma Staging and Classification on dermatologists and their patients. 2010 , 29, 142-7	9
2227	Office management of melanoma patients. 2010 , 29, 232-7	5
2226	New therapeutic options in the medical management of advanced melanoma. 2010 , 29, 249-57	11
2225	Sentinel node biopsy for melanoma: an update after two decades of experience. 2010 , 29, 238-48	27
2224	Valoraci3n inicial, diagn3stico, estadificaci3n, tratamiento y seguimiento de los pacientes con melanoma maligno primario de la piel. Documento de consenso de la âarxa de Centres de Melanoma de Catalunya i Balearsâ. 2010 , 101, 129-142	17
2223	Risk factors associated with local and in-transit recurrence of cutaneous melanoma. 2010 , 200, 770-4; discussion 774-5	42
2222	Alpha 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma. 2010 , 23, 575-8	15
2221	Quantitative measurement of circulating lymphoid-specific helicase (HELLS) gene transcript: a potential serum biomarker for melanoma metastasis. 2010 , 23, 845-8	9
2220	Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma. 2010 , 10, 897-919	35

2219	Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. 2011 , 12, 2695-706	30
2218	Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. 2011 , 7, 1383-94	7
2217	Systematic review of medical treatment in melanoma: current status and future prospects. 2011 , 16, 5-24	394
2216	Prognostic biomarkers in ovarian cancer. 2010 , 8, 231-51	25
2215	Regional treatment strategies for in-transit melanoma metastasis. 2011 , 20, 79-103	25
2214	Melanoma pathology: important issues for clinicians involved in the multidisciplinary care of melanoma patients. 2011 , 20, 19-37	16
2213	The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma. 2012 , 351, 181-220	12
2212	Metastasectomy for stage IV melanoma: for whom and how much?. 2011 , 20, 133-44	23
2211	Advanced Stages of Melanoma: Role of Structural Imaging. 2011 , 6, 37-54	
2210	Sentinel lymph node biopsy for melanoma: critical assessment at its twentieth anniversary. 2011 , 20, 57-78	17
2209	Circulating serologic and molecular biomarkers in malignant melanoma. 2011 , 86, 981-90	62
2208	Recurrence of Melanoma. 2011 , 6, 55-70	2
2207	What does ulceration of a melanoma mean for prognosis?. 2011 , 45, 225-36	5
2206	Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsy-FDG-PET/CT. 2011 , 6, 9-25	4
2205	Primary Cutaneous Melanoma: Prognostic Factors Not Included in the Classification of the American Joint Committee on Cancer. 2011 , 102, 255-263	
2204	Sentinel lymph node biopsy in melanoma: The Oxford ten year clinical experience. 2011 , 64, 1284-90	15
2203	Primary malignant melanoma of the vagina with repeated local recurrences and brain metastasis. 2011 , 74, 376-9	9
2202	Regulation of pathological lymphangiogenesis requires factors distinct from those governing physiological lymphangiogenesis. 2011 , 61, 85-93	13

2201	The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. 2011 , 61, 187-93	153
2200	Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. 2011 , 62, 116-23	35
2199	Role of Chemokines in Melanoma Progression. 2011 , 102, 498-504	1
2198	Sentinel Node Biopsy in Melanoma: An Update. 2011 , 102, 749-753	
2197	Descriptive Analysis of Cutaneous Recurrence Patterns in Patients with Melanoma. 2011 , 102, 791-796	
2196	Ipilimumab: a novel treatment for metastatic melanoma. 2011 , 45, 510-9	41
2195	Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. 2011 , 24, 487-94	39
2194	Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?. 2011 , 5, 137-49	36
2193	Immunologic functions as prognostic indicators in melanoma. 2011 , 5, 183-9	18
2192	Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. 2011 , 5, 124-36	103
2191	Quality assurance parameters and predictors of outcome for ilioinguinal and inguinal dissection in a contemporary melanoma patient population. 2011 , 18, 2521-8	37
2190	Fibroblasts contribute to melanoma tumor growth and drug resistance. 2011 , 8, 2039-49	90
2189	Fotemustine for the treatment of melanoma. 2011 , 12, 2891-904	17
2188	In vivo photoacoustic microscopy of human cutaneous microvasculature and a nevus. 2011 , 16, 016015	86
2187	Sentinel-lymph-node biopsy for cutaneous melanoma. 2011 , 364, 1738-45	104
2186	Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. 2011 , 13, 352-8	63
2185	Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines. 2011 , 26, 407-15	18
2184	Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. 2011 , 364, 2517-26	3396

2183	The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. 2011 , 11, 1395-407	7
2182	Staging and prognosis of cutaneous melanoma. 2011 , 20, 1-17	115
2181	[Primary cutaneous melanoma: prognostic factors not included in the classification of the American Joint Committee on Cancer]. 2011 , 102, 255-63	4
2180	[Role of chemokines in melanoma progression]. 2011 , 102, 498-504	7
2179	[Sentinel node biopsy in melanoma: an update]. 2011 , 102, 749-53	6
2178	[Descriptive analysis of cutaneous recurrence patterns in patients with melanoma]. 2011 , 102, 791-6	8
2177	Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. 2011 , 66, 224-36	43
2176	Technique and outcomes of isolated limb infusion for locally advanced malignant melanoma--a radiological perspective. 2011 , 66, 1175-80	3
2175	Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach. 2011 , 37, 133-42	9
2174	Methods of detection of circulating melanoma cells: a comparative overview. 2011 , 37, 284-90	22
2173	A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up. 2011 , 47, 1977-89	47
2172	New drugs in melanoma: it's a whole new world. 2011 , 47, 2150-7	145
2171	The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection. 2011 , 37, 225-32	16
2170	Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma. 2011 , 37, 681-7	24
2169	Maximizing the clinical usefulness of a nomogram to select patients candidate to sentinel node biopsy for cutaneous melanoma. 2011 , 37, 675-80	15
2168	Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma. 2011 , 65, 1152-60	27
2167	Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. 2011 , 65, 1032-47	289
2166	Subungual malignant melanoma. 2011 , 36, 704-7	17

2165	Improved survival with vemurafenib in melanoma with BRAF V600E mutation. 2011 , 364, 2507-16	5851
2164	Therapy for metastatic melanoma: an overview and update. 2011 , 11, 725-37	51
2163	Modelling melanoma in mice. 2011 , 24, 1158-76	40
2162	Histopathologische Befundung maligner Melanome in Bereinstimmung mit der AJCC-Klassifikation 2009: Literaturübersicht und Empfehlungen zum praktischen Vorgehen. 2011 , 9, 690-700	2
2161	Diagnosis of Melanoma. 2011 , 6, 1-8	6
2160	2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. 2011 , 378, 1635-42	133
2159	BRAF V600E Mutated Gene Variant as a Circulating Molecular Marker in Metastatic Melanoma Patients. 2011 ,	1
2158	Adaptation to ER Stress as a Mechanism of Resistance of Melanoma to Treatment. 2011 ,	
2157	New Molecular Targets for the Systemic Therapy of Melanoma. 2011 ,	1
2156	The Roles of S100 Proteins and RAGE in Melanoma. 2011 ,	1
2155	Adjuvant peginterferon alfa-2b therapy in stage III melanoma. 2011 , 6, 567-575	
2154	Risk evaluation in cutaneous melanoma patients undergoing lymph node dissection: impact of POSSUM. 2011 , 93, 514-22	8
2153	Cutaneous melanoma: a prospective study of 42 cases. 2011 , 86, 1233-5	1
2152	Promising Experimental Therapies for Metastatic Melanoma. 2011 ,	
2151	Cutaneous Metastases from Malignant Melanoma: Clinical Features and New Therapeutic Perspectives. 2011 ,	2
2150	Challenging Problems in the Surgical Management of Melanoma. 2011 ,	
2149	Non-Invasive Determination of Breslow Index. 2011 ,	
2148	Cutaneous melanoma: a 30-year-long epidemiological study conducted in a city in southern Brazil, from 1980-2009. 2011 , 86, 932-41	23

2147	Common genetic variants of MUTYH are not associated with cutaneous malignant melanoma: application of molecular screening by means of high-resolution melting technique in a pilot case-control study. 2011 , 26, 37-42	4
2146	Malignant melanoma in the elderly: different regional disease and poorer prognosis. 2011 , 2, 538-43	86
2145	Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. 2011 , 4, 137-48	41
2144	Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma. 2011 , 26, 82-7	13
2143	Proteomics in melanoma biomarker discovery: great potential, many obstacles. 2011 , 2011, 181890	22
2142	Clinical utility of serum autoantibodies detected by protein microarray in melanoma. 2011 , 2011, 413742	7
2141	Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. 2011 , 66, 493-9	26
2140	Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma. 2011 , 6, e24632	17
2139	A darkly pigmented lesion with recent changes. 2011 , 343, d5375	
2138	Autoimmunity and treatment outcome in melanoma. 2011 , 23, 170-6	41
2137	Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. 2011 , 23, 183-8	26
2136	Current world literature. 2011 , 23, 227-34	
2135	Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases. 2011 , 21, 152-9	11
2134	Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. 2011 , 21, 431-7	4
2133	The magic of numbers: malignant melanoma between science and pseudoscience. 2011 , 33, 371-8	10
2132	CO27. Interest of Cetuximab in the treatment of cutaneous squamous cell carcinoma. 2011 , 21, e16-e17	
2131	Beclin-1 and LC3A expression in cutaneous malignant melanomas: a biphasic survival pattern for beclin-1. 2011 , 21, 188-95	59
2130	Clinical relevance of detection of lymphovascular invasion in primary melanoma using endothelial markers D2-40 and CD34. 2011 , 35, 1441-9	46

2129	Infantile melanoma--a triple threat: diagnosis and management. 2011 , 67, 85-9	5
2128	P001. What's the best therapy for treating resected stage III melanoma patients?. 2011 , 21, e17	
2127	Defining fast-growing melanomas: reappraisal of epidemiological, clinical, and histological features. 2011 , 21, 131-8	35
2126	Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. 2011 , 21, 228-34	25
2125	Identification of nodal metastases in melanoma using sox-10. 2011 , 33, 474-82	38
2124	Differentiation of melanoma and benign nevi by fluorescence in-situ hybridization. 2011 , 21, 426-30	13
2123	Lésions pigmentées. 2011 , 6, 1-9	
2122	Evaluation and surgical management of melanoma of the head and neck. 2011 , 24, 37-8, 40	
2121	Glycans in melanoma screening. Part 1. The role of α 1,6-branched N-linked oligosaccharides in melanoma. 2011 , 39, 370-3	9
2120	Dermoscopy for the diagnosis of melanoma: primary care diagnostic technology update. 2011 , 61, 416-7	13
2119	Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. 2011 , 6, 355-357	2
2118	Critical analysis of the ultrasonographic criteria for diagnosing lymph node metastasis in patients with cutaneous melanoma: a systematic review. 2011 , 30, 547-60	17
2117	Interferon alpha for the adjuvant treatment of cutaneous melanoma. 2011 ,	6
2116	Is radiotherapy an effective treatment option for recurrent metastatic malignant melanoma? A case report of short-course, large-fraction radiation and a literature review. 2011 , 19, 153-5	1
2115	Noninvasive genomic detection of melanoma. 2011 , 164, 797-806	70
2114	Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. 2011 , 164, 1235-40	28
2113	Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma. 2011 , 165, 506-12	22
2112	Sentinel node biopsy should be offered in thin melanoma with mitotic rate greater than one. 2011 , 37, 1080-8	23

2111	Internet use and anxiety in people with melanoma and nonmelanoma skin cancer. 2011 , 37, 1252-9	12
2110	Calculating microscope field area is important for accurately determining melanoma mitotic rate. 2011 , 37, 1820-1	
2109	Prognostic value of galectin-3 in primary cutaneous melanoma. 2011 , 25, 1174-81	22
2108	Is primary melanoma ulceration a factor of good response to adoptive immunotherapy?. 2011 , 25, 1311-7	
2107	AJCC melanoma staging update: impact on dermatopathology practice and patient management. 2011 , 38, 394-400	38
2106	A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. 2011 , 20, 29-34	39
2105	Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. 2011 , 9, 690-9	20
2104	[Sentinel node biopsy between myth and reality]. 2011 , 9, 919-21	1
2103	[For the benefit of the patient: the sentinel node excision]. 2011 , 9, 922-6	2
2102	Embryonic signaling in melanoma: potential for diagnosis and therapy. 2011 , 91, 819-24	38
2101	Upregulated ankyrin repeat-rich membrane spanning protein contributes to tumour progression in cutaneous melanoma. 2011 , 104, 982-8	11
2100	Optimizing the management of cutaneous melanoma in the elderly. 2011 , 150, 828-35	6
2099	Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: a single centre observational cohort study. 2011 , 20, 259-64	23
2098	In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells. 2011 , 365, 76-86	4
2097	Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. 2011 , 212, 454-60; discussion 460-2	58
2096	Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. 2011 , 213, 306-16	75
2095	Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk or extremities. 2011 , 23, 572-8	6
2094	Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk or extremities. 2011 , 23, 569-71	1

2093	Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. 2011 , 17, 4550-7	1434
2092	In Reply: Sentinel Lymph Node Biopsy in Melanoma. 2011 , 18, 598-599	2
2091	Sentinel node dissection delays recurrence and prolongs melanoma-related survival: an analysis of 673 patients from a single center with long-term follow-up. 2011 , 18, 514-20	31
2090	Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. 2011 , 18, 3300-8	41
2089	[Adjuvant systemic treatment of melanoma]. 2011 , 62, 414, 416-22	0
2088	[Treatment of advanced metastatic melanoma]. 2011 , 62, 423-9	1
2087	[State-of-the-art pharmacotherapy of malignant melanoma]. 2011 , 52, 756-64	
2086	Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. 2011 , 60, 487-93	42
2085	Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?. 2011 , 60, 1153-60	52
2084	Outcomes for lymph node-positive cutaneous melanoma over two decades. 2011 , 35, 1567-72	10
2083	Prognostic significance of autoimmunity during treatment of melanoma with interferon. 2011 , 33, 385-91	24
2082	Skin cancer education for primary care physicians: a systematic review of published evaluated interventions. 2011 , 26, 1027-35	52
2081	Opportunistic screening for skin cancer using a mobile unit in Brazil. 2011 , 11, 12	11
2080	Thick primary melanoma has a heterogeneous tumor biology: an institutional series. 2011 , 9, 40	12
2079	Cutaneous melanoma: a model to study cancer metastasis. 2011 , 103, 538-49	27
2078	Can lymphatic drainage of head and neck melanoma be predicted?. 2011 , 103, 751-5	11
2077	Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. 2011 , 104, 379-85	102
2076	Neoadjuvant therapy for high-risk bulky regional melanoma. 2011 , 104, 386-90	20

2075	Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. 2011 , 104, 111-5	74
2074	Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. 2011 , 104, 420-4	42
2073	Evidence-based treatment of early-stage melanoma. 2011 , 104, 341-53	41
2072	Local and intralesional therapy of in-transit melanoma metastases. 2011 , 104, 391-6	65
2071	Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. 2011 , 117, 1711-20	67
2070	A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. 2011 , 117, 4740-06	103
2069	Association between melanoma thickness, clinical skin examination and socioeconomic status: results of a large population-based study. 2011 , 128, 2158-65	36
2068	Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. 2011 , 129, 1435-42	38
2067	Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma. 2011 , 98, 1400-7	7
2066	Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma (Br J Surg 2011; 98: 1400-1407). 2011 , 98, 1407	
2065	The evolving role of radiation therapy in the management of malignant melanoma. 2011 , 80, 645-54	50
2064	Gene regulatory and clinical effects of interferon γ in patients with metastatic melanoma: a phase II trial. 2011 , 31, 433-40	23
2063	Clinical correlates of NRAS and BRAF mutations in primary human melanoma. 2011 , 17, 229-35	206
2062	Is it good or bad to find a BRAF mutation?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1229-30	2.2 9
2061	Re-inventing intratumoral immunotherapy for melanoma. 2011 , 3, 653-71	20
2060	Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. 2011 , 17, 4882-91	43
2059	Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. 2011 , 10, 1520-8	47
2058	Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management. 2011 , 5, 333-60	5

2057	Towards new therapeutic approaches for malignant melanoma. 2011 , 13, e33			32
2056	Plasma markers for identifying patients with metastatic melanoma. 2011 , 17, 2417-25			71
2055	Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer. 2011 , 147, 1395-402			29
2054	Melanoma imaging with highly specific PET probes: ready for prime time?. 2011 , 52, 5-7			8
2053	Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma?. 2011 , 2011, 521947			4
2052	Immunohistochemical Reactivity of the 14F7 Monoclonal Antibody Raised against N-Glycolyl GM3 Ganglioside in Some Benign and Malignant Skin Neoplasms. 2011 , 2011, 848909			21
2051	Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2199-205	2.2		250
2050	Melanoma staging: implications of histologic sectioning procedures. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3943-4	2.2		0
2049	Debulking surgery in advanced melanoma. 2011 , 11, 1703-12			8
2048	False-negative sentinel lymph node biopsy in head and neck melanoma. 2011 , 145, 606-11			36
2047	Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. 2011 , 6, e19330			44
2046	Sentinel lymph node biopsy status is a key parameter to stratify the prognostic heterogeneity of malignant melanoma in high-risk tumors >4.0 mm. 2011 , 222, 59-66			12
2045	A high proliferative index of recurrent melanoma is associated with worse survival. 2011 , 80, 181-7			12
2044	Enrollment in clinical trials correlates with improved survival in metastatic melanoma. 2011 , 81, 403-9			3
2043	High-resolution ultrasound combined with power Doppler sonography can reduce the number of sentinel lymph node biopsies in cutaneous melanoma. 2011 , 222, 180-8			13
2042	Immunotherapy: Tumor-infiltrating T cells--ready for prime time in melanoma?. 2011 , 8, 449-50			
2041	Prognostic usefulness of sentinel lymph node biopsy for patients who have clinically node negative, localized, primary invasive cutaneous melanoma: a Bayesian analysis using informative published reports. 2011 , 147, 408-15			11
2040	Parameters predicting prognosis in melanoma sentinel nodes. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3588-90; author reply 3590-1	2.2		5

2039	Mitotic rate and sentinel lymph node tumor burden topography: integration into melanoma staging and stratification use in clinical trials. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2137-41	2.2	8
2038	New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances. 2011 , 17, 4922-8		32
2037	Specific challenges in the management of subungual melanoma. 2011 , 11, 749-61		13
2036	TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome. 2011 , 105, 1726-32		29
2035	Metastatic melanoma in the older patient: immunologic insights and treatment outcomes. 2011 , 11, 185-93		14
2034	Epidemiología del melanoma cutáneo en Chile. 2011 , 22, 459-465		
2033	New developments in melanoma: utility of ultrasound imaging (initial staging, follow-up and pre-SLNB). 2011 , 11, 1693-701		35
2032	Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome. 2011 , 136, 74-80		5
2031	Ten-year audit of melanoma in a central England population. 2011 , 91, 440-3		5
2030	Fine needle aspiration cytology of palpable and nonpalpable lymph nodes to detect metastatic melanoma. 2011 , 103, 1771-7		28
2029	Decoding melanoma metastasis. 2010 , 3, 126-63		85
2028	Interval sentinel lymph nodes: an unusual localization in patients with cutaneous melanoma. 2011 , 2011, 506790		2
2027	Gender differences in melanoma survival: female patients have a decreased risk of metastasis. 2011 , 131, 719-26		160
2026	Cutaneous melanoma in situ: translational evidence from a large population-based study. 2011 , 16, 896-903		58
2025	Sorafenib and pegylated interferon- α 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. 2011 , 22, 1667-1674		23
2024	Post-embryonic nerve-associated precursors to adult pigment cells: genetic requirements and dynamics of morphogenesis and differentiation. 2011 , 7, e1002044		91
2023	Salvage surgery for a giant melanoma on the back. 2011 , 3, e28		3
2022	Drug targets and predictive biomarkers in the management of metastatic melanoma. 2012 , 5, 139-48		3

2021	H3K79me3T80ph is a Novel Histone Dual Modification and a Mitotic Indicator in Melanoma. 2012 , 2012, 823534	12
2020	BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. 2012 , 18, 33-9	94
2019	Previous pregnancy is a favourable prognostic factor in women with localised cutaneous melanoma. 2012 , 51, 662-8	9
2018	Mining gene expression signature for the detection of pre-malignant melanocytes and early melanomas with risk for metastasis. 2012 , 7, e44800	16
2017	Kinesin family member 20A is a novel melanoma-associated antigen. 2012 , 92, 593-7	28
2016	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012 , 23 Suppl 7, vii86-91	112
2015	Chronology of metastasis in cutaneous melanoma: growth rate model. 2012 , 132, 1215-21	15
2014	Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. 2012 , 287, 28087-98	136
2013	Marges d'efficacité et recommandations. 2012 , 113-121	
2012	Engineering melanoma progression in a humanized environment in vivo. 2012 , 132, 144-53	21
2011	Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. 2012 , 132, 1247-52	48
2010	Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. 2012 , 132, 1471-8	8
2009	Identifying early melanomas at higher risk for metastases. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1406-7 2.2	12
2008	Targeted therapy for brain metastases. 2012 , 65, 109-42	11
2007	Advances and perspectives in immunotherapy of melanoma. 2012 , 23 Suppl 10, x104-8	13
2006	Polarization speckle imaging as a potential technique for in vivo skin cancer detection. 2013 , 18, 061211	24
2005	Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2912-8	2.2 244
2004	Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. 2012 , 72, 716-25	14

2003	CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. 2012 , 18, 2039-47		390
2002	Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1462-7	2.2	134
2001	Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. 2012 , 22, 1-8		54
2000	A brief history of melanoma: from mummies to mutations. 2012 , 22, 114-22		73
1999	Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. 2012 , 22, 287-93		40
1998	A rare case of primary rhabdoid melanoma of the urinary bladder treated with ipilimumab, an anti-CTLA 4 monoclonal antibody. 2012 , 22, 320-5		10
1997	Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma. 2012 , 22, 302-9		19
1996	Periodic acid Schiff loops and blood lakes associated with metastasis in cutaneous melanoma. 2012 , 22, 424-9		14
1995	Vemurafenib-induced neutrophilic panniculitis. 2012 , 22, 399-401		35
1994	Superficial-spreading and nodular melanomas in Norway: a comparison by body site distribution and latitude gradients. 2012 , 22, 460-5		16
1993	Special issue on melanoma. 2012 , 18, 115-6		1
1992	Validation of the Self-Assessment of Melanoma Risk Score for a melanoma-targeted screening. 2012 , 21, 588-95		24
1991	Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. 2012 , 22, 376-85		37
1990	Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. 2012 , 22, 466-72		95
1989	Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. 2012 , 22, 169-75		13
1988	Outcome following local recurrence or in-transit metastases in cutaneous melanoma. 2012 , 22, 447-53		8
1987	Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. 2012 , 23, 524-30		82
1986	Multicohort model for prevalence estimation of advanced malignant melanoma in the USA: an increasing public health concern. 2012 , 22, 454-9		7

1985	Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2375-83	2.2	175
1984	Advances in the treatment of melanoma. 2012 , 12, 168-71		9
1983	Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline. 2012 , 8, e65-e66		3
1982	Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2678-83	2.2	472
1981	Long-term prognosis and significance of the sentinel lymph node in head and neck melanoma. 2012 , 147, 699-706		34
1980	Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3810-8	2.2	204
1979	Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. 2012 , 18, 1386-94		494
1978	Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. 2012 , 4, 127ra37		1562
1977	Adjuvant therapy in melanoma. 2012 , 58-79		
1976	Targeting CD20 in melanoma patients at high risk of disease recurrence. 2012 , 20, 1056-62		54
1975	Is skin self-examination for cutaneous melanoma detection still adequate? A retrospective study. 2012 , 225, 31-6		17
1974	Molecular profiling reveals low- and high-grade forms of primary melanoma. 2012 , 18, 4026-36		81
1973	Advances in sentinel lymph node mapping for patients with melanoma. 2012 , 8, 191-203		
1972	The contribution of health services research to improved dermatologic care. 2012 , 132, 1003-7		1
1971	RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi. 2012 , 132, 687-94		35
1970	Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site. 2012 , 14, 849-58		11
1969	High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. 2012 , 1, 829-839		128
1968	Targeted treatment for melanoma. 2012 , 12, 1113-5		1

1967	Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. 2012 , 25, 828-37		41
1966	Heat and β -adrenergic responsiveness in human skeletal muscle feed arteries: the role of nitric oxide. 2012 , 113, 1690-8		25
1965	Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. 2012 ,		5
1964	Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. 2012 , 25, 493-504		91
1963	Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. 2012 , 107, 422-8		102
1962	Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. 2012 , 109, 7067-72		31
1961	BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2522-9	2.2	353
1960	Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. 2012 , 18, 3242-9		344
1959	Molecular targets in melanoma: time for 'ethnic personalization'. 2012 , 12, 601-8		7
1958	A Generalized Annular Eruption With Occasional VesiclesâDiagnosis. 2012 , 148, 531		
1957	Erythematous Annular Plaques on the TrunkâDiagnosis. 2012 , 148, 531		
1956	Multiple Brown Macules and Papules on a Female TeenagerâDiagnosis. 2012 , 148, 531		
1955	Review and cross-validation of gene expression signatures and melanoma prognosis. 2012 , 132, 274-83		48
1954	Head and neck melanoma. 2012 , 2012, 948302		25
1953	Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. 2012 , 18, 229-37		47
1952	Biomarkers as key contributors in treating malignant melanoma metastases. 2012 , 2012, 156068		15
1951	Smouldering malignant melanoma and metastatic dormancy: an update and review. 2012 , 2012, 461278		6
1950	Histology and outcomes of newly detected lung lesions in melanoma patients. 2012 , 23, 577-582		15

1949	The prognostic value of a reverse transcriptase-PCR assay of sentinel lymph node biopsy for patients with cutaneous melanoma: a single-center analysis in Japan. 2012 , 22, 38-44		15
1948	Ipilimumab in advanced melanoma: reports of long-lasting responses. 2012 , 22, 263-70		39
1947	The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival. 2012 , 22, 386-91		21
1946	Surgery for distant melanoma metastasis. 2012 , 18, 176-84		60
1945	Sentinel lymph node biopsy in melanoma. 2012 , 18, 185-91		25
1944	Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2240-7	2.2	115
1943	Plaques on a Butcher's FingersâDiagnosis. 2012 , 148, 531		1
1942	Prediction of sentinel lymph node positivity by growth rate of cutaneous melanoma. 2012 , 148, 577-84		20
1941	Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases. 2012 , 44, 661-4		2
1940	Systemic therapy for metastatic melanoma in 2012: dawn of a new era. 2012 , 10, 403-12		22
1939	Squamoproliferative lesions arising in the setting of BRAF inhibition. 2012 , 34, 822-6		38
1938	Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. 2012 , 35, 66-72		99
1937	Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12. 2012 , 35, 680-8		5
1936	Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. 2012 , 255, 1165-70		43
1935	Melphalan in regional chemotherapy for locally recurrent metastatic melanoma. 2012 , 12, 53-60		18
1934	Lower tumour burden and better overall survival in melanoma patients with regional lymph node metastases and negative preoperative ultrasound. 2012 , 46, 60-8		9
1933	Improvement in Patient Performance of Skin Self-examinations After Intervention With Interactive Education and Telecommunication Reminders: A Randomized Controlled Study. 2012 , 148, 1266-72		14
1932	Cellular blue naevus involving the urinary bladder. 2012 , 44, 664-8		2

1931	Unanswered questions about margin recommendations for primary cutaneous melanoma. 2012 , 10, 357-65	8
1930	Controversies in the management of regional nodes in melanoma. 2012 , 10, 414-21	3
1929	Effect of adding a diagnostic aid to best practice to manage suspicious pigmented lesions in primary care: randomised controlled trial. 2012 , 345, e4110	55
1928	Management of melanomas in children and young adults. 2012 , 34 Suppl 2, S51-4	22
1927	Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity?. 2012 , 24, 137-40	35
1926	pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas. 2012 , 34, 266-9	40
1925	Diffuse cutaneous uptake of 18F-fluorodeoxyglucose is associated with adverse prognosis in patients with melanoma. 2012 , 33, 1300-1306	
1924	Tumor necrosis is a prognostic factor in thick cutaneous melanoma. 2012 , 36, 1477-82	15
1923	Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. 2012 , 255, 128-33	83
1922	Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. 2012 , 35, 641-9	62
1921	Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. 2012 , 35, 711-5	23
1920	Mucosal melanoma: a clinically and biologically unique disease entity. 2012 , 10, 345-56	89
1919	Tumors of the Vulva and Vagina. 2012 , 587-599	0
1918	Melanoma. 2012 , 10, 366-400	53
1917	Effect of teledermatology on the prognosis of patients with cutaneous melanoma. 2012 , 148, 1025-8	47
1916	[Melanoma in children: diagnosis and treatment specificities]. 2012 , 99, 881-8	
1915	The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007. 2012 , 148, 30-6	73
1914	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. 2012 , 379, 1893-901	744

1913	Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3819-26	2.2	69
1912	Human skeletal muscle feed arteries: evidence of regulatory potential. 2012 , 206, 135-41		9
1911	Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. 2012 , 25, 630-8		45
1910	The patient journey: a report of skin cancer care across Europe. 2012 , 167 Suppl 2, 43-52		11
1909	Molecular diagnostics of melanoma fine-needle aspirates: a cytology-histology correlation study. 2012 , 138, 670-7		25
1908	Improving triage and management of patients with skin cancer: challenges and considerations for the future. 2012 , 12, 609-21		12
1907	Molecular platforms utilized to detect BRAF V600E mutation in melanoma. 2012 , 31, 267-73		43
1906	Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. 2012 , 65, 9-22		89
1905	New diagnostic aids for melanoma. 2012 , 30, 535-45		43
1904	Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. 2012 , 25, 248-58		81
1903	Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. 2012 , 72, 1070-80		370
1902	Melanoma molecular classes and prognosis in the postgenomic era. 2012 , 13, e205-11		27
1901	A tale of two tumours and a plea for progress. 2012 , 13, 124-5		1
1900	Raf kinase inhibitor RKIP inhibits MDA-9/syntenin-mediated metastasis in melanoma. 2012 , 72, 6217-26		49
1899	[Systemic therapy for malignant melanoma]. 2012 , 63, 885-98		4
1898	[Immunotherapy of melanomas]. 2012 , 63, 952-8		0
1897	Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging?. 2012 , 22, 2451-7		24
1896	A novel mouse model of isolated limb perfusion for extremity melanoma. 2012 , 178, 294-8		6

1895	The role of CCND1 alterations during the progression of cutaneous malignant melanoma. 2012 , 33, 2189-99	37
1894	Lesiones pigmentadas. 2012 , 16, 1-9	
1893	Sentinel node status predicts survival in thick melanomas: the Oxford perspective. 2012 , 38, 936-42	19
1892	The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: contemporary estimates of average years of life lost. 2012 , 30, 637-41	5
1891	Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. 2012 , 12, 1087-99	21
1890	Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports. 2012 , 30, 712-20	9
1889	Sentinel node biopsy is indicated for thin melanomas ≤ 0.76 mm. 2012 , 19, 3335-42	57
1888	Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. 2012 , 19, 3313-24	84
1887	Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. 2012 , 19, 3325-34	40
1886	Melanoma: new insights and new therapies. 2012 , 132, 854-63	121
1885	Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. 2012 , 29, 841-6	14
1884	Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites?. 2012 , 19, 3913-8	19
1883	Prognostic value of BRAF(V600E) mutations in melanoma patients after resection of metastatic lymph nodes. 2012 , 19, 4314-21	78
1882	Can we better identify thin cutaneous melanomas that are likely to metastasize and cause death?. 2012 , 19, 3310-2	6
1881	Is a "Merkel" just like a melanoma? The pathologic analysis of Merkel cell carcinoma specimens. 2012 , 19, 3304-6	1
1880	The unique clinical characteristics of melanoma diagnosed in children. 2012 , 19, 3888-95	54
1879	The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. 2012 , 19, 3301-3	27
1878	Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. 2012 , 25, 1000-10	49

1877	Malignant melanoma: advances in diagnosis, prognosis, and treatment. 2012 , 31, 45-9	6
1876	Dermoscopy: an aid to the detection of amelanotic cutaneous melanoma metastases. 2012 , 38, 1437-44	18
1875	Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. 2012 , 308, 1007-14	97
1874	A possible cross-talk between autophagy and apoptosis in generating an immune response in melanoma. 2012 , 17, 1066-78	39
1873	Tumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond. 2012 , 9, 415-23	9
1872	Pediatric melanomas and the atypical spitzoid melanocytic neoplasms. 2012 , 203, 761-7	23
1871	Lymphatic drainage patterns of head and neck cutaneous melanoma: does primary melanoma site correlate with anatomic distribution of pathologically involved lymph nodes?. 2012 , 41, 413-20	25
1870	Neuropeptide Y expression in cutaneous melanoma. 2012 , 66, e201-8	15
1869	Mechanism of putative neo-antigen formation from N-propionyl-4-S-cysteaminylphenol, a tyrosinase substrate, in melanoma models. 2012 , 84, 646-53	11
1868	Value and prognostic significance of mitotic rate in a retrospective series of pT1 cutaneous malignant melanoma patients. 2012 , 36, 303-5	7
1867	Polymorphisms in base excision DNA repair genes and association with melanoma risk in a pilot study on Central-South Italian population. 2012 , 413, 1519-24	9
1866	Association of galectin-3 expression with melanoma progression and prognosis. 2012 , 48, 865-74	45
1865	Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. 2012 , 48, 218-25	146
1864	Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. 2012 , 48, 1842-52	60
1863	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. 2012 , 48, 2375-90	199
1862	The current status of S-100B as a biomarker in melanoma. 2012 , 38, 281-5	38
1861	Hedgehog-Gli signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells. 2012 , 30, 1808-18	117
1860	Sentinel lymph node biopsy in melanoma: our 8-year clinical experience in a single French institute (2002-2009). 2012 , 12, 21	14

1859	Shared care in the follow-up of early-stage melanoma: a qualitative study of Australian melanoma clinicians' perspectives and models of care. 2012 , 12, 468	14
1858	Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib. 2012 , 10, 155	6
1857	Serum microRNAs as biomarkers for recurrence in melanoma. 2012 , 10, 155	104
1856	Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. 2012 , 10, 185	35
1855	Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. 2012 , 10, 192	47
1854	Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". 2012 , 10, 83	10
1853	RACK1, a clue to the diagnosis of cutaneous melanomas in horses. 2012 , 8, 95	10
1852	Arginine deprivation therapy for malignant melanoma. 2013 , 5, 11-9	18
1851	Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. 2012 , 167, 1153-60	138
1850	Melanoma: epidemiology, diagnosis, treatment, and outcomes. 2012 , 30, 113-24, ix	54
1849	Surgical treatment of malignant melanoma: practical guidelines. 2012 , 30, 487-501	16
1848	Prognostic factors for melanoma. 2012 , 30, 469-85	25
1847	Cutaneous head and neck squamous cell carcinoma with regional metastases: the prognostic importance of soft tissue metastases and extranodal spread. 2012 , 19, 274-9	49
1846	The impact of primary melanoma thickness and microscopic tumor burden in sentinel lymph nodes on melanoma patient survival. 2012 , 19, 1034-42	13
1845	Alternatives for the treatment of local advanced disease: electrochemotherapy, limb perfusion, limb infusion, intralesional IL2. What is the role?. 2012 , 25, 443-51	8
1844	New therapeutical strategies in the treatment of metastatic disease. 2012 , 25, 452-7	10
1843	Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies. 2012 , 72, 2207-22	63
1842	Melanoma staging: where are we now?. 2012 , 30, 581-92, v	10

1841	Targeted therapies for metastatic melanoma. 2012 , 30, 517-24	5
1840	Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. 2012 , 19, 2563-71	17
1839	Skin cancer in organ transplant recipients. 2012 , 7, 37-45	1
1838	A new era for the management of metastatic melanoma. 2012 , 7, 27-35	1
1837	BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. 2012 , 8, 499-507	57
1836	EORTC Melanoma Group achievements. 2012 , 10, 112-119	
1835	Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. 2012 , 13, 1087-95	708
1834	Recognition of melanoma: a dermatologic clinical competency in medical student education. 2012 , 67, 606-11	25
1833	Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses. 2012 , 67, 717-26	55
1832	Histologically challenging melanocytic tumors referred to a tertiary care pigmented lesion clinic. 2012 , 67, 727-35	36
1831	N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model. 2012 , 67, 51-60	12
1830	Expression of AP-2 β , AP-2 γ and ESDN in primary melanomas: correlation with histopathological features and potential prognostic value. 2012 , 68, 202-4	11
1829	Relation of serum lactate dehydrogenase to coronary artery disease. 2012 , 110, 1717-22	18
1828	Unique prognostic factors in acral lentiginous melanoma. 2012 , 204, 874-9; discussion 879-80	31
1827	Setting up an effective and efficient sentinel node biopsy service for malignant melanoma within the NHS. 2012 , 65, 351-5	3
1826	Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience. 2012 , 65, 1396-402	10
1825	Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study). 2012 , 48, 3205-14	22
1824	Outcomes and prognostic factors in nodular melanomas. 2012 , 152, 652-9; discussion 659-60	10

1823	Co-development of a companion diagnostic for targeted cancer therapy. 2012 , 29, 682-8	34
1822	Protein and non-protein biomarkers in melanoma: a critical update. 2012 , 43, 2203-30	41
1821	Spirooxindole derivative SOID-8 induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. 2012 , 7, e49306	25
1820	Driving transcriptional regulators in melanoma metastasis. 2012 , 31, 621-32	32
1819	The pathology of melanoma. 2012 , 30, 445-68	17
1818	Screening and prevention measures for melanoma: is there a survival advantage?. 2012 , 14, 458-67	45
1817	Melanoma with unknown primary: report and analysis of 24 patients. 2012 , 29, 2978-84	8
1816	[Survey concerning exposure of staff to UV radiation at four Brussels hospitals]. 2012 , 139, 91-102	1
1815	Progression of cutaneous melanoma: implications for treatment. 2012 , 29, 775-96	27
1814	A potential role for nilotinib in KIT-mutated melanoma. 2012 , 21, 861-9	16
1813	On Analyzing Process Compliance in Skin Cancer Treatment: An Experience Report from the Evidence-Based Medical Compliance Cluster (EBMC2). 2012 , 398-413	18
1812	Immuntherapie des Melanoms. 2012 , 18, 801-807	
1811	Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma. 2012 , 39, 1592-8	20
1810	Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. 2012 , 4, 159ra149	81
1809	Dabrafenib and its potential for the treatment of metastatic melanoma. 2012 , 6, 391-405	70
1808	TGF- β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. 2012 , 181, 2202-16	50
1807	Rare Tumors In Children and Adolescents. 2012 ,	6
1806	Prognosis of sentinel node staged patients with primary cutaneous melanoma. 2012 , 7, e29791	12

1805	Cell cycle gene networks are associated with melanoma prognosis. 2012 , 7, e34247	28
1804	A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts. 2012 , 7, e38222	57
1803	A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. 2012 , 7, e40805	14
1802	CD3 expression in plasma cell neoplasm (multiple myeloma): a diagnostic pitfall. 2012 , 44, 668-70	6
1801	Melanoma. 366-405	
1800	Adjuvant Therapy for Resected Stage III Melanoma Patients: High-Dose Interferon-Alpha versus Ipilimumab Combined with Kinases Inhibitors. 2012 , 98, 185-190	7
1799	Impact of molecular weight on lymphatic drainage of a biopolymer-based imaging agent. 2012 , 4, 276-95	29
1798	Radiation Therapy and Skin Cancer. 2012 ,	0
1797	Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas. 2012 , 46, 246-52	10
1796	Ten years of progress in melanoma. 2012 , 10, 932-5	2
1795	Clinicopathologic and Survival Differences between Upper and Lower Extremity Melanomas. 2012 , 78, 779-787	9
1794	Early Recurrence in Sentinel Lymph Node Positive Stage III Melanoma Patients. 2012 , 78, 808-813	2
1793	Melanoma and Nonmelanoma Skin Cancers. 2012 , 1329-1334	
1792	Melanoma prevention: are we doing enough? A Canadian perspective. 2012 , 19, e462-7	7
1791	Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. 2012 , 16, 532-45	6
1790	Completeness of TNM cancer staging for melanoma in the Danish Cancer Registry, 2004-2009. 2012 , 4 Suppl 2, 5-10	12
1789	Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. 2012 , 4, 243-52	41
1788	Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. 2012 , 4, 299-307	54

1787	20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. 2012 , 19, 627-35	54
1786	Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma. 2012 , 19, 620-6	15
1785	Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVEfi bioreactor. 2012 , 10, 69	71
1784	Advances in cutaneous melanoma. 2012 , 14, 325-32	4
1783	Sentinel lymph node biopsy for thin melanoma-con. 2012 , 106, 217-8	4
1782	Role of sentinel lymphadenectomy in thin cutaneous melanomas with positive deep margins on initial biopsy. 2012 , 106, 363-8	16
1781	Geographic variation in utilization of sentinel lymph node biopsy for intermediate thickness cutaneous melanoma. 2012 , 106, 807-10	9
1780	Melanoma: from mutations to medicine. 2012 , 26, 1131-55	347
1779	Sylatron: a pegylated interferon for use in melanoma. 2012 , 46, 830-8	12
1778	Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. 2012 , 118, 2476-85	180
1777	Behavioral determinants of successful early melanoma detection: role of self and physician skin examination. 2012 , 118, 3725-34	93
1776	NRAS mutation status is an independent prognostic factor in metastatic melanoma. 2012 , 118, 4014-23	483
1775	Single versus multiple primary melanomas: old questions and new answers. 2012 , 118, 4184-92	42
1774	Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. 2012 , 118, 4519-29	24
1773	Side effects in melanoma patients receiving adjuvant interferon alfa-2b therapy: a nurse's perspective. 2012 , 20, 1601-11	9
1772	Integrating new therapies in the treatment of advanced melanoma. 2012 , 13, 327-39	7
1771	Targeting metastatic melanoma. 2012 , 63, 171-83	47
1770	Insights into melanoma: targeting the mTOR pathway for therapeutics. 2012 , 16, 689-705	31

1769	MMP2 expression is a prognostic marker for primary melanoma patients. 2012 , 35, 207-16	52
1768	Advocating Sentinel Node Biopsy in the Management of Cutaneous Melanoma. 2012 , 1, 76-81	
1767	CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma. 2012 , 29, 625-37	22
1766	Pericardial effusion and tamponade following interferon alpha treatment for locally advanced melanoma. 2012 , 29, 1304-7	13
1765	Histological ulceration as a prognostic factor in cutaneous melanoma: a study of 423 cases in Spain. 2012 , 14, 237-40	6
1764	Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness . 2012 , 39, 581-8	15
1763	Sentinel lymph node status as most important prognostic factor in patients with high-risk cutaneous melanomas (tumour thickness >4.00 mm): outcome analysis from a single institution. 2012 , 39, 1316-25	7
1762	Estimating the whole bone-marrow asset in humans by a computational approach to integrated PET/CT imaging. 2012 , 39, 1326-38	46
1761	Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. 2012 , 61, 1033-43	58
1760	[Mitosis in early invasive malignant melanoma. How reliable is histogenetic classification at stage pT1?]. 2012 , 33, 113-7	2
1759	Upcoming strategies for the treatment of metastatic melanoma. 2012 , 304, 177-84	40
1758	A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma. 2012 , 304, 397-400	17
1757	Quantified visual scoring of metastatic melanoma patient treatment response using computed tomography: improving on the current standard. 2012 , 25, 258-65	1
1756	Disease progression in melanoma patients with negative sentinel lymph node: does false-negative specimens entirely account for this phenomenon?. 2012 , 26, 242-8	16
1755	Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. 2012 , 26, 1084-91	16
1754	Sentinel lymph node biopsy for melanoma is becoming a consensus: a national survey of French centres involved in melanoma care in 2008. 2012 , 26, 1230-5	10
1753	A single centre melanoma thickness trend (1985-2009) in relation to skin areas accessible and non-accessible to self-inspection. 2012 , 53, 32-6	6
1752	Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous melanoma: a multi-institutional study of 450 patients in Japan. 2012 , 39, 130-7	20

1751	The cutaneous manifestations of metastatic malignant melanoma. 2012 , 51, 243-9	8
1750	Prognostic tissue markers in melanoma. 2012 , 60, 679-89	10
1749	Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma. 2012 , 39, 324-30	32
1748	Indocyanine green fluorescence-guided sentinel lymph node biopsy in dermatology. 2012 , 10, 51-7	13
1747	Fluoreszenz-Markierung mittels Indocyanin-Grün bei der Sentinel-Lymphknoten-Exstirpation in der Dermatookologie. 2012 , 10, 51-58	10
1746	A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. 2012 , 214, 608-17; discussion 617-9	24
1745	Discussion. 2012 , 214, 617-619	5
1744	Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. 2012 , 1826, 89-102	39
1743	Recent advances in pathologic evaluation and reporting of melanoma. 2012 , 39, 184-91	9
1742	Vaccines for melanoma and renal cell carcinoma. 2012 , 39, 263-75	26
1741	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. 2012 , 61, 702-10	29
1740	Commentary on C. Garbe et al.: "Histopathological diagnostics of malignant melanomas in accordance with the AJCC classification 2009: Revision of the literature and recommendations for general practice". 2012 , 10, 203-4; author reply 205	
1739	Current advances and perspectives in the treatment of advanced melanoma. 2012 , 10, 319-25	6
1738	Aktuelle Fortschritte und Ausblicke in der Therapie des metastasierten Melanoms. 2012 , 10, 319-325	11
1737	The sweet and bitter sides of galectins in melanoma progression. 2012 , 25, 592-601	30
1736	Digital image analysis: a review of reproducibility, stability and basic requirements for optimal results. 2012 , 120, 276-89	29
1735	Small-diameter melanoma: toward a conceptual and practical reappraisal. 2012 , 39, 721-3	11
1734	Expression of vascular endothelial growth factor-C in primary cutaneous melanoma predicts sentinel lymph node positivity. 2012 , 39, 826-34	19

1733 Importancia del índice mitótico en el manejo del melanoma. **2012**, 27, 111-112

1732 Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. **2012**, 166, 1319-26

7

1731 Improving care for patients with melanoma. **2012**, 82, 3-5

0

1730 Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. **2012**, 19, 1774-81

32

1729 Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma. **2012**, 19, 1782-9

25

1728 Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. **2012**, 118, 1040-7

65

1727 Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990-2006. **2012**, 130, 170-8

59

1726 Surgical resection for bulky or recurrent axillary metastatic melanoma. **2012**, 105, 21-5

8

1725 Melanoma in a patient in treatment with eculizumab. **2012**, 91, 135-6

4

1724 Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma. **2013**, 27, 436-41

8

1723 Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. **2013**, 22, 721-36

39

1722 Increase lymphangiogenesis in melanoma during pregnancy: correlation with the prolactin signalling pathway. **2013**, 27, e144-5

12

1721 MicroRNAs in the pathogenesis of malignant melanoma. **2013**, 27, 142-50

23

1720 Correlation among metallothionein expression, intratumoural macrophage infiltration and the risk of metastasis in human cutaneous malignant melanoma. **2013**, 27, e320-7

31

1719 Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". **2013**, 11, 137

18

1718 Immune cell profile of sentinel lymph nodes in patients with malignant melanoma - FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome. **2013**, 11, 43

33

1717 Histopathology Specimens. **2013**,

43

1716 Cutaneous melanoma metastases arising in the donor and recipient sites of a skin graft: case report and review of the literature. **2013**, 36, 45-48

6

1715	Malignant tumors of the penis. 2013 , 39, 527-47	26
1714	Malignant Melanoma. 2013 , 207-216	7
1713	The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma. 2013 , 46, 518-23	12
1712	Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?. 2013 , 39, 305-12	12
1711	Current treatment of locoregional recurrence of melanoma. 2013 , 15, 465-72	18
1710	Assessment of the XPC (A2920C), XPF (T30028C), TP53 (Arg72Pro) and GSTP1 (Ile105Val) polymorphisms in the risk of cutaneous melanoma. 2013 , 139, 1199-206	12
1709	Sentinel node biopsy in thin and thick melanoma. 2013 , 20, 2780-6	58
1708	S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma. 2013 , 20, 2772-9	32
1707	Local immune response predicts survival in patients with thick (t4) melanomas. 2013 , 20, 3610-7	14
1706	Prognosis of acral melanoma: a series of 281 patients. 2013 , 20, 3618-25	94
1705	Age as a prognostic factor in patients with localized melanoma and regional metastases. 2013 , 20, 3961-8	118
1704	Reproducibility of AJCC staging parameters in primary cutaneous melanoma: an analysis of 4,924 cases. 2013 , 20, 3969-75	19
1703	An opportunity to ensure high-quality melanoma care through the use of a preoperative treatment algorithm. 2013 , 20, 3976-83	4
1702	KIR gene variability in cutaneous malignant melanoma: influence of KIR2D/HLA-C pairings on disease susceptibility and prognosis. 2013 , 65, 333-43	11
1701	Whole-body diffusion-weighted imaging: is it all we need for detecting metastases in melanoma patients?. 2013 , 23, 3466-76	29
1700	Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. 2013 , 133, 1653-63	99
1699	60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. 2013 ,	7
1698	Die neue S3-Leitlinie "Melanom" 2013 , 8, 40-48	0

1697	A 10-year, single-institution analysis of clinicopathologic features and sentinel lymph node biopsy in thin melanomas. 2013 , 69, 693-699	19
1696	New therapeutic options in systemic treatment of advanced cutaneous melanoma. 2013 , 22, 181-90	11
1695	Early mobilization after ilio-inguinal lymph node dissection for melanoma does not increase the wound complication rate. 2013 , 39, 185-90	10
1694	Melanoma. 2013 , 11, 1597-1607	
1693	The cost-effectiveness of a novel SIAscopic diagnostic aid for the management of pigmented skin lesions in primary care: a decision-analytic model. 2013 , 16, 356-66	19
1692	Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences. 2013 , 44, 1472-8	23
1691	A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. 2013 , 5, 493-507	29
1690	Adjuvant therapy for high-risk melanoma. 2013 , 11, 106-8	
1689	Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States. 2013 , 48, 2207-13	78
1688	Assessing rural-urban disparities in the use of sentinel lymph node biopsy for melanoma. 2013 , 184, 1157-60	9
1687	Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. 2013 , 190, 6034-42	118
1686	CYTOKINES AND INTERFERONS. 2013 , 251-305	
1685	Melanoma characteristics at diagnosis from the Spanish National Cutaneous Melanoma Registry: 15 years of experience. 2013 , 104, 789-99	27
1684	Risk Factors for the Development of Locoregional Cutaneous Metastases as the Sole Form of Recurrence in Patients With Melanoma. 2013 , 104, 53-60	1
1683	Management of primary cutaneous and metastatic melanoma. 2013 , 29, 195-205	12
1682	Hypoxia-induced senescence contributes to the regulation of microenvironment in melanomas. 2013 , 209, 640-7	17
1681	Immunotherapy for advanced melanoma: fulfilling the promise. 2013 , 39, 879-85	40
1680	Exploitation of long-lived 3IL excited states for metal-organic photodynamic therapy: verification in a metastatic melanoma model. 2013 , 135, 17161-75	226

1679	Dermatologic Ultrasound with Clinical and Histologic Correlations. 2013 ,	40
1678	Diagnosis, Staging, and Follow-up. 2013 , 29-51	
1677	Handbook of Cutaneous Melanoma. 2013 ,	
1676	In vivo confocal microscopy in dermatology: from research to clinical application. 2013 , 18, 061212	37
1675	Malignant melanoma and melanocortin 1 receptor. 2013 , 78, 1228-37	38
1674	Anaesthetic techniques for unique cancer surgery procedures. 2013 , 27, 513-26	13
1673	Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. 2013 , 168, 779-86	33
1672	Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome. 2013 , 133, 3000-7	11
1671	Cutaneous melanoma follow-up: appropriateness of requests for ultrasound tests--the S.Gallicano National Referral Centre Experience. 2013 , 32, 73	5
1670	Clinical impact of (18)F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience. 2013 , 4, 701-9	7
1669	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. 2013 , 11, 202	28
1668	SLN melanoma micrometastasis predictivity of nodal status: a long term retrospective study. 2013 , 32, 47	4
1667	Outcome of clinical stage III melanoma patients with FDG-PET and whole-body CT added to the diagnostic workup. 2013 , 20, 3098-105	22
1666	Stage IV melanoma: completely resectable patients are scarce. 2013 , 20, 2352-6	18
1665	Use of SPECT/CT for improved sentinel lymph node localization in endometrial cancer. 2013 , 129, 42-8	33
1664	Multiple types of data are required to identify the mechanisms influencing the spatial expansion of melanoma cell colonies. 2013 , 7, 137	39
1663	Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma: a case report. 2013 , 8, 192	5
1662	Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal. 2013 , 31, 1121-9	13

1661	Anorectal malignant melanoma in a hemorrhoidal nodule: a diagnostic and therapeutic problem. 2013 , 163, 499-504	
1660	Targeting MAPK pathway in melanoma therapy. 2013 , 32, 567-84	58
1659	Melanoma risk loci as determinants of melanoma recurrence and survival. 2013 , 11, 279	25
1658	Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset. 2013 , 14, 461-71	10
1657	Current management of melanoma. 2013 , 50, 351-82	31
1656	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. 2013 , 49, 3229-41	35
1655	Synthesis, radiofluorination, and in vivo evaluation of novel fluorinated and iodinated radiotracers for PET imaging and targeted radionuclide therapy of melanoma. 2013 , 56, 8455-67	20
1654	Interferon alpha for the adjuvant treatment of cutaneous melanoma. 2013 , CD008955	88
1653	Impact of age on the management of primary melanoma patients. 2013 , 85, 173-81	14
1652	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. 2013 , 10, 588-98	145
1651	Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. 2013 , 9, 245-53	9
1650	Optimal management of metastatic melanoma: current strategies and future directions. 2013 , 14, 179-94	65
1649	Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. 2013 , 20, 1128-35	15
1648	Follow-up of early stage melanoma: specialist clinician perspectives on the functions of follow-up and implications for extending follow-up intervals. 2013 , 107, 463-8	23
1647	Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma. 2013 , 119, 1860-7	7
1646	Prognostic value of sentinel lymph node biopsy compared with that of Breslow thickness: implications for informed consent in patients with invasive melanoma. 2013 , 39, 1800-12	13
1645	Response to a costly revolution for a subgroup of patients with metastatic melanoma. 2013 , 168, 470-471	
1644	Too much surgery and too little benefit? Sentinel node biopsy for melanoma as it currently stands. 2013 , 169, 233-5	5

1643	Chirurgische behandeling melanomen. 2013 , 56, 290-294	1
1642	Malignant Melanoma. 2013 , 635-661	
1641	BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. 2013 , 19, 1225-31	679
1640	Targeting oncogenic drivers and the immune system in melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 499-506	2.2 82
1639	Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. 2013 , 15, 70-80	61
1638	The characterization and potential impact of melanoma cases with unknown thickness in the United States' Surveillance, Epidemiology, and End Results Program, 1989-2008. 2013 , 37, 64-70	21
1637	Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. 2013 , 73, 19-29	120
1636	Diagnosis and management of melanoma with regional lymph node metastases: a population-based study in France. 2013 , 27, 1081-7	2
1635	Relevance of multiple basin drainage and primary histologic regression in prognosis of trunk melanoma patients with negative sentinel lymph nodes. 2013 , 27, 1132-7	13
1634	The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. 2013 , 133, 1052-62	36
1633	Expression of TLR3, 4, 7 and 9 in cutaneous malignant melanoma: relationship with clinicopathological characteristics and prognosis. 2013 , 305, 59-67	24
1632	A nine-gene signature predicting clinical outcome in cutaneous melanoma. 2013 , 139, 249-58	54
1631	Surgery and the management of cutaneous melanoma. 2013 , 100, 313-5	2
1630	Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience. 2013 , 31, 298-310	20
1629	Melanoma Characteristics at Diagnosis From The Spanish National Cutaneous Melanoma Registry: 15 Years of Experience. 2013 , 104, 789-799	2
1628	β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. 2013 , 49, 3863-71	44
1627	Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. 2013 , 85, 325-34	56
1626	Mãgenes de reseccão oncolãgica en cirugã dermatolãgica. 2013 , 47, 1-9	

1625	Effect of β -blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. 2013 , 88, 1196-203		54
1624	The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs. 2013 , 4, 40-3		1
1623	CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. 2013 , 69, 105-13		10
1622	The lymph node ratio has limited prognostic significance in melanoma. 2013 , 179, 10-7		4
1621	Incidence of sentinel lymph node involvement in a modern, large series of desmoplastic melanoma. 2013 , 217, 37-44; discussion 44-5		12
1620	Targeting BRAF in melanoma: biological and clinical challenges. 2013 , 87, 239-55		32
1619	Do vitamin A serum levels moderate outcome or the protective effect of vitamin D on outcome from malignant melanoma?. 2013 , 32, 1012-6		6
1618	Stage III melanoma in the axilla: patterns of regional recurrence after surgery with and without adjuvant radiation therapy. 2013 , 86, 702-8		5
1617	Sentinel lymph node biopsy for melanoma in pregnant women. 2013 , 20, 689-96		40
1616	Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4252-9	2.2	188
1615	Atypical fibroxanthoma-like amelanotic malignant melanoma: A case report and literature review. 2013 , 31, 140-144		6
1614	Therapy response assessment in metastatic melanoma patients treated with a BRAF inhibitor: adapted Choi criteria can reflect early therapy response better than does RECIST. 2013 , 20, 423-9		4
1613	Expression of the vitamin D-activating enzyme 1 α -hydroxylase (CYP27B1) decreases during melanoma progression. 2013 , 44, 374-87		56
1612	The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases. 2013 , 39, 304-10		10
1611	Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. 2013 , 39, 179-84		19
1610	Melanoma epidemiology, biology and prognosis. 2013 , 11, 81-91		116
1609	Risk factors for the development of locoregional cutaneous metastases as the sole form of recurrence in patients with melanoma. 2013 , 104, 53-60		7
1608	MST1 activation by curcumin mediates JNK activation, Foxo3a nuclear translocation and apoptosis in melanoma cells. 2013 , 441, 53-8		43

1607	Surgical Treatment of Melanoma Liver Metastases. 2013 , 91, 4-8	
1606	Mitotic rate in melanoma should be recorded as the number of mitoses per mm ² (not per high power field): surgeons tell your pathologists!. 2013 , 206, 142-3	5
1605	[Surgical treatment of melanoma liver metastases]. 2013 , 91, 4-8	
1604	Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. 2013 , 85, 149-61	28
1603	Analysis of sentinel lymph node positivity in patients with thin primary melanoma. 2013 , 68, 560-567	43
1602	Selective sentinel lymph node dissection in head and neck cutaneous melanoma. 2013 , 24, 13-18	
1601	A novel o-naphtoquinone inhibits N-cadherin expression and blocks melanoma cell invasion via AKT signaling. 2013 , 27, 2076-83	14
1600	Translational research in melanoma. 2013 , 22, 785-804	
1599	Skin cancer. 2013 , 41, 402-405	10
1598	Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay. 2013 , 334, 202-10	15
1597	Amelanotic acral melanomas: clinicopathological, BRAF mutation, and KIT aberration analyses. 2013 , 69, 700-707	28
1596	Outcomes and prognostic factors in superficial spreading melanoma. 2013 , 206, 861-7; discussion 867-8	12
1595	The challenge of developing useful blood-based biomarkers in melanoma. 2013 , 168, 3	4
1594	'Monster cell' melanoma with pulmonary metastasis and cyclin D1 amplification. 2013 , 40, 61-5	10
1593	DNA repair and replication proteins as prognostic markers in melanoma. 2013 , 62, 343-50	18
1592	A 10-year analysis of primary cutaneous malignant melanoma with sentinel lymph node biopsy and long-term follow-up. 2013 , 52, 220-30	11
1591	Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. 2013 , 73, 1063-75	239
1590	TNF-alpha and melphalan modulate a specific group of early expressed genes in a murine melanoma model. 2013 , 62, 217-25	5

1589	Diversity of stage III melanoma in the era of sentinel lymph node biopsy. 2013 , 20, 956-63	22
1588	Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?. 2013 , 13, 643-56	21
1587	Melanoma. 2013 , 21, 33-42	18
1586	Detection and analysis of irregular streaks in dermoscopic images of skin lesions. 2013 , 32, 849-61	75
1585	Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma. 2013 , 26, 1153-60	56
1584	Melanoma immunotherapy: historical precedents, recent successes and future prospects. 2013 , 5, 169-82	24
1583	Developing melanoma therapeutics: overview and update. 2013 , 5, 257-71	13
1582	Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?. 2013 , 20, 3089-97	58
1581	Vemurafenib in melanoma. 2013 , 13, 513-22	8
1580	Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. 2013 , 31, 237-50	35
1579	1 or 2 cm margins of excision for T2 melanomas: do they impact recurrence or survival?. 2013 , 20, 346-51	33
1578	Molecular networks in melanoma invasion and metastasis. 2013 , 9, 713-26	36
1577	Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. 2013 , 39, 27-43	10
1576	Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease. 2013 , 68, 1.e1-9; quiz 10-12	5
1575	Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. 2013 , 4, e719	103
1574	Présentation et implications cliniques des marqueurs génétiques dans le mélanome malin cutané. 2013 , 15, 83-90	
1573	Ipilimumab and its toxicities: a multidisciplinary approach. 2013 , 18, 733-43	244
1572	Molecularly targeted therapies for melanoma. 2013 , 52, 523-30	13

1571	[Personalized therapy concepts for malignant melanoma]. 2013 , 54, 188-93	3
1570	Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity. 2013 , 191, 5097-106	18
1569	Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas. 2013 , 137, 1063-73	18
1568	Intracerebral metastases of malignant melanoma and their recurrences--a clinical analysis. 2013 , 115, 1721-8	10
1567	MEK inhibition in the treatment of advanced melanoma. 2013 , 15, 473-82	17
1566	Poor correlation between spectrophotometric intracutaneous analysis and histopathology in melanoma and nonmelanoma lesions. 2013 , 18, 061223	13
1565	Nestin is highly expressed in advanced-stage melanomas and neurotized nevi. 2013 , 29, 1595-9	14
1564	CYFRA21-1 as a serum tumor marker for follow-up patients with squamous cell lung carcinoma and oropharynx squamous cell carcinoma. 2013 , 7, 591-9	12
1563	A clinicopathologic analysis of 177 acral melanomas in Koreans: relevance of spreading pattern and physical stress. 2013 , 149, 1281-8	90
1562	Using the 7-point checklist as a diagnostic aid for pigmented skin lesions in general practice: a diagnostic validation study. 2013 , 63, e345-53	34
1561	Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. 2013 , 26, 404-13	66
1560	Polymorphisms of nucleotide excision repair genes predict melanoma survival. 2013 , 133, 1813-21	39
1559	B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. 2013 , 133, 2050-8	97
1558	Pathophysiological characteristics of melanoma in-transit metastasis in a lymphedema mouse model. 2013 , 133, 537-44	11
1557	Methods to improve adoptive T-cell therapy for melanoma: IFN- γ enhances anticancer responses of cell products for infusion. 2013 , 133, 545-52	30
1556	Plasma microRNA-21 is associated with tumor burden in cutaneous melanoma. 2013 , 133, 1381-4	33
1555	Age-related telomere uncapping is associated with cellular senescence and inflammation independent of telomere shortening in human arteries. 2013 , 305, H251-8	65
1554	Interobserver variability of histopathological prognostic parameters in cutaneous malignant melanoma: impact on patient management. 2013 , 93, 411-6	18

1553	Sentinel lymph node biopsy for cutaneous melanoma: a 6 years study. 2013 , 46, 92-7	6
1552	Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. 2013 , 20, e165-9	27
1551	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. 2013 , 24, 1697-703	237
1550	Lack of standards for the detection of melanoma in sentinel lymph nodes: a survey and recommendations. 2013 , 137, 1603-9	19
1549	The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. 2013 , 133, 751-758	71
1548	Aggravating cough in a patient with suspected sarcoidosis. 2013 , 68, 117-8	1
1547	Jatrorrhizine hydrochloride inhibits the proliferation and neovascularization of C8161 metastatic melanoma cells. 2013 , 24, 667-76	36
1546	Prognostic significance of drainage to pelvic nodes at sentinel lymph node mapping in patients with extremity melanoma. 2013 , 23, 40-6	7
1545	Socioeconomic status as a predictor of melanoma survival in a series of 1083 cases from Brazil: just a marker of health services accessibility?. 2013 , 23, 199-205	13
1544	Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis. 2013 , 23, 461-7	19
1543	Ambiguous melanocytic tumors in a tertiary referral center: the contribution of fluorescence in situ hybridization (FISH) to conventional histopathologic and immunophenotypic analyses. 2013 , 37, 1783-96	26
1542	Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. 2013 , 23, 47-54	41
1541	Characteristics and survival of patients with invasive amelanotic melanoma in the USA. 2013 , 23, 408-13	35
1540	Update on the role of ipilimumab in melanoma and first data on new combination therapies. 2013 , 25, 166-72	22
1539	Indicators of the standard of care for melanoma: Tuscany data. 2013 , 23, 283-9	6
1538	Completion lymph node dissection after a positive sentinel node: no longer a must?. 2013 , 25, 152-9	17
1537	Opportunistic screening strategy for cutaneous melanoma does not change the incidence of nodular and thick lesions nor reduce mortality: a population-based descriptive study in the European region with the highest incidence. 2013 , 23, 402-7	13
1536	Molecular biomarkers of prognosis in melanoma: how far are we from the clinic?. 2013 , 23, 423-5	3

1535	Multiple primary cutaneous melanomas: recent studies highlight features associated with more indolent behaviour. 2013 , 45, 1-3		2
1534	New developments in biomarkers for melanoma. 2013 , 25, 145-51		17
1533	High hERG1 expression in advanced melanoma. 2013 , 23, 185-90		2
1532	Is the mitotic rate of 1/mm ² the correct cutoff point for performing sentinel lymph node biopsy in pregnant patients with thin melanoma?. 2013 , 23, 420-1		
1531	Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma. 2013 , 9, 2427-33		10
1530	Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4387-93	2.2	173
1529	Preoperative risk factors of lymph node metastasis in cutaneous squamous cell carcinoma. 2013 , 47, 204-8		6
1528	Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma. 2013 , 149, 1403-6		18
1527	Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. 2013 , 24, 2174-80		130
1526	B-Mode Ultrasound Imaging, Doppler Imaging, and Real-Time Elastography in Cutaneous Malignant Melanoma and Lymph Node Metastases. 2013 , 1, 84-95		8
1525	Host risk factors, ultraviolet index of residence, and incident malignant melanoma in situ among US women and men. 2013 , 177, 997-1005		17
1524	Who should be offered a sentinel node biopsy for melanoma less than 1 mm in thickness?. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4385-6	2.2	3
1523	Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. 2013 , 22, 827-34		16
1522	Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. 2013 , 6, ra7		96
1521	Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. 2013 , 5, 105-18		31
1520	BRAF in melanoma: current strategies and future directions. 2013 , 19, 4326-34		65
1519	New combinations and immunotherapies for melanoma: latest evidence and clinical utility. 2013 , 5, 278-85		21
1518	Clinical characteristics and survival data of melanoma patients with nevus cell aggregates within sentinel lymph nodes. 2013 , 139, 566-73		26

1517	Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy. 2013 , 36, 52-6		5
1516	Comments and controversies: sentinel node and lymphadenectomy in melanoma: staging or therapeutical?: what to expect from the multicenter selective lymphadenectomy trial-1 results in melanoma?. 2013 , 23, 181-4		2
1515	Dabrafenib for treatment of BRAF-mutant melanoma. 2014 , 7, 21-9		12
1514	Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. 2013 , 2013, 898719		12
1513	Immunotherapy in advanced cutaneous melanoma patients. 2013 , 5, 429-433		
1512	Immunotherapy in the management of melanoma: current status. 2013 , 2, 1-10		2
1511	Accuracy of diagnostic biopsy for cutaneous melanoma: implications for surgical oncologists. 2013 , 2013, 196493		13
1510	Sentinel lymph node biopsy in patients with thick primary cutaneous melanoma: patterns of use and underuse utilizing a population-based model. 2013 , 2013, 315609		3
1509	Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPRCAP, and Magnetite Nanoparticles. 2013 , 2013, 742925		10
1508	Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. 2013 , 2013, 857519		151
1507	Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids. 2013 , 2013, 897348		14
1506	Prediction of sentinel node status and clinical outcome in a melanoma centre. 2013 , 2013, 904701		6
1505	Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. 2013 , 19, 3977-86		111
1504	Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. 2013 , 2, e25564		6
1503	Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2337-46	2.2	103
1502	Favourable prognostic role of regression of primary melanoma in AJCC stage I-II patients. 2013 , 169, 1240-5		39
1501	Clinicopathologic analysis of 66 Japanese thin melanomas with metastasis of sentinel or regional lymph node. 2013 , 40, 1027-34		4
1500	Importance of vertical pathology of debulking specimens during Mohs micrographic surgery for lentigo maligna and melanoma in situ. 2013 , 39, 365-71		28

1499	Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment. 2013 , 54, 163-72	10
1498	Dynamic prognostication using conditional survival estimates. 2013 , 119, 3589-92	67
1497	Expression analysis of ovostatin 2 reveals its involvement in proliferation, invasion and angiogenesis of cutaneous malignant melanoma. 2013 , 40, 901-10	4
1496	A costly revolution for a subgroup of patients with metastatic melanoma. 2013 , 168, 467-70; discussion 470-1	3
1495	CD133+ cell content correlates with tumour growth in melanomas from skin with chronic sun-induced damage. 2013 , 169, 830-7	7
1494	Commentary: transecting melanomas: does it matter?. 2013 , 39, 616-7	
1493	Serum epidermal growth factor receptor levels in patients with malignant melanoma. 2013 , 38, 172-7	3
1492	Prognostic sub-classifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark level of invasion. Results of a population-based study from the Swedish Melanoma Register. 2013 , 168, 685-6	1
1491	Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden. 2013 , 26, 708-22	10
1490	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. 2013 , 2, 76-85	102
1489	Malignancies of the eyelid: a review of primary and metastatic cancers. 2013 , 52, 903-26; quiz 922-3, 926	5
1488	Prognosis of patients with transected melanomas. 2013 , 39, 605-15	8
1487	Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases. 2013 , 169, 172-6	19
1486	Icariside II induces apoptosis of melanoma cells through the downregulation of survival pathways. 2013 , 65, 110-7	22
1485	Vemurafenib enhances MHC induction in BRAF homozygous melanoma cells. 2013 , 2, e22890	104
1484	Longitudinal melanonychia: detection and management of nail melanoma. 2013 , 18, 133-9	26
1483	Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. 2013 , 16, 202-12	40
1482	Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. 2013 , 105, 33-46	78

1481	Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients. 2013 , 108, 1641-7		17
1480	The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987-2009: a registry-based cohort study. 2013 , 109, 265-71		27
1479	Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3831-7	2.2	70
1478	BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. 2013 , 133, 509-17		131
1477	Sentinel lymph node biopsy followed by lymph node dissection for early cutaneous melanoma. 2013 ,		1
1476	Malignes Melanom S3-Leitlinie âDiagnostik, Therapie und Nachsorge des Melanomsâ 2013 , 11, 1-126		3
1475	Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". 2013 , 11 Suppl 6, 1-116, 1-126		79
1474	The epidemiology of melanoma in young adults. 2013 , 8, 707-716		
1473	Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients. 2013 , 227, 55-61		12
1472	Recent advances in the treatment of melanoma. 2013 , 20, 244-5		0
1471	New targeted therapies in melanoma. 2013 , 20, 282-8		10
1470	Care and monitoring of a mouse model of melanoma. 2013 , 42, 92-8		2
1469	Surgical management of subungual melanoma: mayo clinic experience of 124 cases. 2013 , 71, 346-54		39
1468	Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma. 2013 , 226 Suppl 1, 22-7		4
1467	Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. 2013 , 20, 289-97		80
1466	Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. 2013 , 148, 879-84		38
1465	Predicting disease progression after regional therapy for in-transit melanoma. 2013 , 148, 493-8		8
1464	Das Wichtigste ff.die Praxis. 2013 , 29, 294-301		

1463	Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. 2013 , 35, 125-8	3
1462	Differences in tumor thickness between hematoxylin and eosin and Melan-A immunohistochemically stained primary cutaneous melanomas. 2013 , 35, 56-63	13
1461	Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. 2013 , 37, 61-5	254
1460	S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version. 2013 , 11, 563-602	29
1459	The new AJCC guidelines in practice: utility of the MITF immunohistochemical stain in the evaluation of single-cell metastasis in melanoma sentinel lymph nodes. 2013 , 37, 933-7	10
1458	Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. 2013 , 37, 676-84	141
1457	Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis. 2013 , 37, 882-9	25
1456	Managing malignant melanoma. 2013 , 132, 446e-460e	32
1455	Evidence-based medicine: facial skin malignancy. 2013 , 132, 1631-1643	9
1454	Anal versus rectal melanoma: does site of origin predict outcome?. 2013 , 56, 150-7	46
1453	Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study. 2013 , 149, 921-7	26
1452	Plasma osteopontin concentrations in patients with cutaneous melanoma. 2013 , 30, 1575-80	11
1451	[Stage distribution of malignant melanomas in a Hungarian centre]. 2013 , 154, 969-76	1
1450	Melanoma epidemiology of Austria reveals gender-related differences. 2013 , 23, 872-8	11
1449	Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. 2013 , 32, 82	16
1448	Encyclopedia of Otolaryngology, Head and Neck Surgery. 2013 , 1463-1463	
1447	Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases. 2013 , 13, 306-13	29
1446	Sentinel node biopsy should not be recommended for patients with thick melanoma. 2013 , 40, 127-9	6

1445	Dermoscopic features of thin melanomas: a comparative study of melanoma in situ and invasive melanomas smaller than or equal to 1mm. 2013 , 88, 712-7	30
1444	Melanoma follow up: time to generate the evidence. 2013 , 37, 501-3	1
1443	Accuracy of preoperative MRI with microscopy coil in evaluation of primary tumor thickness of malignant melanoma of the skin with histopathologic correlation. 2013 , 14, 287-93	6
1442	Epidemiological aspects of melanoma at a university hospital dermatology center over a period of 20 years. 2013 , 88, 344-53	10
1441	Primary dermal melanoma latent for more than 10 years. 2013 , 25, 385-6	2
1440	Diagnostic implications of loss of 5-hydroxymethylcytosine for melanoma. 2013 , 8, 99-101	3
1439	Electron Paramagnetic Resonance Spectrometry and Imaging in Melanomas: Comparison between Pigmented and Nonpigmented Human Malignant Melanomas. 2013 , 12, 7290.2012.00037	14
1438	Integrative genomics identifies gene signature associated with melanoma ulceration. 2013 , 8, e54958	24
1437	A patient-centered methodology that improves the accuracy of prognostic predictions in cancer. 2013 , 8, e56435	4
1436	Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. 2013 , 8, e57665	30
1435	Lipopeptide biosurfactant pseudofactin II induced apoptosis of melanoma A 375 cells by specific interaction with the plasma membrane. 2013 , 8, e57991	47
1434	Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis. 2013 , 8, e63137	18
1433	Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour. 2013 , 8, e66953	18
1432	In-depth characterization of microRNA transcriptome in melanoma. 2013 , 8, e72699	98
1431	Decreased expression of nuclear p300 is associated with disease progression and worse prognosis of melanoma patients. 2013 , 8, e75405	16
1430	Joint effect of multiple common SNPs predicts melanoma susceptibility. 2013 , 8, e85642	36
1429	18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma. 2013 , 52, 198-203	18
1428	Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. 2013 , 17, 257-62	8

1427	Treatment outcomes of advanced stage malignant melanoma in hand and foot after amputation in Korean patients. 2013 , 5, 314-20	0
1426	Penile primary melanoma: analysis of 6 patients treated at Brazilian National Cancer Institute in the last eight years. 2013 , 39, 823-31	14
1425	Signal transduction in human cutaneous melanoma and target drugs. 2013 , 13, 843-66	44
1424	Overcoming Resistance to BRAF and MEK Inhibitors by Simultaneous Suppression of CDK4. 2013 ,	
1423	Challenges involved in risk assessment of atypical Spitz tumors. 2013 , 8, 217-219	
1422	Acquired Resistance to Targeted MAPK Inhibition in Melanoma. 2013 ,	
1421	Current Management of Malignant Melanoma: State of the Art. 2013 ,	3
1420	Prevalence of BRAF and NRAS Mutations and a Comparative Analysis in Primary and Metastatic Melanoma of Korean Patients. 2014 , 37, 30	2
1419	BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. 2014 , 124, 5074-84	46
1418	Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. 2014 , 6, 279-89	17
1417	Benign Melanocytic Lesions and Melanoma. 2014 , 1182-1192	
1416	Survival according to BRAF-V600 tumor mutations--an analysis of 437 patients with primary melanoma. 2014 , 9, e86194	35
1415	A natural bacterial-derived product, the metalloprotease arzyme, inhibits metastatic murine melanoma by inducing MMP-8 cross-reactive antibodies. 2014 , 9, e96141	6
1414	Insulin-like-growth-factor-binding-protein-3 (IGFBP-3) contrasts melanoma progression in vitro and in vivo. 2014 , 9, e98641	13
1413	Current and future roles of targeted therapy and immunotherapy in advanced melanoma. 2014 , 20, 346-56	44
1412	Sentinel lymph node biopsy for melanoma: an important risk-stratification tool. 2014 , 201, 442-4	1
1411	Polypoid melanoma and superficial spreading melanoma different subtypes in the same lesion. 2014 , 89, 666-8	5
1410	Malignant Melanoma. 2013 , 2, 1-19	22

1409	Established and Emerging Biomarkers in Cutaneous Malignant Melanoma. 2014 , 2, 60-73	6
1408	Update and Review on the Surgical Management of Primary Cutaneous Melanoma. 2014 , 2, 234-49	12
1407	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. 2014 , 5, 165	99
1406	STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFN- γ Therapy in Stage III Melanoma Patients. 2014 , 1, 47	0
1405	Mucosal melanomas in the elderly: challenging cases and review of the literature. 2014 , 9, 929-37	14
1404	Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study. 2014 , 33, 356-64	36
1403	Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study. 2014 , 26, 195-202	21
1402	The clinical features and optimal treatment of anorectal malignant melanoma. 2014 , 87, 113-7	26
1401	Long-term survival analysis and clinical follow-up in acral lentiginous malignant melanoma undergoing sentinel lymph node biopsy in korean patients. 2014 , 26, 177-83	8
1400	Clinicopathological Predictive Factors of Melanoma Lung Metastases. 2014 , 03,	
1399	Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure. 2014 , 26, 485-90	15
1398	Melanoma developed during pregnancy--a case report. 2014 , 89, 157-9	3
1397	Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. 2014 , 32, 808-14	6
1396	Dormancy of growth-stunted malignant melanoma: sustainable and smoldering patterns. 2014 , 8, 252	7
1395	An incidental finding of a nodal recurrence of cutaneous malignant melanoma after a 45-year disease-free period. 2014 , 2014,	3
1394	Health-related quality of life in patients with melanoma expressed as utilities and disability weights. 2014 , 171, 1443-50	22
1393	Biomarkers in melanoma: where are we now?. 2014 , 1, 139-150	1
1392	Excision of fascia in melanoma thicker than 2 mm: no evidence for improved clinical outcome. 2014 , 171, 1391-6	11

1391	The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis. 2014 , 25, 240-6	29
1390	Society for Melanoma Research 2014 Congress. 2014 , 27, 1169-1241	8
1389	A pilot study of extralevator abdominoperineal excision for primary melanoma of the anorectum. 2014 , 18, 1113-6	3
1388	HF ultrasound vs PET-CT and telethermography in the diagnosis of In-transit metastases from melanoma: a prospective study and review of the literature. 2014 , 33, 96	18
1387	The role of skin self-examination at the Swiss skin cancer day. 2014 , 14, 581	5
1386	Risk prediction models for melanoma: a systematic review. 2014 , 23, 1450-63	80
1385	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. 2014 , 12, 277	10
1384	Malignant melanoma metastasis to the colon: a curable lesion. 2014 , 18, 1189-90	2
1383	Prognostic impact of p62 expression in cutaneous malignant melanoma. 2014 , 134, 1476-1478	30
1382	Molecular pathology of cutaneous melanoma. 2014 , 1, 151-164	3
1381	Successes and limitations of targeted cancer therapy in melanoma. 2014 , 41, 78-88	3
1380	Sentinel lymph node biopsy in melanoma: controversies and current guidelines. 2014 , 10, 429-42	10
1379	Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib. 2014 , 12, 151-4	
1378	A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms. 2014 , 134, 1359-1368	35
1377	Prognostic impact of PHIP copy number in melanoma: linkage to ulceration. 2014 , 134, 783-790	9
1376	Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. 2014 , 13, 2769-83	51
1375	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program. 2014 , 32, 144-9	74
1374	Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. 2014 , 134, 2202-2211	42

1373	Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. 2014 , 25, 747-753	42
1372	Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. 2014 , 20, 1601-9	192
1371	Vemurafenib. 2014 , 201, 215-25	23
1370	Primary anorectal malignant melanoma treated with neoadjuvant chemoradiotherapy and sphincter-sparing surgery: A case report. 2014 , 7, 1605-1607	3
1369	Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal. 2014 , 12, e1001966	86
1368	Association of TNFRSF10D DNA-methylation with the survival of melanoma patients. 2014 , 15, 11984-95	5
1367	Vaccines against Cancer. 2014 ,	
1366	Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. 2014 , 150, 1306-314	101
1365	A single institution retrospective analysis of malignant melanoma. 2014 , 10, 38-42	11
1364	Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. 2014 , 11, e1001604	37
1363	Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. 2014 , 94, 45-9	34
1362	Final trial report of sentinel-node biopsy versus nodal observation in melanoma. 2014 , 370, 599-609	910
1361	Association of sentinel lymph node biopsy with survival for head and neck melanoma: survival analysis using the SEER database. 2014 , 140, 1101-9	29
1360	'This isn't what mine looked like': a qualitative study of symptom appraisal and help seeking in people recently diagnosed with melanoma. 2014 , 4, e005566	44
1359	Key regulators of apoptosis execution as biomarker candidates in melanoma. 2014 , 1, e964037	10
1358	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. 2014 , 26, 193-201	14
1357	High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. 2014 , 1, 7-10	1
1356	Tree Structure for Modeling Skin Lesion Growth. 2014 , 191-209	

1355	Systemic treatments for metastatic cutaneous melanoma. 2014,	7
1354	Molecular pathology of skin neoplasms of the head and neck. 2014, 138, 759-87	37
1353	Adenovirus-mediated FKHL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide. 2014, 25, 186-95	9
1352	Budget impact analysis of a novel gene expression assay for the diagnosis of malignant melanoma. 2014, 17, 782-91	9
1351	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. 2014, 40, 1056-64	146
1350	Epigenetic markers of prognosis in melanoma. 2014, 1102, 481-99	5
1349	Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab. 2014, 270, 425-34	22
1348	Histopathological characteristics of subsequent melanomas in patients with multiple primary melanomas. 2014, 28, 58-64	15
1347	Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients. 2014, 23, 202-4	32
1346	Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. 2014, 13, 3210-8	20
1345	Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy. 2014, 134, 1686-1692	69
1344	Vemurafenib significantly decreases glomerular filtration rate. 2014, 28, 978-9	16
1343	Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients. 2014, 229, 183-9	12
1342	Metastatic melanoma to the upper aerodigestive tract: a systematic review of the literature. 2014, 124, 1143-9	12
1341	Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions. 2014, 170, 802-8	111
1340	Inherited variation in the PARP1 gene and survival from melanoma. 2014, 135, 1625-33	22
1339	Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. 2014, 110, 770-5	47
1338	To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence?. 2014, 68, 761-70	28

1337	Survival after cutaneous melanoma in kidney transplant recipients: a population-based matched cohort study. 2014 , 14, 1368-75	32
1336	Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma. 2014 , 25, 2052-2058	46
1335	Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study. 2014 , 170, 930-8	46
1334	Loss of XRCC1 confers a metastatic phenotype to melanoma cells and is associated with poor survival in patients with melanoma. 2014 , 27, 366-75	12
1333	The association of host and genetic melanoma risk factors with Breslow thickness in the Western Australian Melanoma Health Study. 2014 , 170, 851-7	8
1332	Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma. 2014 , 109, 314-9	32
1331	Combined clearance of pelvic and superficial nodes for clinical groin melanoma. 2014 , 67, 1711-8	3
1330	Mucosal melanoma of the head and neck: a systematic review of the literature. 2014 , 90, 1108-18	80
1329	High expression of FOXP3 in primary melanoma is associated with tumour progression. 2014 , 170, 103-9	40
1328	Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. 2014 , 109, 780-5	21
1327	Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. 2014 , 170, 20-30	48
1326	The Italian Euromelanoma Day: evaluation of results and implications for future prevention campaigns. 2014 , 53, 699-706	12
1325	Why is melanoma so metastatic?. 2014 , 27, 19-36	69
1324	High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. 2014 , 29, 53-7	13
1323	Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice. 2014 , 53, e499-506	4
1322	Podoplanin expression in cancer-associated fibroblasts predicts aggressive behavior in melanoma. 2014 , 41, 561-7	32
1321	Assessment of SIAscopy in the triage of suspicious skin tumours. 2014 , 20, 440-4	13
1320	Clinical and prognostic factors for melanoma of the skin using SEER registries: collaborative stage data collection system, version 1 and version 2. 2014 , 120 Suppl 23, 3807-14	36

1319	Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses. 2014 , 2, 668-78	66
1318	Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. 2014 , 25, 2277-2284	108
1317	Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. 2014 , 10, 1355-64	15
1316	The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation. 2014 , 10 Suppl S3, 1-15	2
1315	Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma. 2014 , 171, 403-8	10
1314	Quality assurance for care of melanoma patients based on guideline-derived quality indicators and certification. 2014 , 12, 139-47	8
1313	Expression and prognostic significance of CIP2A in cutaneous malignant melanoma. 2014 , 19, 70-6	11
1312	Characteristics and associations of high-mitotic-rate melanoma. 2014 , 150, 1048-55	50
1311	Association between sleep disordered breathing and aggressiveness markers of malignant cutaneous melanoma. 2014 , 43, 1661-8	72
1310	MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma. 2014 , 13, 1599-610	20
1309	A probabilistic analysis of mitotic counts in melanoma. 2014 , 141, 213-8	7
1308	New options for the adjuvant treatment of cutaneous melanoma?. 2014 , 16, 409	6
1307	Distinguishing between benign and malignant melanocytic nevi by in vivo multiphoton microscopy. 2014 , 74, 2688-97	70
1306	Prognostic differences across sexes in melanoma patients: what has changed from the past?. 2014 , 24, 568-76	19
1305	Melanomas of unknown primary frequently harbor TERT-promoter mutations. 2014 , 24, 131-6	30
1304	Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. 2014 , 24, 150-7	10
1303	Inpatient homogeneity of BRAFV600E expression in melanoma. 2014 , 38, 377-82	56
1302	Mitotic rate for thin melanomas: should a single mitotic figure warrant a sentinel lymph node biopsy?. 2014 , 40, 937-45	15

1301	Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. 2014 , 36, 363-79	69
1300	A qualitative assessment of psychosocial impact, coping and adjustment in high-risk melanoma patients and caregivers. 2014 , 24, 252-60	30
1299	Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma. 2014 , 24, 468-74	32
1298	EGFR and cyclin D1 in nodular melanoma: correlation with pathohistological parameters and overall survival. 2014 , 24, 584-91	20
1297	Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node?. 2014 , 24, 454-61	35
1296	BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression. 2014 , 22, 648-51	14
1295	Histopathologic evaluation of the sentinel lymph node for malignant melanoma: the unstandardized process. 2014 , 36, 80-7	20
1294	Role of arterial telomere dysfunction in hypertension: relative contributions of telomere shortening and telomere uncapping. 2014 , 32, 1293-9	45
1293	Long-term Survival after Metastatic Childhood Melanoma. 2014 , 2, e163	4
1292	Shared decision making in dermato-oncology: preference for involvement of melanoma patients. 2014 , 24, 68-74	29
1291	Multiple primary melanomas versus single melanoma of the head and neck: a comparison of genetic, diagnostic, and therapeutic implications. 2014 , 24, 267-72	3
1290	Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions. 2014 , 37, 374-81	19
1289	Pigmentation in the sentinel node correlates with increased sentinel node tumor burden in melanoma patients. 2014 , 24, 261-6	6
1288	Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. 2014 , 38, 934-40	110
1287	Health-related quality of life, fatigue, and depression under low-dose IFN- α therapy in melanoma patients. 2014 , 37, 461-7	9
1286	Current systemic therapies for melanoma. 2014 , 40, 948-63	22
1285	Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain. 2014 , 36, 64-7	9
1284	Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients. 2014 , 24, 295-304	33

1283	Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas. 2014 , 36, 211-6	16
1282	Management of melanomas of the gynaecological tract. 2014 , 26, 508-13	15
1281	Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. 2014 , 24, 349-53	29
1280	Caring for patients with melanoma in the primary care setting. 2014 , 27, 25-30	2
1279	Management of conjunctival malignant melanoma: a review and update. 2014 , 9, 185-204	82
1278	Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. 2014 , 74, 130-40	24
1277	WNT5A-mediated β -catenin-independent signalling is a novel regulator of cancer cell metabolism. 2014 , 35, 784-94	39
1276	Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach. 2014 , 34, 343-51	44
1275	Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. 2014 , 25, 246-50	36
1274	Clinical skin examination outcomes after a video-based behavioral intervention: analysis from a randomized clinical trial. 2014 , 150, 372-9	23
1273	Dermatopathology. 2014 ,	2
1272	Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. 2014 , 171, 1099-107	117
1271	The clinical presentation of the high-mitotic-rate melanoma. 2014 , 150, 1047	
1270	International multi-institutional management and outcome of melanoma patients with positive sentinel lymph nodes in more than one nodal basin. 2014 , 21, 4324-9	9
1269	Prognostic Factors in Cutaneous Melanoma. 2014 , 569-602	3
1268	Evaluating biomarkers in melanoma. 2014 , 4, 383	33
1267	Gene expression differences predict treatment outcome of merkel cell carcinoma patients. 2014 , 2014, 596459	6
1266	Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma. 2014 , 2014, 843214	7

1265	Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival. 2014 , 3, 333	10
1264	BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT. 2014 , 39-41	
1263	Cytodiagnosis of epithelioid malignant melanoma (amelanotic) and diagnostic dilemmas. 2014 , 31, 207-9	4
1262	Increasing the Efficacy of SLNB in Cases of Malignant Melanoma Located in Close Proximity to the Lymphatic Basin. 2014 , 2014, 920349	
1261	Prognostic stratification of ulcerated melanoma: not only the extent matters. 2014 , 142, 845-56	21
1260	Four cases of rituximab-associated melanoma. 2014 , 24, 401-3	13
1259	Melanoma in children, adolescents, and young adults: a clinical pathological study in a Brazilian population. 2014 , 36, 620-8	6
1258	DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features. 2014 , 27, 1097-105	14
1257	Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients. 2014 , 27, 1106-16	13
1256	Cutaneous melanoma. 2014 , 383, 816-27	379
1255	Melanoma depth in patients with an established dermatologist. 2014 , 70, 841-6	10
1254	Are we seeing the effects of public awareness campaigns? A 10-year analysis of Breslow thickness at presentation of malignant melanoma in the South West of England. 2014 , 67, 324-30	10
1253	Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. 2014 , 70, 1036-44	12
1252	Clinical impact of sentinel lymph node biopsy in patients with thick (>4 mm) melanomas. 2014 , 207, 702-7; discussion 707	10
1251	Staging and follow-up of patients with melanoma: which tests for which patients?. 2014 , 105, 531-4	2
1250	Recomendaciones para la determinaci3n de biomarcadores en el melanoma metast3sico. Consenso Nacional de la Sociedad Espa3ola de Anatom3a Patol3gica y de la Sociedad Espa3ola de Oncolog3a M3dica. 2014 , 47, 9-21	0
1249	Stage IIIC Solitary Dermal Melanoma. 2014 , 105, 433-434	
1248	Comparison of sentinel lymph node micrometastatic tumor burden measurements in melanoma. 2014 , 218, 519-28	31

1247	Cutaneous melanoma: medical specialists' opinions on follow-up and sentinel lymph node biopsy. 2014 , 40, 1276-83	7
1246	Stage IIIC solitary dermal melanoma. 2014 , 105, 433-4	
1245	Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma. 2014 , 207, 549-54	28
1244	Automated quantification of MART1-verified Ki-67 indices: useful diagnostic aid in melanocytic lesions. 2014 , 45, 1153-61	12
1243	Sentinel Lymph Node Status in Melanoma: Prognostic Value in a Tertiary Hospital and Correlation with Mitotic Activity. 2014 , 105, 60-68	
1242	Immunological Basis of Melanoma-Associated Vitiligo-Like Depigmentation. 2014 , 105, 122-127	1
1241	Hot or not? The 10% rule in sentinel lymph node biopsy for malignant melanoma revisited. 2014 , 67, 316-9	11
1240	Targeted therapies for cutaneous melanoma. 2014 , 28, 491-505	10
1239	Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma. 2014 , 134, 176-182	37
1238	Immunohistochemical analysis of O(6)-methylguanine-DNA methyltransferase in human melanoma in comparison with skin squamous cell carcinoma. 2014 , 47, 8-13	2
1237	Melanoma brain metastases: the impact of nodal disease. 2014 , 31, 81-5	6
1236	Surgical management of intraabdominal metastases from melanoma: role of the neutrophil to lymphocyte ratio as a potential prognostic factor. 2014 , 38, 1542-50	24
1235	Patterns of recurrence and survival after lymphadenectomy in melanoma patients: clarifying the effects of timing of surgery and lymph node tumor burden. 2014 , 21, 292-9	25
1234	Non-squamous cell carcinoma of the penis: single-center, 15-year experience. 2014 , 32, 1347-53	11
1233	Emerging insights into resistance to BRAF inhibitors in melanoma. 2014 , 87, 381-9	66
1232	Association between genetic polymorphisms in apoptosis-related genes and risk of cutaneous melanoma in women and men. 2014 , 74, 135-41	7
1231	Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. 2014 , 21, 1075-81	101
1230	Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy. 2014 , 21, 1016-23	26

1229	Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma. 2014 , 21, 650-5	20
1228	Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy. 2014 , 21, 643-9	33
1227	A four-marker signature of TNF-RII, TGF- β TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. 2014 , 12, 19	34
1226	Tissue prognostic biomarkers in primary cutaneous melanoma. 2014 , 464, 265-81	38
1225	Human relevance of NRAS/BRAF mouse melanoma models. 2014 , 93, 82-6	16
1224	Topical application of Gallic acid suppresses the 7,12-DMBA/Croton oil induced two-step skin carcinogenesis by modulating anti-oxidants and MMP-2/MMP-9 in Swiss albino mice. 2014 , 66, 44-55	45
1223	Metastatic melanoma in the chest and abdomen: the great radiologic imitator. 2014 , 35, 272-89	5
1222	Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. 2014 , 15, e178-83	117
1221	BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. 2014 , 20, 1965-77	340
1220	Extracellular adenosine metabolism in immune cells in melanoma. 2014 , 63, 1073-80	42
1219	Perioral lesions and dermatoses. 2014 , 58, 401-35	6
1218	Management of regional metastatic disease in head and neck cutaneous malignancy. 2. Cutaneous malignant melanoma. 2014 , 52, 301-7	10
1217	Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas. 2014 , 187, 518-24	25
1216	The scope of nanoparticle therapies for future metastatic melanoma treatment. 2014 , 15, e22-32	66
1215	Molecular Testing in Cancer. 2014 ,	1
1214	Expression of proteins involved in epigenetic regulation in human cutaneous melanoma and peritumoral skin. 2014 , 35, 8225-33	14
1213	. 2014 ,	6
1212	Epigenetic biomarkers in skin cancer. 2014 , 342, 170-7	62

1211	Sentinel lymph node status in melanoma: prognostic value in a tertiary hospital and correlation with mitotic activity. 2014 , 105, 60-8	4
1210	Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. 2014 , 1102, 287-324	61
1209	Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. 2014 , 429, 168-74	18
1208	Advances in adjuvant therapy: potential for prognostic and predictive biomarkers. 2014 , 1102, 45-69	3
1207	Concepts in Breast and Melanoma Surgery. 2014 , 969-978	
1206	A Practical Guide to Human Cancer Genetics. 2014 ,	7
1205	Sex disparities in melanoma outcomes: the role of biology. 2014 , 563, 42-50	38
1204	Section IV: non-small cell lung cancer and malignant melanoma. 2014 , 38, 180-98	2
1203	Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis. 2014 , 101, 811-9	13
1202	Intra-lesional interleukin-2 therapy for in transit melanoma. 2014 , 109, 327-31	27
1201	Recent developments in the medical and surgical treatment of melanoma. 2014 , 64, 171-85	46
1200	Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. 2014 , 170, 87-95	11
1199	Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry. 2014 , 27, 442-53	73
1198	Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. 2014 , 71, 1102-1109.e1	58
1197	MicroRNA-mediated regulation of melanoma. 2014 , 171, 234-41	25
1196	Autophagy induced by resveratrol suppresses BMSH-induced melanogenesis. 2014 , 23, 204-6	35
1195	The Australasian College of Dermatologists 47th Annual Scientific Meeting, 18-21 May, 2014, Melbourne, Victoria. 2014 , 55 Suppl 1, 1-58	6
1194	Pigmentation of axillary sentinel nodes from extensive skin tattoo mimics metastatic melanoma: case report. 2014 , 53, 773-6	10

1193	Isolated limb infusion as a model to test new agents to treat metastatic melanoma. 2014 , 109, 357-65		7
1192	Increased frequency of minimal homozygous deletions is associated with poor prognosis in primary malignant melanoma patients. 2014 , 53, 487-96		7
1191	Observational study on the mitotic rate and other prognostic factors in cutaneous primary melanoma arising from naevi and from melanoma de novo. 2014 , 28, 1738-41		9
1190	Clinical implications of distinct metastasizing preferences of different melanoma subtypes. 2014 , 24, 236-41		13
1189	Ein âu frâgibt es nicht. 2014 , 156, 37-41		
1188	Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. 2014 , 27, 1468-78		40
1187	Primary dermal melanoma: a unique subtype of melanoma to be distinguished from cutaneous metastatic melanoma: a clinical, histologic, and gene expression-profiling study. 2014 , 71, 1083-92		22
1186	Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. 2014 , 20, 5527-36		103
1185	Isolated hepatic perfusion for metastatic melanoma. 2014 , 109, 383-8		9
1184	Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2.2		83
1183	Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays. 2014 , 45, 2281-93		39
1182	Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection. 2014 , 171, 108-14		23
1181	Segmentation of Pigmented Melanocytic Skin Lesions Based on Learned Dictionaries and Normalized Graph Cuts. 2014 ,		3
1180	Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification. 2014 , 13, 1315-26		7
1179	High-frequency ultrasonography but not 930-nm optical coherence tomography reliably evaluates melanoma thickness in vivo: a prospective validation study. 2014 , 171, 799-805		23
1178	The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. 2014 , 563, 28-34		85
1177	PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates. 2014 , 55, 1856-63		37
1176	No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. 2014 , 8, 1140-58		39

1175	A new look at drugs targeting malignant melanoma--an application for mass spectrometry imaging. 2014 , 14, 1963-70		25
1174	Analysis of clinical, dermoscopic and histopathological features of primary melanomas of patients with metastatic disease--a retrospective study at the Department of Dermatology, Medical University of Graz, 2000-2010. 2014 , 28, 1776-81		7
1173	Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass. 2014 , 134, 3000-3003		5
1172	Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. 2014 , 14, 955-67		20
1171	Contemporary controversies and perspectives in the staging and treatment of patients with lymph node metastasis from melanoma, especially with regards positive sentinel lymph node biopsy. 2014 , 40, 893-9		18
1170	Management of melanoma. 2014 , 111, 149-62		50
1169	Prediction of survival in patients with thin melanoma: results from a multi-institution study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2479-85	2.2	78
1168	Systemic treatment for BRAF-mutant melanoma: where do we go next?. 2014 , 15, e371-81		114
1167	Ultrasound-guided fine needle aspiration cytology as an addendum to sentinel lymph node biopsy can perfect the staging strategy in melanoma patients. 2014 , 50, 2280-8		37
1166	Surviving cutaneous melanoma: a clinical review of follow-up practices, surveillance, and management of recurrence. 2014 , 94, 989-1002, vii-viii		27
1165	Impact of mitotic activity on the pathological substaging of pT1 cutaneous melanoma. 2014 , 170, 874-7		7
1164	Melanocytic Lesions. 2014 ,		1
1163	Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. 2014 , 14, 560		25
1162	Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. 2014 , 2, 27		6
1161	Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 816-23	2.2	17
1160	Locoregional therapies in melanoma. 2014 , 94, 1003-15, viii		22
1159	Principles of surgical treatment of malignant melanoma. 2014 , 94, 973-88, vii		11
1158	Unusual presentations of melanoma: melanoma of unknown primary site, melanoma arising in childhood, and melanoma arising in the eye and on mucosal surfaces. 2014 , 94, 1059-73, ix		7

1157	Head and neck melanoma. 2014 , 94, 1091-113, ix	14
1156	Metabolic dysregulation in melanoma: cause or consequence?. 2014 , 4, 390-1	9
1155	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. 2014 , 63, 449-58	207
1154	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. 2014 , 63, 675-83	205
1153	Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma. 2014 , 74, 77-84	22
1152	Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. 2014 , 306, 521-6	28
1151	Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas. 2014 , 464, 603-12	10
1150	Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. 2014 , 5, 4255	109
1149	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. 2014 , 33, 30	76
1148	Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. 2014 , 21, 2525-31	11
1147	Pathology review significantly affects diagnosis and treatment of melanoma patients: an analysis of 5011 patients treated at a melanoma treatment center. 2014 , 21, 2245-51	27
1146	Sentinel node location in trunk and extremity melanomas: uncommon or multiple lymph drainage does not affect survival. 2014 , 21, 3386-94	5
1145	Factors influencing the use of sentinel lymph node biopsy in the Netherlands. 2014 , 21, 3395-400	9
1144	Discordance in histopathologic evaluation of melanoma sentinel lymph node biopsy with clinical follow-up: results from a prospectively collected database. 2014 , 21, 3406-11	6
1143	Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. 2014 , 21, 4317-23	15
1142	Primary melanoma location on the scalp is an important risk factor for brain metastasis: a study of 1,687 patients with cutaneous head and neck melanomas. 2014 , 21, 3985-91	25
1141	Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies. 2014 , 14, 621-39	15
1140	Distinct melanoma types based on reflectance confocal microscopy. 2014 , 23, 414-8	51

1139	High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma. 2014 , 142, 121-32	16
1138	Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. 2014 , 50, 1120-4	11
1137	What is the role of chemotherapy in the treatment of melanoma?. 2014 , 15, 321-35	18
1136	Update on vaccines for high-risk melanoma. 2014 , 15, 269-80	7
1135	Thin melanoma and late recurrences: it is never too thin and never too late. 2014 , 31, 909	10
1134	Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. 2014 , 16, 362-73	5
1133	Melanoma in Pregnancy: Therapeutic Challenges. 2014 , 3, 149-152	
1132	A combination of p300 and Braf expression in the diagnosis and prognosis of melanoma. 2014 , 14, 398	19
1131	Discrepant alterations in main candidate genes among multiple primary melanomas. 2014 , 12, 117	21
1130	TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. 2014 , 106,	164
1129	BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy. 2014 , 50, 2668-76	50
1128	Melanoma: diagnosis, staging, and treatment. Consensus group recommendations. 2014 , 31, 945-60	33
1127	Melanoma: immune checkpoint blockade story gets better. 2014 , 384, 1078-9	9
1126	Red meat and fruit intake is prognostic among patients with localized cutaneous melanomas more than 1mm thick. 2014 , 38, 599-607	6
1125	Isolation and molecular characterization of circulating melanoma cells. 2014 , 7, 645-53	81
1124	Lymphoscintigraphy in clinical routine practice: reproducibility and accuracy in melanoma patients with a long-term follow-up. 2014 , 40, 55-60	20
1123	Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp. 2014 , 70, 435-42	21
1122	Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. 2014 , 70, 637-643	92

1121	Immunological basis of melanoma-associated vitiligo-like depigmentation. 2014 , 105, 122-7	3
1120	Commentary: Molecular testing in melanoma. 2014 , 70, 863-70	4
1119	Pediatric melanoma, moles, and sun safety. 2014 , 61, 279-91	11
1118	Curcumin-induced melanoma cell death is associated with mitochondrial permeability transition pore (mPTP) opening. 2014 , 448, 15-21	60
1117	Rôle de la TEP/TDM dans la prise en charge du mélanome. 2014 , 38, 216-220	
1116	The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. 2014 , 50, 111-20	102
1115	Lymphatics in nanophysiology. 2014 , 74, 12-8	11
1114	Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. 2014 , 88, 986-97	112
1113	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. 2014 , 15, 620-30	78
1112	Residual melanoma after an excisional biopsy is an independent prognostic factor for local recurrence and overall survival. 2014 , 40, 1271-5	6
1111	Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. 2014 , 15, 436-44	206
1110	Cutaneous melanoma in children and adolescents: the Italian rare tumors in pediatric age project experience. 2014 , 164, 376-82.e1-2	41
1109	Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based study. 2014 , 38, 93-9	18
1108	Nomograms to predict recurrence and survival in stage IIIB and IIIC melanoma after therapeutic lymphadenectomy. 2014 , 50, 1301-9	20
1107	TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. 2014 , 134, 2251-2257	85
1106	Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention. 2014 , 11, 248-9	11
1105	Treatments for noncutaneous melanoma. 2014 , 28, 507-21	11
1104	A review of novel therapies for melanoma. 2014 , 15, 323-37	44

1103	Surgical management of melanoma. 2014 , 28, 455-70	8
1102	Melanoma adjuvant therapy. 2014 , 28, 471-89	12
1101	The role of accessibility policies and other determinants of health care provision in the initial prognosis of malignant melanoma: a cross-sectional study. 2014 , 71, 507-15	22
1100	Understanding the biology of melanoma and therapeutic implications. 2014 , 28, 437-53	27
1099	Staging and Follow-Up of Patients With Melanoma: Which Tests for Which Patients?. 2014 , 105, 531-534	
1098	State of melanoma: an historic overview of a field in transition. 2014 , 28, 415-35	25
1097	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. 2014 , 50, 121-7	126
1096	The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. 2014 , 4, 105-11	34
1095	Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. 2014 , 12, 210-8	126
1094	Melanoma metastasis: new concepts and evolving paradigms. 2014 , 33, 2413-22	87
1093	Mitotic rate is a more reliable unfavorable prognosticator than ulceration for early cutaneous melanoma: a 5-year survival analysis. 2014 , 32, 2735-43	20
1092	Melanoma. 2014 , 254-364	
1091	The future of elderly care in Turkey. 2014 , 64, 14-5	1
1090	Diagnostic biopsy of melanoma: primary or secondary care?. 2014 , 64, 14	
1089	Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome. 2014 , 8, 47-54	29
1088	Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). 2014 , 32, 875-86	32
1087	Subcutaneous metastases from melanoma: a discussion of clinical experience. 2014 , 1, 31-40	1
1086	Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma. 2014 , 911-928	

1085	The role of chemotherapy in the modern management of melanoma. 2014 , 1, 173-184	1
1084	Tumor volume as a prognostic factor in resectable malignant melanoma. 2014 , 228, 66-70	17
1083	Advances in targeted therapy for melanoma: a focus on MEK inhibition. 2014 , 4, 903-913	
1082	Follow-up in patients with low-risk cutaneous melanoma: is it worth it?. 2014 , 1, 115-125	1
1081	Maspin expression and melanoma progression: a matter of sub-cellular localization. 2014 , 27, 412-9	11
1080	BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. 2014 , 21, 221-30	61
1079	Unanswered questions in the management of stage I-III Merkel cell carcinoma. 2014 , 12, 425-31; quiz 431	7
1078	The optimum excision margin and regional node management for primary cutaneous T3 melanomas (2-4 mm in Thickness): a retrospective study of 1587 patients treated at a single center. 2014 , 260, 1095-102	9
1077	Advances in molecular profiling of malignant melanoma: ready for clinical practice?. 2014 , 1, 3-6	
1076	Outcome following sentinel node biopsy plus wide local excision versus wide local excision only for primary cutaneous melanoma: analysis of 5840 patients treated at a single institution. 2014 , 260, 149-57	33
1075	Leitlinienbasierte Qualitätsindikatoren und Zertifizierung als Grundlage ff.die Qualitätssicherung der Versorgung von Patienten mit Melanom. 2014 , 12, 139-147	8
1074	Indocyanine green SPY elite-assisted sentinel lymph node biopsy in cutaneous melanoma. 2014 , 133, 914-922	46
1073	Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. 2014 , 259, 1215-22	35
1072	Melanoma and nuclear medicine. 2014 , 1, 57-74	7
1071	Foudroyant metastasierendes, Vemurafenibtherapieresistentes malignes Melanom mit einer seltenen BRAF-Alteration. 2014 , 12, 151-154	2
1070	Long non-coding RNAs drive metastatic progression in melanoma (Review). 2014 , 45, 2181-6	9
1069	Income-associated discrepancies in melanoma survival. 2015 , 4, 143-147	2
1068	Predicting the outcome of melanoma: can we tell the future of a patient's melanoma?. 2015 , 2, 217-224	4

1067	Morphogenesis of early stage melanoma. 2015 , 130, 1	1
1066	Multi-center evaluation of the novel fully-automated PCR-based Idylla® BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. 2015 , 99, 485-91	36
1065	Revisiting determinants of prognosis in cutaneous melanoma. 2015 , 121, 4108-23	40
1064	Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years. 2015 , 136, 2453-7	30
1063	25-Hydroxyvitamin D2 /D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort. 2015 , 136, 2890-9	42
1062	Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma. 2015 , CD010307	19
1061	Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma. 2015 , 25, 392-403	11
1060	Photodynamic Therapy. 2015 , 413-467	
1059	Tests to assist in the diagnosis of cutaneous melanoma in adults: a generic protocol. 2015 ,	17
1058	Long-term outcomes of helper peptide vaccination for metastatic melanoma. 2015 , 262, 456-64; discussion 462-4	21
1057	Global Pattern Classification in Dermoscopic Images. 2015 , 199-226	5
1056	Melanozytäre Nävi und Melanom. 2015 , 1-87	
1055	Morphology of melanocytic lesions in situ. 2014 , 4, 3622	13
1054	FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor. 2015 , 47, 557-63	19
1053	Icariside II inhibits cell proliferation and induces cell cycle arrest through the ROS-p38-p53 signaling pathway in A375 human melanoma cells. 2015 , 11, 410-6	18
1052	Photoacoustic Tomography for Biomedical Applications. 2015 , 1-34	
1051	The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer. 2015 , 34, 2219-36	138
1050	Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update. 2015 , 2, 15-42	46

1049	Clinicopathologic features of primary cutaneous melanoma: a single centre analysis of a Swiss regional population. 2015 , 25, 127-32	1
1048	BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. 2015 , 25, 486-95	68
1047	The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. 2015 , 38, 252-8	24
1046	Sentinel lymph node biopsy in melanoma: Our experience over 8 years in a university hospital. 2015 , 83, 378-385	2
1045	Workflow for large-scale analysis of melanoma tissue samples. 2015 , 8, 78-84	4
1044	Primary Melanoma of Infra Temporal Fossa: A Case Report. 2015 , 6, 276-9	
1043	Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch. 2015 , 51, 133-145	11
1042	Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. 2015 , 13, 319	21
1041	Focal invasiveness in complete histological analyses of a large acral lentiginous melanoma. 2015 , 10, 73	1
1040	A single-center retrospective study on 659 re-excisions of melanoma and 769 sentinel node biopsies in 2008-2012. 2015 , 38, 471-478	2
1039	Prospective study of patterns of surgical management in adults with primary cutaneous melanoma at high risk of spread, in Queensland, Australia. 2015 , 112, 359-65	22
1038	Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia. 2015 , 24, 763-70	38
1037	Novel CDKN2A mutations in Austrian melanoma patients. 2015 , 25, 412-20	7
1036	Hair shaft miRNA-221 levels as a new tumor marker of malignant melanoma. 2015 , 42, 198-201	6
1035	Sentinel lymph node biopsy for 102 patients with primary cutaneous melanoma at a single Japanese institute. 2015 , 42, 954-61	2
1034	Melanoma of the lower extremities: foot site is an independent risk factor for clinical outcome. 2015 , 54, 1023-9	7
1033	Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma. 2015 , 29, 912-8	8
1032	Increased mortality for pregnancy-associated melanoma: systematic review and meta-analysis. 2015 , 29, 1457-66	42

1031	From personalized to patient-specific treatment of metastatic melanoma. 2015 , 2, 193-197	
1030	Epigenetic markers in melanoma. 2015 , 2, 367-382	1
1029	TrkA is amplified in malignant melanoma patients and induces an anti-proliferative response in cell lines. 2015 , 15, 777	11
1028	The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique. 2015 , 13, 299	7
1027	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. 2015 , 13, 351	47
1026	Utility of sentinel lymph node biopsy for solitary dermal melanomas. 2015 , 111, 800-7	6
1025	Results of second-stage screening for skin cancers in Oita Prefecture, Japan. 2015 , 42, 1160-4	2
1024	MSLT-I: it's all about the lymph nodes. 2015 , 173, 626-7	3
1023	Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity. 2015 , 35, 301-5	4
1022	Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. 2015 , 24, 724-33	26
1021	Evaluation of melanoma features and their relationship with nodal disease: the importance of the pathological report. 2015 , 101, 501-5	11
1020	Ultrasound-guided core needle biopsy of superficial lymph nodes: an alternative to fine-needle aspiration cytology for the diagnosis of lymph node metastasis in cutaneous melanoma. 2015 , 25, 519-27	13
1019	Melanomas' fatal attraction to lysophosphatidic acid trails: a new prognostic and therapeutic approach?. 2015 , 2, 97-100	
1018	Surgical management of malignant melanoma of the lung. 2015 , 2, 301-303	0
1017	A population-based assessment of melanoma: Does treatment in a regional cancer center make a difference?. 2015 , 112, 173-8	7
1016	Prognostic significance of tumor mitotic rate in T2 melanoma staged with sentinel lymphadenectomy. 2015 , 111, 711-5	5
1015	Is histopathological overdiagnosis of melanoma a good insurance for the future?. 2015 , 2, 21-25	3
1014	The role of BRAF mutations in primary melanoma growth rate and survival. 2015 , 173, 76-82	27

1013	Systemic therapy of metastatic melanoma. 2015 , 13, 1223-35; quiz 1236-7	6
1012	Association between tumor size and Breslow's thickness in malignant melanoma: a cross-sectional, multicenter study. 2015 , 25, 450-2	14
1011	Does pregnancy after a diagnosis of melanoma affect prognosis? Systematic review and meta-analysis. 2015 , 41, 875-82	19
1010	Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases. 2015 , 25, 427-31	10
1009	Controversies in Sentinel Lymph Node Biopsy for Ocular Neoplasms. 2015 , 55, 73-9	7
1008	Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients. 2015 , 94, e1433	14
1007	Systemtherapie des metastasierten malignen Melanoms. 2015 , 13, 1223-1238	6
1006	In vivo visualization of mesoscopic anatomy of healthy and pathological lymph nodes using 7T MRI: a feasibility study. 2015 , 41, 1405-12	4
1005	Primary dermal melanoma: a West Australian cohort. 2015 , 85, 664-7	10
1004	Impact of the 2009 AJCC staging guidelines for melanoma on the number of mitotic figures reported by dermatopathologists at one institution. 2015 , 42, 536-41	5
1003	Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma. 2015 , 29, 1938-44	15
1002	Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma. 2015 , 137, 2607-17	22
1001	Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of (18) F-FDG-PET and (18) F-FLT-PET. 2015 , 10, 203-10	6
1000	Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. 2015 , 121, 3826-35	33
999	Prognostic value of S100/CD31 and S100/podoplanin double immunostaining in mucosal malignant melanoma of the head and neck. 2015 , 37, 1368-74	8
998	Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival. 2015 , 137, 638-45	39
997	Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. 2015 , 42, 308-17	11
996	Peritumoral D2-40 Chalkley score independently predicts metastases and survival in patients with cutaneous malignant melanoma. 2015 , 42, 699-711	7

995	Venous free flaps for the treatment of skin cancers of the digits. 2015 , 74, 536-42	8
994	The cost of ipilimumab toxicity: a single-centre analysis. 2015 , 25, 259-64	17
993	Tumor-infiltrating lymphocytes predict cutaneous melanoma survival. 2015 , 25, 306-11	49
992	BRAF mutation screening in melanoma: is sentinel lymph node reliable?. 2015 , 25, 328-34	6
991	Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?. 2015 , 25, 362-6	24
990	Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. 2015 , 25, 503-9	49
989	Management of melanoma. 499-512	
988	. 2015 ,	9
987	Increased expression of neuropilin-1 in melanoma progression and its prognostic significance in patients with melanoma. 2015 , 12, 2668-76	19
986	Classification of clinical outcomes using high-throughput informatics: Part 1 - nonparametric method reviews. 2015 , 10, 3-23	4
985	Evaluation of outpatient discharge in patients with cutaneous melanoma. 2015 , 42, 70-4	
984	Improving outcomes in patients with melanoma: strategies to ensure an early diagnosis. 2015 , 6, 229-42	14
983	Comparative Aspects of BRAF Mutations in Canine Cancers. 2015 , 2, 231-245	9
982	The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial. 2015 , 19, 280-3	2
981	The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β and interferon γ in metastatic lymph nodes in malignant melanoma. 2015 , 66, 376-82	13
980	Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells. 2015 , 8, 1043-51	5
979	The Role of Nuclear Medicine in Malignant Melanoma. 2015 , 06,	
978	Role of age and sex in the diagnosis of early-stage malignant melanoma: a cross-sectional study. 2015 , 95, 940-2	5

977	CUANDO Y COMO REALIZAR UNA BIOPSIA DE LAS LESIONES CUTANEAS FRECUENTES: LO QUE EL CIRUJANO DEBE SABER. 2015 , 67, 538-544	
976	New developments in the management of advanced melanoma - role of pembrolizumab. 2015 , 8, 2535-43	13
975	From dismal prognosis to rising star: melanoma leading the way with new generation cancer therapies. 2015 , 202, 115-6	2
974	Neoadjuvant therapy for melanoma: a promising therapeutic approach and an ideal platform in drug development. 2015 , e535-42	5
973	Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy. 2015 , e528-34	16
972	Melanoma in the Italian Population and Regional Environmental Influences: A National Retrospective Survey on 2001-2008 Hospitalization Records. 2015 , 12, 9102-18	5
971	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. 2015 , 5, 183	62
970	CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma. 2015 , 5, 234	7
969	Hedgehog-Gli signaling in basal cell carcinoma and other skin cancers: prospects for therapy. 2015 , 55	2
968	Guidelines of the Brazilian Dermatology Society for diagnosis, treatment and follow up of primary cutaneous melanoma--Part I. 2015 , 90, 851-61	15
967	Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells. 2015 , 10, e0117021	17
966	Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. 2015 , 10, e0118564	155
965	Inherited variation at MC1R and histological characteristics of primary melanoma. 2015 , 10, e0119920	18
964	A protein deep sequencing evaluation of metastatic melanoma tissues. 2015 , 10, e0123661	17
963	Vitamin D deficiency at melanoma diagnosis is associated with higher Breslow thickness. 2015 , 10, e0126394	30
962	Periostin Is a Key Niche Component for Wound Metastasis of Melanoma. 2015 , 10, e0129704	36
961	Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients. 2015 , 10, e0133363	11
960	Computer-Aided Decision Support for Melanoma Detection Applied on Melanocytic and Nonmelanocytic Skin Lesions: A Comparison of Two Systems Based on Automatic Analysis of Dermoscopic Images. 2015 , 2015, 579282	13

959	Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis. 2015 , 2015, 505302	13
958	MHC class I chain-related gene a diversity in patients with cutaneous malignant melanoma from southeastern Spain. 2015 , 2015, 831864	4
957	Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. 2015 , 30, 48-57	2
956	Surgery and Staging of Melanoma. 2015 ,	
955	Current therapeutic leads for the treatment of melanoma: targeted immunotherapy in the post-genomic era. 2014 , 7, 33-43	3
954	Psychological Stress and Immunological Modulations in Early-stage Melanoma Patients. 2015 , 95, 691-5	4
953	RAGE and Its Ligands in Melanoma. 2015 ,	
952	Melanocytic tumour with unknown malignant potential--a Danish study of 67 patients. 2015 , 25, 64-7	4
951	The ipilimumab lesson in melanoma: achieving long-term survival. 2015 , 42, 387-401	23
950	Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. 2015 , 112, 2521-6	13
949	Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. 2015 , 11, 997-1009	2
948	Dermoscopic appearance of intraluminal hematogenous and lymphatic patterns of cutaneous melanoma metastases. 2015 , 151, 103-5	0
947	Liquiritigenin Potentiates the Inhibitory Effects of Cisplatin on Invasion and Metastasis Via Downregulation MMP-2/9 and PI3 K/AKT Signaling Pathway in B16F10 Melanoma Cells and Mice Model. 2015 , 67, 761-70	34
946	Cancer of the Vulva and Vagina. 2015 , 85-131	
945	Serum markers in early-stage and locally advanced melanoma. 2015 , 36, 8277-85	26
944	Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness. 2015 , 36, 8593-600	22
943	Implications of the MSLT-1 for sentinel lymph node biopsy in cutaneous head and neck melanoma. 2015 , 51, 629-33	6
942	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. 2015 , 7, 107-21	8

941	Uncertainties in the management of melanoma nodal metastasis. 2015 , 41, 811-3	2
940	Melanoma. 2015 , 88-99	
939	Clinical significance of microscopic melanoma metastases in the nonhottest sentinel lymph nodes. 2015 , 150, 465-72	8
938	Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression. 2015 , 51, 642-52	25
937	Nail apparatus melanoma: A comparative, clinicoprognostic study of the initial clinical and morphological characteristics of 49 patients. 2015 , 73, 213-20	17
936	Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. 2015 , 19, 733-45	15
935	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. 2015 , 11, 133-40	9
934	Vemurafenib for the treatment of BRAF mutant metastatic melanoma. 2015 , 11, 579-89	15
933	Favorable in vitro effects of combined IL-12 and IL-18 treatment on NK cell cytotoxicity and CD25 receptor expression in metastatic melanoma patients. 2015 , 13, 120	30
932	C-reactive protein as a marker of melanoma progression. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1389-96 2.2	55
931	Lymph-Node Ratio in Patients with Cutaneous Melanoma: A Multi-Institution Prognostic Study. 2015 , 22, 2127-34	16
930	How Often Do Patients with Localized Melanoma Attend Follow-Up at a Specialist Center?. 2015 , 22 Suppl 3, S1164-71	10
929	Enhanced FHL2 and TGF- β 1 Expression Is Associated With Invasive Growth and Poor Survival in Malignant Melanomas. 2015 , 143, 248-56; quiz 307	9
928	Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. 2015 , 21, 712-20	180
927	ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. 2015 , 13, 1206-17	31
926	A retrospective study of 1- versus 2-cm excision margins for cutaneous malignant melanomas thicker than 2 mm. 2015 , 72, 1054-9	11
925	Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. 2015 , 1, 359-68	123
924	Specialized surveillance for individuals at high risk for melanoma: a cost analysis of a high-risk clinic. 2015 , 151, 178-86	21

923	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. 2015 , 64, 1075-82	12
922	Functional Variants in Notch Pathway Genes NCOR2, NCSTN, and MAML2 Predict Survival of Patients with Cutaneous Melanoma. 2015 , 24, 1101-10	16
921	Emerging clinical applications of selected biomarkers in melanoma. 2015 , 8, 35-46	16
920	Lymphoscintigraphy and sentinel nodes. 2015 , 56, 901-7	39
919	Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. 2015 , 25, 421-6	65
918	Nab-paclitaxel in patients with metastatic melanoma. 2015 , 15, 1371-7	8
917	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2015 , 26 Suppl 5, v126-32	262
916	Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging. 2015 , 7, 317ra199	183
915	The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation. 2015 , 8, ra124	27
914	Prognostic score for patients with advanced melanoma treated with ipilimumab. 2015 , 51, 2785-91	38
913	Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study. 2015 , 5, e007471	9
912	[Malignant head and neck melanoma: Part 2: Therapy]. 2015 , 63, 593-602; quiz 603-4	1
911	The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. 2015 , 2, 353-366	1
910	Erfolge und Grenzen zielgerichteter Krebstherapien beim Melanom. 2015 , 3, 65-72	
909	Técnica e indicaci3n del ganglio centinela en la cirug3a de los tumores cut3neos. 2015 , 23, 1-13	
908	Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. 2015 , 122, 1907-16	46
907	Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. 2015 , 16, 2257-63	8
906	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. 2015 , 7, 181-91	17

905	Detection of mitotic figures in thin melanomas--immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin-eosin stain. 2015 , 73, 637-44	13
904	Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. 2015 , 76, 969-75	28
903	Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients. 2015 , 107, djv264	33
902	Increasing time trends of thin melanomas in The Netherlands: What are the explanations of recent accelerations?. 2015 , 51, 2833-41	26
901	[What's new in oncodermatology in 2015?]. 2015 , 142 Suppl 3, S36-48	
900	A 10-Year Follow-Up Study of Subjects Recruited in a Health Campaign for the Early Diagnosis of Cutaneous Melanoma: Suggestions for the Screening Timetable. 2015 , 231, 345-52	7
899	Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation inhibits melanoma cell proliferation by decreasing FUT4/LeY expression. 2015 , 46, 1667-76	42
898	Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation. 2015 , 231, 378-84	31
897	Malignant melanoma in elderly patients: biological, surgical and medical issues. 2015 , 15, 101-8	26
896	Circulating biomarkers in malignant melanoma. 2015 , 69, 47-89	29
895	Pathology of melanoma. 2015 , 24, 229-37	8
894	Who and how to screen for cancer in at-risk inflammatory bowel disease patients. 2015 , 9, 731-46	8
893	Identification of metastasis-suppressive microRNAs in primary melanoma. 2015 , 107,	38
892	Diagnostic Imaging in Dermatology: Utility of PET-CT in Cutaneous Melanoma. 2015 , 106, 29-34	
891	Lymphangiogenesis: Implications for Diagnosis, Treatment, and Prognosis in Patients With Melanoma. 2015 , 106, 7-16	1
890	Commentary: mitotic counts in thin melanomas: coming together over division. 2015 , 72, 410-1	1
889	Assessment of tumor mitotic rate in primary cutaneous malignant melanomas 1 mm or less in thickness. 2015 , 72, 405-9	4
888	[Melanoma: introduction and special demands on radiology]. 2015 , 55, 93-8	2

887	Targeting drivers of melanoma with synthetic small molecules and phytochemicals. 2015 , 359, 20-35	58
886	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. 2015 , 25, 208-24	126
885	Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. 2015 , 26, 415-21	65
884	Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. 2015 , 52, 231-9	16
883	EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. 2015 , 5, 274-87	77
882	Sentinel node in melanoma and breast cancer. Current considerations. 2015 , 34, 30-44	
881	Recent advances in targeted nanoparticles drug delivery to melanoma. 2015 , 11, 769-94	75
880	Infrared imaging of primary melanomas reveals hints of regional and distant metastases. 2015 , 140, 2144-55	28
879	Molecular Basis for Treating Cutaneous Melanoma. 2015 , 591-600.e3	
878	TRIB2 as a biomarker for diagnosis and progression of melanoma. 2015 , 36, 469-77	22
877	Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. 2015 , 136, 863-74	48
876	The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. 2015 , 28, 94-104	23
875	RSK1 activation promotes invasion in nodular melanoma. 2015 , 185, 704-16	12
874	Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. 2015 , 22, 2135-42	107
873	Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. 2015 , 12, 016008	28
872	Prognosis associated with cutaneous melanoma metastases. 2015 , 56, 25-8	7
871	Tumor thickness as a prognostic factor in extramammary Paget's disease. 2015 , 42, 269-75	26
870	Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role?. 2015 , 22, 1967-73	57

869	Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. 2015 , 22, 482-8		29
868	Quality of life after isolated limb infusion for in-transit melanoma of the extremity. 2015 , 22, 1694-700		20
867	Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?. 2015 , 22, 4052-9		8
866	The Contemporary Role of Major Amputation in the Management of Advanced Limb Melanoma. 2015 , 22, 4067-72		12
865	Behaviour of four different B16 murine melanoma cell sublines: C57BL/6J skin. 2015 , 96, 73-80		15
864	Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. 2015 , 172, 239-43		32
863	Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases. 2015 , 22, 1959-66		58
862	Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2015 , 33, 773-81	2.2	381
861	Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. 2015 , 22, 2978-87		25
860	Sex differences in melanoma survival are not related to mitotic rate of the primary tumor. 2015 , 22, 1598-603		14
859	Genomic Classification of Cutaneous Melanoma. 2015 , 161, 1681-96		1807
858	Evolving Concepts: Immunity in Oncology from Targets to Treatments. 2015 , 2015, 847383		20
857	SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma. 2015 , 113, 91-8		21
856	Primary gastric melanoma: case report of a rare malignancy. 2015 , 7, 5683		12
855	Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. 2015 , 16, 1049-1060		125
854	Malignant Melanoma With Osteoclast-Like Differentiation. 2015 , 23, 478-82		8
853	(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. 2015 , 205, 259-70		41
852	Predictors of Sentinel Lymph Node Status in Cutaneous Melanoma: A Classification and Regression Tree Analysis. 2015 , 106, 208-218		1

- 851 Cost Analysis of Sentinel Lymph Node Biopsy in Melanoma. **2015**, 106, 201-207
- 850 Portable Gamma Camera Guidance in Sentinel Lymph Node Biopsy: Prospective Observational Study of Consecutive Cases. **2015**, 106, 408-414
- 849 Melanoma: Advances in Targeted Therapy and Molecular Markers. **2015**, 22, 3451-8 13
- 848 Onconephrology. **2015**,
- 847 The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. **2015**, 2, 671-80 67
- 846 Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. **2015**, 51, 2086-94 36
- 845 Pembrolizumab for the treatment of melanoma. **2015**, 8, 515-27 2
- 844 Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma. **2015**, 17, 616-22 2
- 843 Activin A is anti-lymphangiogenic in a melanoma mouse model. **2015**, 135, 212-221 17
- 842 99m Tc-DTPA-bis-c(RGDfK) a potential alpha(v)beta3 integrin based homobivalent radioligand for imaging neoangiogenesis in malignant glioma and melanoma. **2015**, 5, 60161-60171 3
- 841 More people die from thin melanomas (?1 mm) than from thick melanomas (>4 mm) in Queensland, Australia. **2015**, 135, 1190-1193 103
- 840 Photodynamic therapy of melanoma using new, synthetic porphyrins and phthalocyanines as photosensitisers - a comparative study. **2015**, 88, 175-80 14
- 839 Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. **2015**, 5, 11198 127
- 838 A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. **2015**, 21, 4903-12 49
- 837 A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. **2015**, 26, 573-82 17
- 836 Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. **2015**, 64, 1193-203 14
- 835 High-Resolution Microscopy-Coil MR Imaging of Skin Tumors: Techniques and Novel Clinical Applications. **2015**, 35, 1077-90 17
- 834 Metabolic reprogramming supports the invasive phenotype in malignant melanoma. **2015**, 366, 71-83 60

833	Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. 2015 , 21, 5222-34		4
832	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. 2015 , 7, 611-9		98
831	Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2509-15	2.2	45
830	Melanoma. 2015 , 49, 1-20		
829	Melanoma in situ: Part I. Epidemiology, screening, and clinical features. 2015 , 73, 181-90, quiz 191-2		69
828	Antineoplastic effects of <i>Rhodiola crenulata</i> treatment on B16-F10 melanoma. 2015 , 36, 9795-805		8
827	Accuracy of self-reported nevus and pigmentation phenotype compared with clinical assessment in a population-based study of young Australian adults. 2015 , 24, 736-43		12
826	Topical therapies for skin cancer and actinic keratosis. 2015 , 77, 279-89		39
825	Metastatic melanoma - a review of current and future treatment options. 2015 , 95, 516-24		153
824	Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma. 2015 , 19, 169-77		22
823	Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. 2015 , 51, 1780-93		21
822	Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. 2015 , 21, 175-83		166
821	Magnetic guidance for cancer surgery. 2015 , 102, e12-4		5
820	Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. 2015 , 121, 1628-36		32
819	Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. 2015 , 33, 893-904		6
818	443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. 2015 , 51, 861-8		37
817	Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. 2015 , 51, 653-67		36
816	Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma. 2015 , 56, 129-39		22

815	Enhancement of Customary Dermoscopy Education With Spaced Education e-Learning: A Prospective Controlled Trial. 2015 , 151, 847-53	21
814	Tecnica e indicazione del linfonodo sentinella nella chirurgia dei tumori cutanei. 2015 , 13, 1-13	
813	Predictors of sentinel lymph node status in cutaneous melanoma: a classification and regression tree analysis. 2015 , 106, 208-18	13
812	Sentinel node biopsy in cutaneous melanoma: time for consensus to better inform patient choice. 2015 , 172, 552-4	11
811	The impact of nodal tumour burden on lymphoscintigraphic imaging in patients with melanomas. 2015 , 42, 231-40	10
810	Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. 2015 , 64, 381-8	59
809	Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial. 2015 , 64, 769-76	2
808	The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy. 2015 , 32, 440	6
807	Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma management: response to 'No survival benefit for patients with melanoma undergoing sentinel lymph node biopsy: critical appraisal of the Multicenter Selective Lymphadenectomy Trial-I final report'. 2015 , 172, 571-3	16
806	Prognostic survival model for people diagnosed with invasive cutaneous melanoma. 2015 , 15, 27	16
805	Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. 2015 , 8, 4	24
804	Deep lymph node metastases in the groin significantly affects prognosis, particularly in sentinel node-positive melanoma patients. 2015 , 22, 279-86	8
803	In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. 2015 , 22, 475-81	99
802	Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease. 2015 , 22, 1950-8	13
801	Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival. 2015 , 22, 4073-80	21
800	Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma. 2015 , 211, 521-7	7
799	Ganglion sentinelle et mlanome. 2015 , 39, 339-347	
798	Long-term outcomes and prognostic factors of high-risk malignant melanoma patients after surgery and adjuvant high-dose interferon treatment: a single-center experience. 2014 , 60, 228-38	5

797	Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. 2015 , 72, 780-5.e3	114
796	Low recurrence rates for in situ and invasive melanomas using Mohs micrographic surgery with melanoma antigen recognized by T cells 1 (MART-1) immunostaining: tissue processing methodology to optimize pathologic staging and margin assessment. 2015 , 72, 840-50	90
795	Serum-based miRNAs in the prediction and detection of recurrence in melanoma patients. 2015 , 121, 51-9	79
794	Cutaneous malignancy of the head and neck. 2015 , 24, 593-613	14
793	Regional therapies for in-transit disease. 2015 , 24, 309-22	7
792	Metastasectomy for stage IV melanoma. 2015 , 24, 279-98	18
791	Sentinel lymph node mapping in melanoma in the twenty-first century. 2015 , 24, 249-60	16
790	The prognostic impact of the extent of ulceration in patients with clinical stage I-II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI). 2021 , 184, 281-288	6
789	Survival in 31 670 patients with thin melanomas: a Swedish population-based study. 2021 , 184, 60-67	7
788	Survival Differences Between Pediatric Head and Neck Versus Body Melanoma in the Surveillance, Epidemiology, and End Results Program. 2021 , 131, E635-E641	1
787	The role of technology in melanoma screening and diagnosis. 2021 , 34, 288-300	5
786	Immune metabolism in PD-1 blockade-based cancer immunotherapy. 2021 , 33, 17-26	10
785	Comprehensive Investigation into the Role of Ubiquitin-Conjugating Enzyme E2S in Melanoma Development. 2021 , 141, 374-384	6
784	Deep learning techniques for skin lesion analysis and melanoma cancer detection: a survey of state-of-the-art. 2021 , 54, 811-841	48
783	A mixed methods analysis of access barriers to dermatology care in a rural state. 2021 , 77, 355-366	2
782	Survival Outcomes Following Lymph Node Biopsy in Thin Melanoma-A Propensity-Matched Analysis. 2021 , 28, 1634-1641	2
781	Lymphoscintigraphy for Sentinel Node Mapping in Head and Neck Cancer. 2021 , 51, 39-49	9
780	Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010-2017. 2021 , 141, 830-839.e3	4

779	Flow Cytometry for Detection and Quantification of Micrometastases in Sentinel Lymph Nodes from Patients with Primary Melanoma. 2021 , 257, 477-485	1
778	Cholecystectomy as treatment for isolated melanoma metastasis to the gallbladder. 2021 , 91, E310-E311	1
777	Primary Dermal Melanoma (PDM): Histological and Clinical Interdependence to Guide Therapy. 2021 , 25, 53-58	2
776	Current Management of Melanoma. 2021 ,	
775	Sleep disorders and cancer: State of the art and future perspectives. 2021 , 56, 101409	20
774	Five-year survival in patients with nodular and superficial spreading melanomas in the US population. 2021 , 84, 1015-1022	5
773	Risk factors for positive sentinel lymph nodes in head and neck melanoma - a survival analysis. 2021 , 87, 103-109	
772	Automated skin lesion segmentation using attention-based deep convolutional neural network. 2021 , 65, 102358	13
771	Downregulation of dihydrolipoyl dehydrogenase by UVA suppresses melanoma progression via triggering oxidative stress and altering energy metabolism. 2021 , 162, 77-87	7
770	State of Melanoma: An Historic Overview of a Field in Transition. 2021 , 35, 1-27	1
769	Stage IIIa Melanoma and Impact of Multiple Positive Lymph Nodes on Survival. 2021 , 232, 517-524.e1	1
768	Handheld reflectance confocal microscopy: Personalized and accurate presurgical delineation of lentigo maligna (melanoma). 2021 , 43, 895-902	2
767	Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma. 2021 , 48, 1498-1510	2
766	Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma. 2021 , 184, 944-951	11
765	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. 2021 , 14, 9-23	3
764	Melanoma Screening. 2021 , 185-193	
763	Identification of IL10RA by Weighted Correlation Network Analysis and Validation of Its Association With Prognosis of Metastatic Melanoma. 2020 , 8, 630790	5
762	Malignant Melanoma: From Molecular Characterization to Targeted Therapies. 2021 ,	

761	Melanocytic Neoplasms. 2021 , 289-313	
760	Percutaneous contrast-enhanced ultrasound for localization and qualitative diagnosis of sentinel lymph nodes in cutaneous malignant melanoma of lower extremities: a preliminary study.. 2022 , 12, 366-375	0
759	References and Further Reading. 2021 , 445-447	
758	Pathology of Melanoma and Skin Carcinomas. 2021 , 3-30	0
757	AI-driven Deep Visual Proteomics defines cell identity and heterogeneity.	12
756	Prognostic factors for postoperative survival in melanoma patients with bone metastasis. 2021 , 100, e24558	
755	Novel Prognostic Models Predicting the Cancer-Specific Survival in Patients with Cutaneous Melanoma Based on Metastatic Lymph Node Status. 2021 , 28, 4572-4581	0
754	Mortality in cutaneous malignant melanoma and its association with Neutrophil-to-Lymphocyte ratio. 2021 , 29, 100464	1
753	Trends in the characteristics of skin melanoma in accordance with time intervals: A single Turkish tertiary referral center experience. 2021 , 17, 1119-1122	0
752	Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma. 2021 , 28, 4582-4589	6
751	Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance. 2021 , 27, 2074-2086	3
750	Genomic Landscapes of Acral Melanomas in East Asia. 2021 , 18, 83-92	1
749	SegCaps: An efficient SegCaps network-based skin lesion segmentation in dermoscopic images. 2021 , 31, 874-894	1
748	Aqueous Extract of Adansonia digitata reversed Cotton Seed Extract-Induced Testicular Damage in Wistar rats. 2021 , 25, 257-265	0
747	Multivariate analysis of prognostic factors in patients with nodular melanoma. 2021 , 147, 2759-2764	1
746	The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma. 2021 , 2021, 6686284	4
745	Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy. 2021 , 81, 2545-2555	3
744	Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry. 2021 , 144, 242-251	6

743	Skin melanoma deaths within 1 or 3 years from diagnosis in Europe. 2021 , 148, 2898-2905	1
742	Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina. 2021 , 9, 167-185	1
741	Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study. 2021 , 360, 104274	3
740	Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis. 2020 , 10, 637161	2
739	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). 2021 , 27, 301-309	65
738	Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma. 2021 , 25, 364-370	0
737	UTRN inhibits melanoma growth by suppressing p38 and JNK/c-Jun signaling pathways. 2021 , 21, 88	6
736	Early detection of melanoma in specialised primary care practice in Australia. 2021 , 70, 101872	3
735	Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. 2021 , 21, 323	5
734	Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study. 2021 , 145, 29-37	4
733	Long noncoding RNA LINC00518 induces radioresistance by regulating glycolysis through an miR-33a-3p/HIF-1 β negative feedback loop in melanoma. 2021 , 12, 245	9
732	Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. 2021 , 4, e210980	4
731	Ultra-high-frequency ultrasound and machine learning approaches for the differential diagnosis of melanocytic lesions. 2021 ,	5
730	Design, Synthesis, and Evaluation of Small Molecule G β /11 Protein Inhibitors for the Treatment of Uveal Melanoma. 2021 , 64, 3131-3152	0
729	A review of the AJCC melanoma staging system in the TNM classification (eighth edition). 2021 , 51, 671-674	2
728	Sentinel node biopsy for primary cutaneous melanoma. 2021 , 32, 290-292	4
727	A Four-Gene-Based Prognostic Model Predicts Overall Survival in Patients With Cutaneous Melanoma. 2021 , 11, 639874	3
726	Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2021 , 39, 944-946	2.2

725	Recent advancements in melanoma management. 2021 , 51, 327-333	1
724	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. 2021 , 32, 375-383	4
723	Treatment of Cutaneous Melanoma of the Head and Neck With Wide Local Excision Versus Mohs. 2021 , 131, 2490-2496	1
722	Patient-identified early clinical warning signs of nodular melanoma: a qualitative study. 2021 , 21, 371	1
721	Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma. 2021 , 1	2
720	Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial. 2021 , 274, 383-389	7
719	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. 2021 , 13, 419-432	3
718	A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma. 2021 , 6, 100050	5
717	Human KIT+ myeloid cells facilitate visceral metastasis by melanoma. 2021 , 218,	1
716	Predictive biomarkers for response to immune checkpoint inhibition. 2021 , 79, 4-4	17
715	Pediatric Melanoma-Diagnosis, Management, and Anticipated Outcomes. 2021 , 30, 373-388	
714	Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. 2021 , 13,	2
713	Risk factors and patterns of recurrence after sentinel lymph node biopsy for thin melanoma. 2021 , 1	
712	Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: Implications for clinical practice. 2021 , 161, 202-210	2
711	Immunohistochemical expression and prognostic role of CD10, CD271 and Nestin in primary and recurrent cutaneous melanoma. 2021 , 156,	
710	To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma. 2021 , 127, 2333-2341	0
709	The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. 2021 , 19, 142	1
708	The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden. 2021 , 13,	0

707	Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors. 2021 , 2021, 9935076	0
706	Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study. 2021 , 13, 521-535	0
705	Retrospective evaluation of malignant melanoma patients: A single-center experience. 98-104	
704	Development and external validation of a nomogram predicting overall survival after curative resection of colon cancer. 2021 , 49, 3000605211015023	2
703	Melanoma With an Unknown Primary in an Asymptomatic Elderly Male With Unilateral Lymphadenopathy. 2021 , 13, e15140	
702	Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis. 2021 , 2021, 6660571	0
701	Dermoscopic Predictors of Tumor Thickness in Cutaneous Melanoma: A Retrospective Analysis of 245 Melanomas. 2021 , 11, e2021059	0
700	Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. 2021 , 149, 222-232	8
699	Current management of melanoma patients with nodal metastases. 2021 , 1	3
698	Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators. 2021 , 11, 659754	1
697	Survival models induced by zero-modified power series discrete frailty: Application with a melanoma data set. 2021 , 30, 1874-1889	
696	Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism. 2021 , 22,	4
695	ETS1 promoted cell growth, metastasis and epithelial-mesenchymal transition process in melanoma by regulating miR-16-mediated SOX4 expression. 2021 , 31, 298-308	2
694	m6A-Related lncRNAs Are Potential Biomarkers for the Prognosis of Metastatic Skin Cutaneous Melanoma. 2021 , 8, 687760	5
693	Targeting Solid Tumors Using CD3 Bispecific Antibodies. 2021 , 20, 1350-1358	3
692	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. 2021 , 22, 643-654	58
691	The Negative Binomial Beta Prime Regression Model with Cure Rate: Application with a Melanoma Dataset. 2021 , 15, 1	1
690	Fortuitous discovery of melanomas in the ENT Department - a histopathological and immunohistochemical study. 2020 , 61, 1163-1171	

689	Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. 2021 , 161, 645-652	4
688	5-Year Outcomes with Cobimetinib plus Vemurafenib in Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. 2021 ,	10
687	A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma. 2021 , 125, 699-713	4
686	Landmark Series on Disparities in Surgical Oncology: Melanoma. 2021 , 28, 6986-6993	1
685	RTP4 is a novel prognosis-related hub gene in cutaneous melanoma. 2021 , 158, 22	1
684	Sentinel lymph node biopsy guideline concordance in melanoma: Analysis of the National Cancer Database. 2021 , 124, 669-678	1
683	Usefulness of High-Frequency Ultrasonography in the Diagnosis of Melanoma: Mini Review. 2021 , 11, 673026	4
682	Nomogram Incorporating the WNT/ β -Catenin Signaling Pathway for Predicting the Survival of Cutaneous Melanoma. 2021 , 14, 2751-2761	0
681	Identification of Potential Prognostic Biomarkers Associated With Cancerometastasis in Skin Cutaneous Melanoma. 2021 , 12, 687979	0
680	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma. 2021 , 11, e2021165S	
679	Melanoma of vulva in situ, presentation of a case. 2021 , 12,	
678	W-net and inception residual network for skin lesion segmentation and classification. 1	6
677	Malignant melanoma without primary, presenting as solitary pulmonary nodule: a case report. 2021 , 15, 347	
676	Reduction in the number of early melanomas diagnosed during the COVID-19 pandemic: a single-centre cohort study. 2021 , 35, e735-e737	2
675	Interferon- β for the treatment of metastatic melanoma: results of a retrospective study. 2021 , 32, 1105-1110	1
674	Unraveling the Wide Spectrum of Melanoma Biomarkers. 2021 , 11,	20
673	Molecular characterization of fast-growing melanomas. 2021 ,	0
672	Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer.	2

671	Recognition, Staging, and Management of Melanoma. 2021 , 105, 643-661		1
670	FAC-Net: Feedback Attention Network Based on Context Encoder Network for Skin Lesion Segmentation. 2021 , 21,		4
669	A Multi-path CNN for Automated Skin Lesion Segmentation. 2021 ,		
668	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. 2021 , 91 Suppl 2, 3-13		2
667	Pulmonary metastatic melanoma: current state of diagnostic imaging and treatments.. 2021 , 8, MMT58		1
666	Investigating the depolarization property of skin tissue by degree of polarization uniformity contrast using polarization-sensitive optical coherence tomography. 2021 , 12, 5073-5088		5
665	Characterization and Clinical Utility of Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma. 2021 , 13,		0
664	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies.. 2022 , 59, 101030		0
663	The Role of Glycosylation in Melanoma Progression. 2021 , 10,		2
662	Performance Evaluation of Novel Convolution Neural Network Architecture for Melanoma Skin Cancer Diagnosis on Different Hardware Processing Units. 2021 , 1950, 012039		0
661	ANN-based diagnosis method for skin cancers using dermoscopic images. bs202108		
660	Expression of the cancer stem cell marker OCT4 is associated with worse prognosis and survival in cutaneous melanoma. 2021 , 31, 439-448		2
659	Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3829-3838	2.2	9
658	Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas. 2021 , 16, 78		0
657	Need to restage Korean melanoma patients following publication of the 8th edition of the American Joint Committee on Cancer staging manual. 2021 , 1-5		
656	CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma. 2021 , 13,		1
655	Application of generated mask method based on Mask R-CNN in classification and detection of melanoma. 2021 , 207, 106174		5
654	Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases). 2021 , 64-74		1

653	Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. 2021 , 13, 1011-1029	1
652	Next-Generation Immunotherapy Approaches in Melanoma. 2021 , 23, 116	1
651	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. 2021 , 9,	7
650	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. 2021 , 13,	0
649	Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. 2021 , 11, 1481-1496	1
648	A mechanism of cooling hot tumors: Lactate attenuates inflammation in dendritic cells. 2021 , 24, 103067	1
647	A faithful in vivo model of human macrophages in metastatic melanoma.	
646	HLA-DRB116:01 and HLA-DQB105:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma. 2021 , 2021, 3801143	1
645	Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas. 2021 , 22,	
644	Top Ten Tips Palliative Care Clinicians Should Know About Prognostication in Oncology, Dementia, Frailty, and Pulmonary Diseases. 2021 , 24, 1391-1397	1
643	Contemporary update of SPECT tracers and novelties in radioguided surgery: a perspective based on urology. 2021 , 65, 215-228	3
642	Primary Melanoma Characteristics of Metastatic Disease: A Nationwide Cancer Registry Study. 2021 , 13,	0
641	Adjuvant treatment for melanoma in clinical practice - Trial versus reality. 2021 , 158, 234-245	1
640	Improving Dermal Delivery of Rose Bengal by Deformable Lipid Nanovesicles for Topical Treatment of Melanoma. 2021 , 18, 4046-4057	2
639	Health-related quality of life using the FACT-M questionnaire in patients with malignant melanoma: A systematic review. 2021 ,	1
638	ZnO nanoparticles stimulate oxidative stress to induce apoptosis of B16F10 melanoma cells:andstudies. 2021 , 7,	4
637	On a new piecewise regression model with cure rate: Diagnostics and application to medical data. 2021 , 40, 6723-6742	1
636	A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio. 2021 , 31, 566-574	2

635	Prospective study of clinical characteristics of melanoma patients with retinopathy caused by a high-dose interferon α b. 2021 , 31, 550-554	0
634	Sentinel Lymph Node Biopsy, Lymph Node Dissection, and Lymphedema Management Options in Melanoma. 2021 , 48, 607-616	1
633	American Joint Committee on Cancer Staging and Other Platforms to Assess Prognosis and Risk. 2021 , 48, 599-606	1
632	Practical Considerations When Interpreting FDG PET/CT Imaging for Staging and Treatment Response Assessment in Melanoma Patients. 2021 , 51, 544-553	0
631	The increasing role of pigment epithelium-derived factor in metastasis: from biological importance to a promising target. 2021 , 193, 114787	3
630	Sex-specific survival benefit in early skin melanoma based on 8th AJCC edition: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database. 2021 , 9, 53	0
629	Development of an immune-related gene pairs index for the prognosis analysis of metastatic melanoma. 2021 , 11, 1253	2
628	ARNT deficiency represses pyruvate dehydrogenase kinase 1 to trigger ROS production and melanoma metastasis. 2021 , 10, 11	3
627	Assessing the Educational and Supportive Care Needs of Canadian Metastatic Melanoma Patients and Survivors Attending an Outpatient Clinic. 2021 , 8, 23743735211033126	0
626	Automated Skin Lesion Segmentation Via an Adaptive Dual Attention Module. 2021 , 40, 357-370	26
625	Anti-metastatic Effects of Cationic KT2 Peptide (a Lysine/Tryptophan-rich Peptide) on Human Melanoma A375.S2 Cells. 2021 , 35, 215-227	4
624	Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis. 2021 , 39, 928-948	2
623	Prognostic Significance of Epidermal Growth Factor Receptor Expression in Distant Metastatic Melanoma from Primary Cutaneous Melanoma. 2021 , 33, 432-439	1
622	Cutaneous Melanoma. 2013 , 153-165	1
621	Malignant Melanoma of the Vulva. 2015 , 243-263	2
620	Validation of Circulating Tumor DNA Assays for Detection of Metastatic Melanoma. 2020 , 2055, 155-180	5
619	Melanocytic Neoplasms II: Molecular Staging. 2011 , 105-130	2
618	Introduction to Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. 2012 , 1-7	1

617	MicroRNA Biomarkers in Melanoma. 2012 , 113-126	1
616	Current status of diagnostic and prognostic markers in melanoma. 2014 , 1102, 177-97	7
615	Construction and analysis of multiparameter prognostic models for melanoma outcome. 2014 , 1102, 227-58	5
614	Pathological staging of melanoma. 2014 , 1102, 325-51	5
613	Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients. 2014 , 1102, 513-22	10
612	Surveillance and Follow-Up of Melanoma Patients. 2020 , 851-866	1
611	Systemic Therapy for Mucosal, Acral, and Uveal Melanoma. 2020 , 1301-1335	2
610	Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. 2020 , 767-793	1
609	Skin Cancer for Primary Care. 2019 , 171-208	1
608	Immunotherapy for Melanoma. 2020 , 1244, 51-68	19
607	Comparative effectiveness in melanoma. 2015 , 164, 31-49	2
606	Radioguided Surgery for Malignant Melanoma. 2016 , 1-33	1
605	Melanoma of the Skin. 2017 , 563-586	58
604	Clinicopathologic Overview of Melanoma. 2017 , 1-5	1
603	Systemic Therapy for Mucosal, Acral and Uveal Melanoma. 2019 , 1-37	1
602	Melanoma. 2015 , 597-611	1
601	Melanoma: From Tumor-Specific Mutations to a New Molecular Taxonomy and Innovative Therapeutics. 2015 , 7-27	0
600	Melanom. 2018 , 1869-1885	0

599	Melanoma: Perspectives of a Vaccine Based on Peptides. 2013 , 397-412	2
598	Melanoma and Non-Melanoma Skin Cancers. 2014 , 435-452	1
597	Melanoma. 2014 , 1071-1091.e3	1
596	Sentinel Lymph Node Biopsy: Indications and Technique. 2020 , 29, 401-414	2
595	Tumour gene expression signature in primary melanoma predicts long-term outcomes. 2021 , 12, 1137	5
594	Limited-duration anti-PD-1 therapy for patients with metastatic melanoma. 2020 , 59, 438-443	3
593	The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. 2018 , 18, 775-784	81
592	Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany. 2020 , 9, 1861804	3
591	Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). 2021 , 31, 67-75	6
590	Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. 2010 , 20, 240-6	39
589	The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past. 2010 , 20, 422-6	38
588	An unsupervised feature extraction and selection strategy for identifying epithelial-mesenchymal transition state metrics in breast cancer and melanoma.	1
587	Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy. 2020 , 61, e310-e318	4
586	Optical coherence tomography for the diagnosis of malignant skin tumors: a meta-analysis. 2018 , 23, 1-10	25
585	Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. 2015 , 2015,	31
584	Protocol for the melatools skin self-monitoring trial: a phase II randomised controlled trial of an intervention for primary care patients at higher risk of melanoma. 2017 , 7, e017934	6
583	Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. 2020 , 8,	13
582	Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. 2017 , 2,	30

581	Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. 2017 , 2,	44
580	IgG4 subclass antibodies impair antitumor immunity in melanoma. 2013 , 123, 1457-74	125
579	Methylation-Mediated Silencing of MicroRNA-211 Decreases the Sensitivity of Melanoma Cells to Cisplatin. 2019 , 25, 1590-1599	14
578	Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report. 2020 , 8, 4100-4108	0
577	Up-regulated Dicer expression in patients with cutaneous melanoma. 2011 , 6, e20494	49
576	Time course and pattern of metastasis of cutaneous melanoma differ between men and women. 2012 , 7, e32955	60
575	High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. 2012 , 7, e38254	88
574	An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma. 2012 , 7, e49865	12
573	Characterization of human $\gamma\delta$ lymphocytes infiltrating primary malignant melanomas. 2012 , 7, e49878	92
572	Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600). 2013 , 8, e59221	8
571	Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. 2014 , 9, e87705	220
570	P-selectin-mediated platelet adhesion promotes the metastasis of murine melanoma cells. 2014 , 9, e91320	28
569	Primary localization and tumor thickness as prognostic factors of survival in patients with mucosal melanoma. 2014 , 9, e112535	17
568	Uveal melanoma cells utilize a novel route for transendothelial migration. 2014 , 9, e115472	17
567	A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with <i>Listeria monocytogenes</i> . 2015 , 10, e0117923	12
566	Clinicopathologic predictors of survival in patients with desmoplastic melanoma. 2015 , 10, e0119716	22
565	Mechanisms contributing to differential regulation of PAX3 downstream target genes in normal human epidermal melanocytes versus melanoma cells. 2015 , 10, e0124154	7
564	Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes. 2015 , 10, e0131934	10

563	Investigation of FOXM1 as a Potential New Target for Melanoma. 2015 , 10, e0144241	28
562	Absence of Tumor-Infiltrating Lymphocyte Is a Reproducible Predictive Factor for Sentinel Lymph Node Metastasis: A Multicenter Database Study by the Brazilian Melanoma Group. 2016 , 11, e0148160	12
561	CD10-Equipped Melanoma Cells Acquire Highly Potent Tumorigenic Activity: A Plausible Explanation of Their Significance for a Poor Prognosis. 2016 , 11, e0149285	5
560	No prognostic value added by vitamin D pathway SNPs to current prognostic system for melanoma survival. 2017 , 12, e0174234	7
559	Dermoscopic characteristics of melanoma according to the criteria "ulceration" and "mitotic rate" of the AJCC 2009 staging system for melanoma. 2017 , 12, e0174871	17
558	Study of metastatic kinetics in metastatic melanoma treated with B-RAF inhibitors: Introducing mathematical modelling of kinetics into the therapeutic decision. 2017 , 12, e0176080	4
557	SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanoma. 2017 , 12, e0180392	2
556	Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma. 2013 , e320-e325	1
555	Sentinel Lymph Node Biopsy in Patients With Thick Primary Cutaneous Melanoma. 2019 , 10, 112-117	1
554	Children with malignant melanoma: a single center experience from Turkey. 2020 , 55, 39-45	1
553	Primary Anorectal Amelanotic Melanoma: The First Case Report from Saudi Arabia. 2019 , 11, 166-173	2
552	Nanomedicine in Melanoma: Current Trends and Future Perspectives. 143-159	3
551	Biomarkers in Malignant Melanoma: Recent Trends and Critical Perspective. 2017 , 39-56	6
550	Ulcerated Melanoma: Aspects and Prognostic Impact. 67-75	2
549	Clinical Presentation and Staging of Melanoma. 79-89	20
548	Surgical Management of Melanoma. 91-100	6
547	Melanoma of Unknown Primary. 99-116	12
546	The prognostic significance of BRAF mutation status in stage III B&C melanoma. 2013 , 8, 127-129	2

- 545 Prognostic role of sentinel lymph node biopsy for patients with cutaneous melanoma: A retrospective study of surveillance, epidemiology, and end-result population-based data. **2016**, 7, 45671-45677¹³
- 544 Different growth and metastatic phenotypes associated with a cell-intrinsic change of Met in metastatic melanoma. **2016**, 7, 70779-70793 20
- 543 PAK4 suppresses PDZ-RhoGEF activity to drive invadopodia maturation in melanoma cells. **2016**, 7, 70881-70897⁹
- 542 The prognostic significance of heparanase expression in metastatic melanoma. **2016**, 7, 74678-74685 18
- 541 The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. **2016**, 7, 81493-81511 12
- 540 The neurotrophin Neuritin1 (cpg15) is involved in melanoma migration, attachment independent growth, and vascular mimicry. **2017**, 8, 1117-1131 10
- 539 Histamine therapeutic efficacy in metastatic melanoma: Role of histamine H4 receptor agonists and opportunity for combination with radiation. **2017**, 8, 26471-26491 14
- 538 Impact of phosphoinositide-3-kinase and vitamin D3 nuclear receptor single-nucleotide polymorphisms on the outcome of malignant melanoma patients. **2017**, 8, 75914-75923 4
- 537 Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. **2017**, 8, 67355-67368 34
- 536 Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. **2017**, 8, 67439-67456¹²
- 535 Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. **2017**, 8, 79731-79741 59
- 534 Inactivation/deficiency of DHODH induces cell cycle arrest and programmed cell death in melanoma. **2017**, 8, 112354-112370 19
- 533 The clinical significance of mutations in metastatic oral mucosal melanoma in China. **2017**, 8, 82661-82673 12
- 532 PAX3d mRNA over 2.76 copies/ μ L in the bloodstream predicts cutaneous malignant melanoma relapse. **2017**, 8, 85479-85491 2
- 531 Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. **2017**, 8, 105000-105010 6
- 530 Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway. **2014**, 5, 6387-403 42
- 529 Alisertib promotes apoptosis and autophagy in melanoma through p38 MAPK-mediated aurora a signaling. **2017**, 8, 107076-107088 15
- 528 Targeting the oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib. **2017**, 8, 113472-113493 10

527	CKS1 expression in melanocytic nevi and melanoma. 2018 , 9, 4173-4187	1
526	Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF -mutant melanoma. 2018 , 9, 10905-10919	11
525	Genetic alterations in main candidate genes during melanoma progression. 2018 , 9, 8531-8541	35
524	Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. 2014 , 5, 9609-18	51
523	Cofilin-1 levels and intracellular localization are associated with melanoma prognosis in a cohort of patients. 2018 , 9, 24097-24108	8
522	The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. 2018 , 9, 26217-26225	3
521	Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. 2019 , 10, 113-122	13
520	Stage-specific prognostic biomarkers in melanoma. 2015 , 6, 4180-9	20
519	A direct plasma assay of circulating microRNA-210 of hypoxia can identify early systemic metastasis recurrence in melanoma patients. 2015 , 6, 7053-64	61
518	Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. 2015 , 6, 11683-93	34
517	Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. 2015 , 6, 12297-309	102
516	Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. 2015 , 6, 19868-79	6
515	Analysis of SDHD promoter mutations in various types of melanoma. 2015 , 6, 25868-82	8
514	High LIFr expression stimulates melanoma cell migration and is associated with unfavorable prognosis in melanoma. 2015 , 6, 25484-98	28
513	The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. 2012 , 3, 336-44	19
512	Frequent DPH3 promoter mutations in skin cancers. 2015 , 6, 35922-30	42
511	Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner. 2016 , 7, 3171-85	25
510	Validation of a preclinical model for assessment of drug efficacy in melanoma. 2016 , 7, 13069-81	9

509	Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression. 2016 , 7, 15065-92	28
508	Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. 2016 , 7, 19997-20015	20
507	Exceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a <i>Listeria</i> peptide proposed against metastatic melanoma. 2016 , 7, 16855-65	9
506	Hypoxia-regulated gene expression explains differences between melanoma cell line-derived xenografts and patient-derived xenografts. 2016 , 7, 23801-11	7
505	Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations. 2016 , 7, 30365-78	9
504	Reprogramming human A375 amelanotic melanoma cells by catalase overexpression: Upregulation of antioxidant genes correlates with regression of melanoma malignancy and with malignant progression when downregulated. 2016 , 7, 41154-41171	19
503	The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies.. 2020 , 3, 117-139	3
502	Melanoma immunotherapy dominates the field. 2016 , 4, 269	14
501	The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab. 2019 , 7, S24	6
500	Treatment of cutaneous melanoma: current approaches and future prospects. 2010 , 2, 197-211	29
499	Deep Learning Approaches Towards Skin Lesion Segmentation and Classification from Dermoscopic Images - A Review. 2020 , 16, 513-533	15
498	Malignant Cutaneous Melanoma: Updates in PET Imaging. 2020 , 13, 14-23	5
497	Pharmacological effects of gallic acid in health and diseases: A mechanistic review. 2019 , 22, 225-237	138
496	Prognostic factors in head and neck melanoma according to facial aesthetic units. 2020 , 155, 41-45	12
495	Management of cutaneous melanoma: comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology. 2020 , 155, 126-145	3
494	VivaScopefi 1500 and 3000 systems for detecting and monitoring skin lesions: a systematic review and economic evaluation. 2016 , 20, 1-260	19
493	Assessment of the Antitumor Potential of Umbelliprenin, a Naturally Occurring Sesquiterpene Coumarin. 2020 , 8,	7
492	The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. 2015 , 7, 1154-77	19

491	Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?. 2015 , 7, 1900-24	15
490	Grapefruit-Derived Micro and Nanovesicles Show Distinct Metabolome Profiles and Anticancer Activities in the A375 Human Melanoma Cell Line. 2020 , 9,	16
489	Activation of PGK1 under hypoxic conditions promotes glycolysis and increases stem cell-like properties and the epithelial-mesenchymal transition in oral squamous cell carcinoma cells via the AKT signalling pathway. 2020 , 57, 743-755	9
488	Prognostic genes of melanoma identified by weighted gene co-expression network analysis and drug repositioning using a network-based method. 2019 , 18, 6066-6078	6
487	New Systemic Treatment for Malignant Melanoma. 2013 , 85, 357	3
486	Somatic DNA mutation analysis in targeted therapy of solid tumours. 2015 , 4, 125-38	16
485	Update in genetic susceptibility in melanoma. 2015 , 3, 210	65
484	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). 2015 , 3, 322	21
483	Malignant melanoma--diagnosis, treatment and follow-up in Norway. 2013 , 133, 2154-9	8
482	Predictive factors for loco regional recurrence and distant metastasis following primary surgical treatment of cutaneous melanoma. 2014 , 59, 241-6	4
481	Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. 2017 , 49, 44-53	19
480	Identifying Persons at Highest Risk of Melanoma Using Self-Assessed Risk Factors. 2011 , 2,	19
479	The Application and Indications for Sentinel Lymph Node Biopsy in Pediatric Solid Tumors: Current Status and Future Directions. 2014 , 05, 1130-1141	1
478	Nuclear Odontogenic Ameloblast-Associated Protein (ODAM) Correlates with Melanoma Sentinel Lymph Node Metastasis. 2013 , 04, 1283-1289	2
477	Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab. 2015 , 06, 833-840	8
476	Medical Costs by Disease Stage in Medicare Patients with Metastatic Melanoma. 2017 , 08, 913-923	1
475	Metastatic malignant melanoma of the urinary bladder: Case report and literature review. 2012 , 65, 232-4	8
474	Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. 2016 , 7, 174-88	14

473	Novel anti-melanoma treatment: focus on immunotherapy. 2014 , 33, 458-65	8
472	"Mitogenicity"-the latest and most hilarious episode in the slapstick comedy of melanoma management. 2012 , 2, 203a11	1
471	Systematic review of diagnostic accuracy of reflectance confocal microscopy for melanoma diagnosis in patients with clinically equivocal skin lesions. 2013 , 3, 19-27	63
470	Evaluation of electrical impedance spectroscopy as an adjunct to dermoscopy in short-term monitoring of atypical melanocytic lesions. 2016 , 6, 1-6	6
469	Use of and intentions to use dermoscopy among physicians in the United States. 2017 , 7, 7-16	5
468	Thin melanoma. 2011 , 135, 342-6	15
467	Sentinel lymph nodes in cutaneous melanoma: handling, examination, and clinical repercussion. 2010 , 134, 1764-9	29
466	Molecular diagnostics in melanoma: current status and perspectives. 2011 , 135, 860-9	24
465	Prognostication in thin cutaneous melanomas. 2010 , 134, 1758-63	31
464	Management of malignant melanoma. 2012 , 39, 565-74	8
463	Pembrolizumab: First in Class for Treatment of Metastatic Melanoma. 2015 , 6, 234-8	3
462	FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. 2013 , 68, 1018-27	15
461	A spindle cell squamous cell carcinoma on the cheek presenting with in-transit metastases and a satellite lesion. 2020 , 21, 58-63	2
460	Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer. 2012 , 13, 2355-62	10
459	A retrospective multicenter evaluation of cutaneous melanomas in Turkey. 2014 , 15, 10451-6	7
458	Do not let to be late: overview of reasons for melanoma delayed diagnosis. 2014 , 15, 3873-7	15
457	Metastatic melanoma - a review of current and future drugs. 2012 , 2012, 212242	20
456	Treatment with combined dabrafenib and trametinib in -mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation. 2018 , 7, 212515	8

455	Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report. 2017 , 11, XD06-XD08	1
454	The impact of neuropsychological assessment in epileptic focus localization. 2021 , 50, 45-49	
453	Morbidity and Mortality of Melanoma on the Trunk and Extremities Treated With Mohs Surgery Versus Wide Excision: A Systematic Review. 2021 ,	0
452	CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma. 2021 ,	0
451	Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. 2021 , 27, 1789-1796	10
450	Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors. 2021 ,	
449	Malignes Melanom ohne Primärtumor, das als solitärer pulmonaler Rundherd imponiert: ein Fallbericht. 1-4	
448	Head and neck melanoma: outcome and predictors in a population-based cohort study. 2021 , 17, 45	0
447	Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. 2021 , 158, 225-233	3
446	Machine learning for the identification of decision boundaries during the transition from radial to vertical growth phase superficial spreading melanomas. 2021 , 31, 533-540	
445	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. 2021 , 12,	1
444	Risk factors of recurrence and distant metastasis in primary cutaneous melanoma in Taiwan. 2021 , 11, 21012	1
443	Deep attention branch networks for skin lesion classification. 2021 , 212, 106447	5
442	Melanocytic Tumors. 2010 , 169-196	
441	Surgical treatment for metastatic disease. 2010 , 25, 288-292	
440	Immunotherapy of Melanoma: A New Era. 2011 , 359-372	
439	Common Benign and Malignant Skin Lesions. 2011 , 1221-1243	
438	A Case of multiple in-transit metastases from penile malignant melanoma after total lymph node dissection. 2011 , 26, 342-347	

- 437 Prognostic Factors and Staging in Melanoma. **2011**, 282-294
- 436 Regional Lymph Node Surgery in Melanoma Patients. **2011**, 544-558
- 435 Pathology of Melanoma. **2011**, 295-317 1
- 434 Treatment of Disseminated Melanoma. **2011**, 629-633
- 433 Dermatookologie. **2011**, 69-102
- 432 Management of the Patient with Melanoma. **2011**, 318-326
- 431 Introduction. **2011**, 1-5 1
- 430 An update on reporting histopathologic prognostic factors in melanoma. **2011**, 135, 825-9 19
- 429 The importance of mitosis as a factor for predicting sentinel lymph node biopsy for thin melanoma. **2011**, 86, S107-9 1
- 428 Rare Tumors of the Skin and Subcutaneous Tissues. **2012**, 455-482
- 427 Serological Biomarkers in Melanoma. **2012**, 195-208
- 426 Tissue-Based Protein Biomarkers in Melanoma: Immunohistochemistry: (B) Prognostication. **2012**, 177-188
- 425 Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview. **2012**, 305-317 1
- 424 Mohs Micrographic Surgery for the Treatment of Cutaneous Melanoma. **2012**, 211-223
- 423 Molecular Markers of Lymph Node Disease in Melanoma. **2012**, 209-226
- 422 Staging of Melanoma. **2012**, 39-48
- 421 Diagnostic and Prognostic Biomarkers in Melanoma: Current State of Play. **2012**, 9-18 2
- 420 Epigenetic Biomarkers in Melanoma. **2012**, 89-112

419 Melanom. **2012**, 1710-1726

418 Melanoma. **2012**, 1221-1267

417 Surgical treatment of melanoma: from excision to sentinel node biopsy. **2012**, 44-56

416 Treatment of Occupational Skin Cancer. **2012**, 1079-1085

415 Melanoma and Cutaneous Malignancies. **2012**, 742-767

414 A Case of Primary Dermal Melanoma. **2012**, 74, 146-148

413 Melanoma and Other Skin Cancers. **2012**, 439-468

412 [Nevus or malignant melanoma?]. **2012**, 132, 511

1

411 Melanoma classification, diagnosis and staging. **2012**, 18-28

410 References and Further Reading. **2012**, 427-429

409 Diseases of the Skin. **2012**, 187-277

408 Melanoma of the vulva: A retrospective study of 46 cases from Queensland. **2012**, 02, 120-126

407 Skin. **2013**, 373-388

406 Desmoplastic melanoma and metastatic melanoma. **2012**, 247-253

405 Cutaneous Melanoma Surveillance Counterpoint: USA. **2013**, 255-263

404 Treatment of Distant and Irresectable Metastatic Disease. **2013**, 79-104

403 Applications of immunohistochemistry. **2013**, 577-584

402 Locoregional Staging of Melanoma. **2013**, 293-343

1

401 Clinical Features and Classification. **2013**, 13-27

400 Treatment of Primary Tumor and Locoregional Disease. **2013**, 53-77

399 8 Herkenning en behandeling van maligne huidtumoren in het aangezicht. **2013**, 115-136

398 Cancer Staging. **2013**, 275-278

397 Interferon Alpha. **2013**, 1-28

396 Hauttumoren. **2013**, 879-910

395 Malignant Skin Tumors and the Ethnic Patient. 143-158

394 Skin. **2014**, 177-217

393 Melanocytic Neoplasms. **2014**, 271-293

392 Emerging clinical issues in melanoma in the molecularly targeted era. **2014**, 1102, 11-26

391 Nanotechnology Applications in Dermatology. **2013**, 85-194

390 The epidemiology of melanoma in young adults. 1-10

389 In-transit disease and regional therapy. **2013**, 144-157

388 Melanom. **2014**, 31-97

387 Melanoom: chirurgische behandeling. **2014**, 179-188

386 Primary Versus Metastatic Malignant Melanoma. **2014**, 283-301

385 Another Case of Pulmonary Edema or May Be Not: An Unusual Presentation of Metastatic Melanoma. **2014**, 5, 183-186

384 Metastatic Melanoma. **2014**, 529-567

- 383 Vemurafenib in the treatment of brain metastases from melanoma. **2014**, 3, 85
- 382 Cutaneous Melanoma. **2014**, 331-487
- 381 Melanoma. Part I. Risk Assessment, Diagnosis, and Prognosis: Using Molecular Tools to Diagnose Melanoma, Predict Its Behavior, and Evaluate for Inheritable Forms. **2014**, 63-96 1
- 380 Approach to Microstaging of Primary Melanoma and Evaluation of Prognostic Variables. **2014**, 359-377
- 379 Molecular testing in Cutaneous Melanoma. **2014**, 363-374
- 378 Explanatory Notes à Specific Anatomical Sites. 30-133
- 377 Histopathologic Staging and Reporting of Melanocytic Lesions. **2015**, 7-22
- 376 Liver Metastases from Melanoma Cancer. **2015**, 69-77
- 375 Tumor Staging in Dermatology. **2015**, 103-118
- 374 Lymphoscintigraphy for Extremities à Dedemas and for Sentinel Lymph Node Mapping in Cutaneous Melanomas of the Torso. **2014**, 643-672
- 373 Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy. **2015**, 137-162
- 372 Lungenmetastasen beim Melanom. **2015**, 139-149
- 371 Clinical report. Acral melanoma in Cambodia: challenges associated with a rare and aggressive disease encountered in a developing country setting. **2014**, 8, 809-814
- 370 Melanoma of the Head and Neck. **2014**, 831-856
- 369 Immunology of Cutaneous Tumors and Immunotherapy for Melanoma. **2015**, 277-298
- 368 Cancer in the Kidney Transplant Recipient. **2015**, 319-350
- 367 Universal BRAF State Detection by the Pyrosequencingfi -Based U-BRAF(Và) Assay. **2015**, 1315, 63-82
- 366 Recently Changed Skin Lesion. **2015**, 367-376

- 365 Pigmented Pre-malignant and Malignant Lesions of Skin with Special Reference to Atypical Presentations. **2015**, 9, EC10-2
- 364 Melanoma and immunotherapy. **2015**, 199-212
- 363 Sarginio limfmazgio nustatymas sergant melanoma. Pirmoji Klaipėdos universitetinė ligoninė patirtis. **2015**, 25, 24-30
- 362 Therapie des malignen Melanoms. **2016**, 169-178
- 361 Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. **2016**, 1-39
- 360 Melanoma—Diagnosis, Subtypes and AJCC Stages. **2016**, 21-47
- 359 Brain Metastases from Cutaneous Melanoma. **2016**, 237-254
- 358 Melanom. **2016**, 1-17
- 357 Risk Reductions of Recurrence and Mortality in Melanoma Patients Using IFN- β . **2016**, 49-63
- 356 Pathology of Melanoma. **2016**, 85-113
- 355 Melanozytäre Nävi und Melanom. **2016**, 609-668
- 354 Onkologie. **2016**, 177-212
- 353 Sentinel Lymph Node in Melanoma. **2016**, 367-374
- 352 The Role of Sentinel Lymph Node Biopsy in Thin Melanoma (Breslow Thickness \leq 0.75 mm and 0.76 mm - 1.0 mm Respectively): Our Results and Review of the Literature. **2016**, 07, 163-168
- 351 Magnetic Advances in Cancer Surgery. **2016**, 463-470
- 350 Melanoma—Treatment. **2016**, 79-109
- 349 Melanoma—Introduction, History and Epidemiology. **2016**, 3-20
- 348 Controversies in the Surgical Management of Melanoma. **2016**, 159-184

347 Cutaneous Metastasis. **2016**, 103-115

346 Immunohistology of Melanocytic Lesions. **2016**, 311-334

345 Applications of Non-coding RNA in the Molecular Pathology of Cancer. **2016**, 177-217

344 Head and Neck Cutaneous Melanoma. **2016**, 657-663

343 Malignant Melanoma in the Adolescent and Young Adult (AYA) Population. **2017**, 231-267

342 Histologic Processing and Evaluation of Surgical Excision Specimens. **2017**, 89-111

341 Common Skin Disorders in the Elderly. **2017**, 1-12

340 Radioguided Surgery for Malignant Melanoma. **2017**, 1401-1432

339 Malignes Melanom beim alten und geriatrischen Patienten. **2017**, 1-8

338 Cancer After Kidney Transplantation. **2017**, 525-542

337 Skin. **2017**, 415-431

336 Treatment of Nail Unit Melanoma. **2017**, 141-150

335 Melanoma. **2017**, 1-8

o

334 The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. **2017**, 481-506

333 Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. **2017**, 1065-1102

332 Melanoma. **2017**, 359-519

331 A tenebrous tale: malignant melanoma of the oesophagus. **2017**, 2017,

330 Melanoma Masquerading as a Zosteriform Rash. **2017**, 18, 537-540

1

329 Malignant melanoma, incidence, risk factor and early diagnosis. **2017**, 11, 138-143

328 Melanoma and Spitz Nevi in Children. **2018**, 1-15

327 Melanoma Clinical Staging (Historical and Current). **2018**, 1-16

326 Spitz Tumors. **2018**, 1-16

325 Adjuvant Therapy. **2018**, 1-25

324 Discordance of pathological thin melanoma thickness and T stage in SEER registry: impacts on clinical management and research directions. **2017**, 8, 97727-97735

323 REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFESSION ON BRAF AND INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION. **2017**, 6-10

1

322 Personalisiertes Risikomanagement für das maligne Melanom. **2017**, 65, 937-939

321 Cutaneous Pathology of the Head and Neck. **2018**, 1-55

320 Melanom der Vulva. **2018**, 155-173

319 Malignes Melanom beim alten und geriatrischen Patienten. **2018**, 527-534

318 Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes. **2018**, 1-44

317 Cutaneous Pathology of the Head and Neck. **2018**, 1-55

316 Malignant Melanoma of the Breast. **2018**, 189-192

315 Melanoma of the Ear Canal and Temporal Bone. **2018**, 109-119

314 Melanoma. **2018**, 117-141

313 Different presentations of vulvar malignant melanoma: Report of two cases. 801-805

312 Malign Melanomda Cerrahi Sonrası Adjuvan İmmunoterapi ve Kemoterapi Deneyimimiz.

- 311 Introduction. **2019**, 1-24
- 310 Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients. **2019**, 1-27
- 309 Assessing the efficacy of a 10-point referral tool in the triaging of pigmented lesions to a Dermatology clinic. **2018**, 93, 932-933
- 308 Skin Lesions and Pressure Ulcers. **2019**, 1-41
- 307 Local and Recurrent Regional Metastases of Melanoma. **2019**, 1-33
- 306 CYTOLOGICAL EVALUATION OF METASTATIC MELANOMA- A SERIES OF 3 CASES. **2019**, 8, 88-90
- 305 Invasive Melanoma. **2019**, 1095-1116
- 304 Biomarkers for Melanoma. **2019**, 1-32
- 303 Diagnosis of Stage IV Melanoma. **2019**, 1-47 1
- 302 Melanom. **2019**, 45-134
- 301 Hybrid Imaging of Melanoma and Other Cutaneous Malignancies. **2019**, 645-653
- 300 Surveillance and Follow-Up of Melanoma Patients. **2019**, 1-16
- 299 Applications of immunohistochemistry. **2019**, 509-515
- 298 Melanoma Prognosis and Staging. **2019**, 1-27
- 297 The large spectrum of Spitzoid tumors: a retrospective survival study. **2019**, 154, 315-320 2
- 296 A new clinical tool to predict outcome in early-stage melanoma patients.
- 295 miR-26a regulates extracellular vesicle secretion from prostate cancer cells via targeting SHC4, PFDN4 and CHORDC1.
- 294 FEATURES OF DEFEATS OF SENTINEL LYMPH NODES AT PRIMARY MELANOMA OF SKIN. **2019**, 26, 54-60

- 293 Evaluation of Kindlin-1 and Ki-67 immunohistochemical expression in primary cutaneous malignant melanoma: a clinical series. **2019**, 39,
- 292 Interleukin 1 receptor antagonist gene variable number of tandem repeats polymorphism and cutaneous melanoma. **2019**, 18, 5759-5768 2
- 291 Recently Changed Skin Lesion. **2020**, 63-71
- 290 Primary malignant melanoma without melanosis of the colon. **2019**, 17, 561-564
- 289 Determining Missing Key Elements in Oncology Information System to Improve Patient Experience and Clinical Care. **2020**, 567-586
- 288 Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. **2019**, 14, 203-225 0
- 287 CRISPR Screens Identify Essential Cell Growth Mediators in BRAF-inhibitor Resistant Melanoma.
- 286 Isolated Limb Perfusion and Infusion in the Management of In-Transit Melanoma of the Extremities: Modern Data Affecting Practice. **2020**, 379-394
- 285 Thick melanoma in Tuscany. **2019**, 154, 638-645 0
- 284 A History of Melanoma: From Hunter to Morton. **2020**, 1457-1475
- 283 Adequacy of sentinel lymph node biopsy in malignant melanoma of the trunk and extremities: Clinical observations regarding prognosis. **2020**, 47, 42-48 2
- 282 Melanoma. **2020**, 1-17
- 281 Surgery for Stage IV Melanoma. **2021**, 171-189
- 280 Melanoma Epidemiology, Staging and Prognostic Factors. **2021**, 61-81
- 279 Lymphedema secondary to melanoma treatments: diagnosis, evaluation, and treatments. **2020**, 2, 227-234 2
- 278 Risk stratification of cutaneous melanoma reveals carcinogen metabolism enrichment and immune inhibition in high-risk patients. **2020**, 12, 16457-16475 0
- 277 Features associated with melanoma metastasis in Latvia. **2020**, 20, 117
- 276 PET/CT in restaging, prognosis, and recurrence in patients with malignant melanoma. **2020**, 51, 3

- 275 Classification of human skin cancer using Stokes-Mueller decomposition method and artificial intelligence models. **2021**, 249, 168239 0
- 274 Prognostic value of key genes of the JAK-STAT signaling pathway in patients with cutaneous melanoma. **2020**, 19, 1928-1946 0
- 273 Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. **2021**, 21, 162-186 0
- 272 Multidimensional indicators of scholarly impact in the skin oncology literature: is there a correlation between bibliometric and altmetric profiles?. **2021**, 55, 232-241 1
- 271 Prognostic significance of regression and mitotic rate in head and neck cutaneous melanoma. **2021**, 6, 109-115 1
- 270 Complications and outcomes following inguinal lymphadenectomy for malignant melanoma in an Asian population. **2020**, 16, 71-78
- 269 DE-Net: A deep edge network with boundary information for automatic skin lesion segmentation. **2022**, 468, 71-84 1
- 268 Skin Lesions and Pressure Ulcers. **2020**, 743-782
- 267 Reconstruction Principles of Localized Non-melanoma Skin Cancer and Cutaneous Melanoma. **2020**, 243-263
- 266 Local and Recurrent Regional Metastases of Melanoma. **2020**, 705-737 1
- 265 Total Body Photography as an Aid for the Early Detection of Skin Cancer. **2020**, 253-269
- 264 Raman Spectroscopy Techniques for Skin Cancer Detection and Diagnosis. **2020**, 359-393 0
- 263 Nose and Ear Reconstruction Following Tumor Extirpation. **2020**, 295-334
- 262 Diagnosis of Stage IV Melanoma. **2020**, 997-1043
- 261 PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract. **2020**, 19, 2481-2488 1
- 260 ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. **2020**, B-1-B30-3
- 259 Nonmelanoma Skin Cancer and Cutaneous Melanoma in the Pediatric Population. **2020**, 615-634
- 258 Melanoma Prognosis and Staging. **2020**, 271-297 1

257	Pathological Diagnosis and Analysis of Four Cases of Melanoma in Yunan Black Pigs. 2020 , 09, 50-55	
256	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. 2020 , 41-68	
255	Non-melanoma Skin Cancer and Cutaneous Melanoma for the Plastic and Reconstructive Surgeon. 2020 , 153-239	1
254	The Role of the Sentinel Lymph Node Biopsy in the Treatment of Nonmelanoma Skin Cancer and Cutaneous Melanoma. 2020 , 647-704	1
253	Tumour gene expression signature in primary melanoma predicts long-term outcomes: A prospective multicentre study.	2
252	Association of Gender with Survival in Melanoma In Situ of the Head and Neck: A National Database Study. 2020 , 12, e6924	1
251	MELANOMA OF NASAL CAVITY.LITERATURE REVIEW AND CLINICAL CASE REPORT. 2020 , 44, 94-99	
250	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. 2021 , 159, 113-124	0
249	Approaches to metastatic skin melanoma therapy in 2020: a dynamic way forward. 2020 , 80-93	
248	Surgical Technique and Indications of Radical Dissection: Groin. 2021 , 107-114	
247	Medical Treatment of Melanoma: Adjuvant and Neoadjuvant Therapies. 2021 , 157-165	
246	The Role of Nuclear Medicine in Mapping Sentinel Lymph Nodes and Staging Metastatic Melanoma. 2021 , 55-69	
245	Methodological and Technological Evolution of Sentinel Lymph Node Biopsy: An 8-Year Experience. 2021 , 71-84	
244	Vitexin inhibited the invasion, metastasis, and progression of human melanoma cells by targeting STAT3 signaling pathway.	
243	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. 2020 , 14, 199-204	
242	Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. 2021 , 29, 3578-3587	1
241	Cancer of the Vulva: A Review. 2021 , 47, 174-183	3
240	Clinical Significance of Serum Ykl-40 (Chitinase-3-Like-1 Protein) as a Biomarker in Melanoma: an Analysis of 112 Turkish Patients. 2017 , 18, 1383-1387	9

239	Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. 2010 , 10, 9	78
238	Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. 2010 , 10, 108-16	2
237	Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. 2012 , 37, 503-30	72
236	Histologic features of conjunctival melanoma predictive of metastasis and death (an American Ophthalmological thesis). 2012 , 110, 64-73	24
235	A Global Review of Melanoma Follow-up Guidelines. 2013 , 6, 18-26	108
234	Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review. 2013 , 4, 17-28	37
233	(68)Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes. 2013 , 4, 60-9	27
232	Letter to the editor. 2011 , 1, 83-4	
231	Diagnostic and prognostic biomarkers in melanoma. 2014 , 7, 13-24	57
230	The era of personalized medicine in oncology: novel biomarkers ushering in new approaches to cancer therapy. 2011 , 4, 387-8	1
229	Melanoma screening by means of complete skin exams for all patients in a dermatology practice reduces the thickness of primary melanomas at diagnosis. 2014 , 7, 18-22	11
228	MiR-199a inhibits the ability of proliferation and migration by regulating CD44-Ezrin signaling in cutaneous squamous cell carcinoma cells. 2014 , 7, 7131-41	30
227	CD24 expression predicts poor prognosis for patients with cutaneous malignant melanoma. 2014 , 7, 4337-41	8
226	Survival rates of patients with metastatic malignant melanoma. 2014 , 7, 572-6	149
225	Controversies in the diagnosis and treatment of early cutaneous melanoma. 2015 , 8, 132-41	6
224	Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma. 2015 , 8, 3097-103	32
223	Down-regulation of tissue microRNA-126 was associated with poor prognosis in patients with cutaneous melanoma. 2015 , 8, 4297-301	6
222	Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. 2015 , 88, 389-95	3

221	Expression of miR-203 is decreased and associated with the prognosis of melanoma patients. 2015 , 8, 13249-54	13
220	Significantly high lymphatic vessel density in cutaneous metastasizing melanoma. 2015 , 19, 210-5	5
219	Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma. 2016 , 6, 277-285	9
218	Systemic Therapies for Late-stage Melanoma. 2016 , 9, 36-40	1
217	Improving Melanoma Path Reports: the Importance of Histopathological Parameters in Diagnosis of Cutaneous Melanoma. 2015 , 10, 226-230	
216	Precision Diagnosis Of Melanoma And Other Skin Lesions From Digital Images. 2017 , 2017, 220-226	7
215	Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. 2016 , 82, 1009-1013	9
214	Demographic and Pathologic Characteristics of Malignant Melanoma in West Part of Romania. 2018 , 47, 606-607	2
213	Proteomics and melanoma: a current perspective. 2016 , 3, 366-370	1
212	Melanoma in situ: a case report from the patient's perspective. 2018 , 62, 56-61	
211	Promising clinical application of ctDNA in evaluating immunotherapy efficacy. 2018 , 8, 1947-1956	6
210	A Survey of Licensed Massage Therapists' Perceptions of Skin Cancer Prevention and Detection Activities. 2018 , 11, 4-10	60
209	Systemic Therapy in Metastatic Melanoma. 2015 , 32, 57S-65S	1
208	Advanced Presentation of Homeopathically treated Giant Melanoma: A Case Report. 2019 , 12, 28-31	1
207	Long-Term Survival of Cutaneous Malignant Melanoma with Metastasis to Paranasal Sinuses: A Case Report and Literature Review. 2018 , 7, e860	
206	Cell-SELEX-based selection of ssDNA aptamers for specifically targeting V600E-mutated melanoma. 2021 ,	2
205	FusionM4Net: A multi-stage multi-modal learning algorithm for multi-label skin lesion classification. 2021 , 76, 102307	4
204	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. 2021 , 9,	2

203	Proportion of Thick versus Thin Melanomas as a Benchmarking Tool. 2021 , 10,	0
202	Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model. 2021 , 25, 1-178	1
201	BAFF attenuates immunosuppressive monocytes in the melanoma tumor microenvironment. 2021 ,	0
200	Socioeconomic Determinants of Melanoma-Related Health Literacy and Attitudes Among College Students in China: A Population-Based Cross-Sectional Study. 2021 , 9, 743368	0
199	Inhibition of ERK5 elicits cellular senescence in melanoma via the cyclin-dependent kinase inhibitor p21. 2021 ,	4
198	Epidemiologã del melanoma en Espaã: estimaciã de los pacientes con melanoma con estadio III candidatos al tratamiento adyuvante. 2021 ,	
197	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. 2021 , 158, 156-168	5
196	Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma. 2021 ,	4
195	Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice. 2021 , 14, 5345-5352	1
194	Immunotherapy for Melanoma.. 2021 , 1342, 81-111	0
193	Predictive Biomarkers of Melanoma. 2021 , 285-299	0
192	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.. 2021 , 12, 810388	4
191	Malignes Melanom. 2015 , 1-9	
190	Fortgeschrittenes malignes Melanom: Kernpunkte der aktualisierten Leitlinie.	
189	A Quaternary Classifier for the Clinical Evaluation of Pigmented Skin Lesions. 2020 ,	1
188	A Multi-Input CNNs with Attention for Skin Lesion Classification. 2020 ,	
187	Adjuvant treatment of high-risk melanoma - cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors.. 2022 , 12, 8	
186	Application of Nanoemulsion in Cancer Treatment. 2022 , 237-258	

185	Therapeutic Potential of Nitric Oxide releasing Selective Estrogen Receptor Modulators (NO-SERMs) in Malignant Melanoma.. 2022 ,	2
184	Seasonal variation in high-risk phenotypes of cutaneous malignant melanoma diagnosed in Eastern England: An observational study.. 2022 ,	0
183	Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy?. 2022 , 14,	1
182	Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study.. 2022 ,	0
181	Single-Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment.. 2022 ,	0
180	PET Imaging of Melanoma. 2022 ,	
179	The efficacy of Tc-rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients.. 2022 , 10, 95	0
178	Fully transformer network for skin lesion analysis.. 2022 , 77, 102357	4
177	Skin melanoma: from systematic biology to the personalized therapy. 2013 , 89, 4-8	
176	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma.. 2022 ,	0
175	Extra-Axial Skeletal Metastasis of Malignant Melanoma: Case Report and Literature Review.. 2022 , 14, e22115	
174	Radioguided Surgery for Malignant Melanoma. 2022 , 1-38	
173	Patient-reported outcomes during checkpoint inhibition: insight into symptom burden in daily clinical practice.. 2022 ,	0
172	Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy.. 2022 , 10, 847901	1
171	[Translated article] Epidemiology of Melanoma in Spain: Estimation of Number of Patients With Stage III Disease Eligible for Adjuvant Therapies.. 2022 ,	
170	Skin layer structure characterization via multi-contrast polarization-sensitive optical coherence tomography. 2022 ,	
169	The Interplay between Tumour Microenvironment Components in Malignant Melanoma.. 2022 , 58,	1
168	Patch-based local deep feature extraction for automated skin cancer classification.	0

- 167 American Joint Committee on Cancer (AJCC) tumor staging system predicts the outcome and metastasis pattern in conjunctival melanoma.. **2022**, 1
- 166 Analyzing Prognostic Hub Genes in the Microenvironment of Cutaneous Melanoma by Computer Integrated Bioinformatics.. **2022**, 2022, 4493347
- 165 Progression of untreated gastric and pulmonary metastasis in a patient with resected acral melanoma.. **2022**, 15,
- 164 Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma.. **2022**, 14, 0
- 163 Long-term control of melanoma adrenal metastasis treated with radiotherapy.. **2022**,
- 162 Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing.. **2022**, 1
- 161 Adjuvant therapy of malignant melanoma: general and practical experience. **2021**, 15, 158-163
- 160 Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF Mutation-Positive Melanoma.. **2021**, 14, 0
- 159 Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. **2022**, 11, 0
- 158 Automated skin lesion segmentation using multi-scale feature extraction scheme and dual-attention mechanism. **2021**,
- 157 Postoperative assessment of malignant melanoma aggressiveness for further treatment personalization. **2021**, 11, 45-51
- 156 Histopathological evaluation of cutaneous malignant melanoma: A retrospective study. **2022**, 23, 0
- 155 Frailty and checkpoint inhibitor toxicity in older patients with melanoma.. **2022**, 1
- 154 Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition.. **2022**, 12, 830627 1
- 153 Imaging and Laboratory Workup for Melanoma.. **2022**, 0
- 152 An Evidence-Based Staging System for Mucosal Melanoma: A Proposal.. **2022**, 1 2
- 151 Data_Sheet_1.PDF. **2021**,
- 150 Table_1.docx. **2020**,

149 Data_Sheet_1.ZIP. 2020,

148 Image_1.pdf. 2020,

147 Presentation_1.PPTX. 2020,

146 Presentation_2.PPTX. 2020,

145 Presentation_3.PPTX. 2020,

144 Table_1.DOCX. 2020,

143 Table_2.DOCX. 2020,

142 Data_Sheet_1.xlsx. 2020,

141 Image_2.TIF. 2020,

140 Image_3.TIF. 2020,

139 Image_4.TIF. 2020,

138 Table_1.DOCX. 2019,

137 Table_2.DOCX. 2019,

136 Table_3.DOCX. 2019,

135 DataSheet_1.zip. 2020,

134 Table_1.docx. 2020,

133 Diet quality is associated with primary melanoma thickness.. 2022,

2

132 Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?. 2021, 1-10

0

- 131 A 41-Year-Old Woman with a Late Cerebral Metastasis 16 Years After an Initial Diagnosis of Cutaneous Melanoma.. **2022**, 23, e935728 1
- 130 Melanoma. **2022**, 1855-1871
- 129 A Mitochondria-Localized Iridium(III)-Chlorin E6 Conjugate for Synergistic Sonodynamic and Two-Photon Photodynamic Therapy Against Melanoma. 0
- 128 Texture Analysis in Diagnosing Skin Pigmented Lesions in Normal and Polarized Light-A Preliminary Report.. **2022**, 11,
- 127 Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study.. **2022**, 1 0
- 126 An efficient U-shaped network combined with edge attention module and context pyramid fusion for skin lesion segmentation.. **2022**, 1 1
- 125 Classification and Staging of Melanoma in the Head and Neck.. **2022**, 34, 221-234 0
- 124 Identification of Transcriptional Heterogeneity and Construction of a Prognostic Model for Melanoma Based on Single-Cell and Bulk Transcriptome Analysis. **2022**, 10, 0
- 123 The management of eyelid tumors. **2012**, 360-372 1
- 122 Noncontrast-enhanced 3-Tesla MRI using surface coil as a complementary test for assessment of distribution and depth of locoregional cutaneous metastases of malignant melanoma.. **2022**,
- 121 European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. **2022**, 5
- 120 Perfil epidemiológico de pacientes com melanoma cutâneo em uma cidade do sul de Santa Catarina. 1-12
- 119 Cutaneous melanoma. **2023**, 370-375
- 118 Radioguided Surgery for Malignant Melanoma. **2022**, 1-38
- 117 Sentinel Lymph Node Biopsy for Primary Cutaneous Malignancy. **2022**, 339-352
- 116 Personalized Systemic Cancer Therapy. **2022**, 739-747
- 115 Role of Circulating MicroRNAs in Prognosis and Diagnosis of Cancers. **2022**, 109-132
- 114 Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. *Journal of Clinical Oncology*, 2.2 0

113	Dense and shuffle attention U-Net for automatic skin lesion segmentation.	0
112	Cutaneous melanoma incidence, mortality, and survival in Manizales, Colombia: a population-based study. 2022 , 50, 030006052211067	
111	Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations. 1-7	
110	Sinonasal Mucosal Melanoma: Role of Tumor Proliferative Indices and Pathological Factors in Survival.	1
109	¹⁸ F-FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. 2022 , 14, 3190	0
108	Histological changes associated with laser interstitial thermal therapy for radiation necrosis: illustrative cases. 2022 , 4,	
107	Association of Systemic Inflammatory and Immune Indices With Survival in Canine Patients With Oral Melanoma, Treated With Experimental Immunotherapy Alone or Experimental Immunotherapy Plus Metronomic Chemotherapy. 9,	0
106	A Novel Necroptosis-Related Gene Signature in Skin Cutaneous Melanoma Prognosis and Tumor Microenvironment. 13,	0
105	Long-term results of wide local excision with concurrent venous free flap reconstruction in subungual melanoma.	
104	EPAC Regulates Melanoma Growth by Stimulating mTORC1 Signaling and Loss of EPAC Signaling Dependence Correlates with Melanoma Progression.	0
103	Management of cutaneous melanoma: radiologists challenging and risk assessment.	6
102	Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma Pathogenesis. 2022 , 14, 3371	0
101	Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T reg reduction and effector T cell activation. 2022 , 7,	4
100	Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma. 2022 , 14, 3587	0
99	Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.	5
98	Association of JAK/STAT genetic variants with cutaneous melanoma. 12,	
97	A shallow deep learning approach to classify skin cancer using down-scaling method to minimize time and space complexity. 2022 , 17, e0269826	0
96	Investigation of CTLA4 Application in Advanced Melanoma with Ipilimumab and Nivolumab. 8, 481-489	

- 95 PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab. 13, ○
- 94 Association of Tumor Metabolic Activity on PET/CT Scan with Pathological Characteristics in Patients with Malignant Melanoma. **2022**, 19, ○
- 93 Reporting of melanoma cell densities in the sentinel node refines outcome prediction. **2022**, 174, 121-130 1
- 92 Metastatic multifocal melanoma of multiple organ systems: A case report. 10, 10136-10145 ○
- 91 Microneedles-mediated drug delivery system for the diagnosis and treatment of melanoma. **2022**, 219, 112818 ○
- 90 Towards Multi-Center Skin Lesion Classification Using Deep Neural Network with Adaptively Weighted Balance Loss. **2022**, 1-1 ○
- 89 Radioguided Surgery for Malignant Melanoma. **2022**, 1595-1631 ○
- 88 Malignant Melanoma in Cerebellopontine Angle: A Case Report and Literature Review. **2022**, 12, 6812-6818 ○
- 87 Reconstructing invisible deviating events: A conformance checking approach for recurring events. **2022**, 19, 11782-11799 ○
- 86 Ulcerated Cutaneous Melanoma: A Review of the Clinical, Histologic, and Molecular Features Associated with a Clinically Aggressive Histologic Phenotype. Volume 15, 1743-1757 ○
- 85 Hypoxia and Ezrin Expression in Primary Melanoma Have High Prognostic Relevance. **2022**, 23, 10745 ○
- 84 Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis. **2022**, 101, e29390 ○
- 83 Neoadjuvant therapy for melanoma: A critical appraisal. ○
- 82 EIF3B stabilizes PTGS2 expression by counteracting MDM2 -mediated ubiquitination to promote the development and progression of malignant melanoma. ○
- 81 Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE). ○
- 80 Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis. **2022**, ○
- 79 Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance. 12, ○
- 78 Is Melanoma Progression Affected by Thyroid Diseases?. **2022**, 23, 10036 1

77	Survival analysis in head and neck melanoma after negative sentinel lymph node biopsy: A seer-based population study. 014556132211263	0
76	The role of tumor-associated macrophages and soluble mediators in pulmonary metastatic melanoma. 13,	0
75	Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). 2022 , 10, e005424	0
74	NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. 2022 , 23, 9985	2
73	Ways and methods of closing tissue defects of the middle zone of the facial skull after removal of malignant tumors with intracranial spread (case from practice). 2022 , 39, 40-49	0
72	Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.	1
71	Treatment with anti-HER2 chimeric antigen receptor tumor-infiltrating lymphocytes (CAR-TILs) is safe and associated with antitumor efficacy in mice and companion dogs.	0
70	High Serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. 2022 ,	0
69	Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.	0
68	Skin lesion classification using CNNs with grouping of multi-scale attention and class-specific loss weighting. 2022 , 226, 107166	1
67	The importance of mitosis $\hat{=}$ in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy. 2022 , 32, 469-476	0
66	Cancer Genomics and Evolution. 1-30	0
65	Prediction of early-stage melanoma recurrence using clinical and histopathologic features. 2022 , 6,	0
64	Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype. 2022 , 12,	0
63	An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability.	0
62	An In Vivo Model of Human Macrophages in Metastatic Melanoma. 2022 , 209, 606-620	0
61	Smartphone and microfluidic systems in medical and food analysis. 2023 , 233-257	1
60	Prognostic significance of age on superficial spreading melanoma after resection: lessons from SEER database involving 12 536 patients.	0

59	Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics.	0
58	Determining the Precise Extent of Sentinel Basins During Laparoscopic Gastrectomy for Early Gastric Cancer.	0
57	Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very-low melanoma mortality.	0
56	Melanoma Treatment. 2022 , 4, 549-551	0
55	Sentinel Lymph Node Biopsy in Cutaneous Melanoma, a Clinical Point of View. 2022 , 58, 1589	1
54	Designing a new deep convolutional neural network for skin lesion recognition.	0
53	Dieckol Inhibits Autophagic Flux and Induces Apoptotic Cell Death in A375 Human Melanoma Cells via Lysosomal Dysfunction and Mitochondrial Membrane Impairment. 2022 , 23, 14149	1
52	Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion.	1
51	Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients.	0
50	Deep Domain Adversarial Neural Network for the Deconvolution of Cell Type Mixtures in Tissue Proteome Profiling.	0
49	A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.	0
48	Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: a population-based analysis. 2022 ,	0
47	Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma.	1
46	Current status and novel insights into the role of metastasectomy in the era of immunotherapy. 1-10	0
45	Prognostic Relevance of Type 2 Diabetes and Metformin Treatment in Head and Neck Melanoma: Results from a Population-Based Cohort Study. 2022 , 29, 9660-9670	0
44	Serum Neu5Gc biomarkers are elevated in primary cutaneous melanoma. 2022 ,	0
43	Neoadjuvant treatment for stage III and IV cutaneous melanoma. 2023 , 2023,	0
42	First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. 2023 , 21,	0

- 41 Risk of Melanoma in Patients with Basal Cell Carcinoma: A Population-based Cohort Study. 103, adv00841 ○
- 40 Neo-Adjuvant Immunotherapy emerges as best medical practice and will be the new standard of care for macroscopic stage III Melanoma. **2023**, ○
- 39 Construction, validation and, visualization of a web-based nomogram to identify the best candidates for primary tumor resection in advanced cutaneous melanoma patients. 9, ○
- 38 Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. 12, ○
- 37 Prognostic model for predicting overall and cancer-specific survival among patients with superficial spreading melanoma: A SEER based study. **2022**, 101, e32521 ○
- 36 Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. **2022**, ○
- 35 Decoupling the correlation between cytotoxic and exhausted T lymphocyte transcriptomic signatures enhances melanoma immunotherapy response prediction. ○
- 34 Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. **2023**, 15, 648 ○
- 33 Oligometastatic disease and visceral resections in advanced malignant melanoma: a propensity-matched analysis. **2023**, 408, ○
- 32 Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. 9, ○
- 31 Oral Mukozal Melanom: Nadir Gfien Bir Vaka Raporu. ○
- 30 ACCPG-Net: A skin lesion segmentation network with Adaptive Channel-Context-Aware Pyramid Attention and Global Feature Fusion. **2023**, 154, 106580 ○
- 29 Melanome der Haut und Schleimhaut. **2022**, 205-236 ○
- 28 A novel soft attention-based multi-modal deep learning framework for multi-label skin lesion classification. **2023**, 120, 105897 ○
- 27 A Novel Framework for Melanoma Lesion Segmentation Using Multiparallel Depthwise Separable and Dilated Convolutions with Swish Activations. **2023**, 2023, 1-15 ○
- 26 Skin lesion segmentation using two-phase cross-domain transfer learning framework. **2023**, 231, 107408 ○
- 25 Self-calibrated magnetic aptamer sensor with dual Lanthanide-assisted Time-resolved luminescence for high-sensitive detection of melanoma exosomal PD-L1. **2023**, 227, 111714 ○
- 24 Nanodelivery systems for cutaneous melanoma treatment. **2023**, 184, 214-247 ○

- 23 FairDisCo: Fairer AI in Dermatology via Disentanglement Contrastive Learning. **2023**, 185-202
- 22 Anatomic Region of Cutaneous Melanoma Impacts Survival and Clinical Outcomes: A Population-Based Analysis. **2023**, 15, 1229
- 21 Determining the precise extent of sentinel basins during laparoscopic gastrectomy for early gastric cancer. **2023**, 21,
- 20 PCF-Net: Position and context information fusion attention convolutional neural network for skin lesion segmentation. **2023**, 9, e13942
- 19 TFormer: A throughout fusion transformer for multi-modal skin lesion diagnosis. **2023**, 157, 106712
- 18 In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: Prospective analysis and case-control study.
- 17 Updates in management strategies of locally advanced sinonasal malignancy. **2023**, 31, 39-44
- 16 Peritoneal Carcinomatosis From Malignant Melanoma After Wide Local Excision of a T1a Lesion: A Case Report. **2023**,
- 15 The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [18F]-fluorodeoxyglucose PET/computed tomography. Publish Ahead of Print,
- 14 Optimization Convolutional Neural Network for Automatic Skin Lesion Diagnosis Using a Genetic Algorithm. **2023**, 13, 3248
- 13 Early inflammatory biomarkers and melanoma survival.
- 12 Prognostic Factors and Outcomes of Cutaneous Malignant Melanoma. Publish Ahead of Print,
- 11 Melanoma of unknown primary origin with skeletal muscle metastasis: a case report. **2023**, 17,
- 10 Similar local recurrence and survival in patients with T1 radial growth phase melanoma on head and neck treated with 5 or 10 mm margins: A retrospective study.
- 9 The Influence of Obesity on Melanoma and Sentinel Lymph Node Diagnosis: A Retrospective Monocentric Study in 1001 Patients. **2023**, 15, 1806
- 8 Does Stage Migration Occur as a Consequence of Omitting Completion Lymph Node Dissection for Melanoma?.
- 7 Is It Time to Supersede the Diagnostic Term "Melanoma In Situ with Regression"? A Narrative Review. **2023**, 10, 120-127
- 6 Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies.

- 5 Melanoma. **2023**, 429-459 ○
- 4 Melanin enhances metastatic melanoma colonization by inhibiting ferroptosis. ○
- 3 Skin Cancer Screening. **2023**, 329, 1296 1
- 2 Surgical Resection of Pulmonary Metastases from Melanoma in Oligometastatic Patients: Results from a Multicentric Study in the Era of Immunoncology and Targeted Therapy. **2023**, 15, 2462 ○
- 1 Mitotic rate as predictive factor for positive sentinel lymph node in pT1 and pT2 melanomas. **2023**, ○